

EULAR 2017 Congress Madrid - Preliminary Scientific Programme - PLEASE OBSERVE THE EMBARGO

Please note that this is a **Preliminary Version** of the Scientific Programme for the EULAR Congress 2017 in Madrid. **The programme is subject to change at any time.**

THE EULAR ABSTRACT EMBARGO IS IN PLACE UNTIL 14 JUNE 2017 00:01 CET. See the EULAR Congress Website

Details on **Oral Abstract Presentations and Poster Tours** will be published approximately one month prior to the congress. Until then, you will see the lecture slot, but without presenter name and without abstract title.

To **select single time slots**, please use the drop down selection option (Standard: Overview all days and sessions).

To print, please use the **'File - Print'** option of your browser. Best results are achieved using **landscape and scaling down to 75 percent** in the printer preferences.

Overview



🕒 Wednesday 14.06.2017 13:00 - 14:30

🏠 Basic and Translational Science Session - South Auditorium

🏠 Joint EULAR - APLAR session: Novel animal models – where no researcher has gone before...

Chair	Burmester Gerd Rüdiger (Germany)		
Chair	Yamamoto Kazuhiko (Japan)		
Speaker	Pap Thomas (Germany)	SP0001	Relevance of animal models in osteoarthritis
Speaker	Yu Xinhua (Germany)	SP0002	Novel animal models in SSc
Speaker	Iwakura Yoichiro (Japan)	SP0003	Novel animal model in arthritis
Speaker	Yamamoto Kazuhiko (Japan)	SP0004	From the animal model to the patient. Similarities and differences

🕒 Wednesday 14.06.2017 13:30 - 14:30

🏠 Health Professionals Session - N101 / N102

🏠 Health Professionals Welcome Session

Chair	Opava Christina H. (Sweden)		
Chair	Gobbo Montoya Milena (Spain)		
Speaker	Vliet Vlieland Thea (Netherlands)	SP0005	Looking back at 70 years of Eular and 30 years of HP involvement: a rehabilitation perspective

Speaker	Hill Jackie (United Kingdom)	SP0006	Looking back at 70 years of Euler and 30 years of HP involvement: a nursing perspective
Speaker	Bijlsma Johannes W.J. (Netherlands)	SP0007	70 years past and a view of the future
Speaker	de Thurah Annette (Denmark)	SP0008	The future for HPs in Rheumatology

Wednesday 14.06.2017 15:00 - 16:30

WIN & HOT Session - Hall 6

WIN & HOT Session

Chair	Collantes Esteves Eduardo (Spain)		
Chair	Sousa Elsa (Portugal)		
Speaker	Machado Pedro (United Kingdom)		WIN Session: Axial and peripheral spondyloarthritis
Speaker	Lories Rik (Belgium)	SP0009	WIN Session: Psoriatic Arthritis

Clinical Science Session - Hall 8

Moving towards new criteria in SLE, Sjögren's and APS

Chair	Cervera Ricardo (Spain)		
Chair	Bootsma Hendrika (Netherlands)		
Speaker	Aringer Martin (Germany)	SP0010	Classification of SLE – challenges and potential solutions
Speaker	Bowman Simon (United Kingdom)	SP0011	Sjögren's criteria revisited!
Speaker	Meroni Pier Luigi (Italy)	SP0012	Advanced APS criteria 2016/2017
Abstract	Morand Eric (Australia)	OP0001	THE LUPUS LOW DISEASE ACTIVITY STATE (LLDAS) DEFINITION DISCRIMINATES RESPONDERS IN A SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) TRIAL: POST-HOC ANALYSIS OF THE PHASE IIB MUSE TRIAL OF ANIFROLUMAB
Abstract	Johnson Sindhu (Canada)	OP0002	MULTICRITERIA DECISION ANALYSIS FOR DEVELOPING NEW CLASSIFICATION CRITERIA FOR SYSTEMIC LUPUS ERYTHEMATOSUS

🏠 Challenges in Clinical Practice Session - Hall 7A

🏠 The differential diagnosis of diffuse skin sclerosis and of Raynaud's phenomenon and a practical approach to assessment

Chair	Herrick Ariane L. (United Kingdom)		
Chair	Gabrielli Armando (Italy)		
Presenter	Suarez Annabel (United Kingdom)	SP0013	Case 1 presentation: Widespread cutaneous thickening – Could this be early diffuse cutaneous systemic sclerosis?
Discussant	Pauling John (United Kingdom)	SP0014	Case 1 discussion: The differential diagnosis of diffuse sclerosing skin disease and a practical approach to assessment
Presenter	Hughes Michael (United Kingdom)	SP0015	Case 2 presentation: New onset Raynaud's phenomenon – Could this be early limited cutaneous systemic sclerosis?
Discussant	Herrick Ariane L. (United Kingdom)	SP0016	Case 2 discussion: The differential diagnosis of Raynaud's phenomenon and practical approach to assessment with a focus on imaging

🏠 From Bench to Bedside - Hall 7B

🏠 Controlling the balance between cancer and autoimmunity

Chair	Calabrese Leonard (United States)		
Chair	Mariette Xavier (France)		
Speaker	Rosen Anthony (United States)	SP0017	The same mechanism at the origin of cancer and autoimmunity
Speaker	Marabelle Aurélien (France)	SP0018	Check points inhibitors - from discovery to clinical applications
Speaker	Schaefferbeke Thierry (France)		Rheumatic immune related adverse events with cancer immunotherapy
Abstract	Calabrese Cassandra (United States)	OP0003	RHEUMATIC IMMUNE RELATED ADVERSE EVENTS OF CHECKPOINT THERAPY FOR CANCER: CASE SERIES OF AN EMERGING NOSOLOGIC ENTITY
Abstract	Belkhir Rakiba (France)	OP0004	RHEUMATOID ARTHRITIS OCCURRING AFTER IMMUNE CHECKPOINT INHIBITORS

Clinical Science Session - N103 / N104

Fibromyalgia: a disease of the peripheral or central nervous system

Chair	McMahon Stephen (United Kingdom)		
Chair	Atzeni Fabiola (Italy)		
Speaker	Treede Rolf-Detlef (Germany)	SP0019	Signs, symptoms and co-morbidities of fibromyalgia
Speaker	Sommer Claudia (Germany)	SP0020	Peripheral pathologies in fibromyalgia
Speaker	Kosek Eva (Sweden)	SP0021	Central pathologies in fibromyalgia
Abstract	Provan Sella (Norway)	OP0005	FIBROMYALGIA IN PATIENTS WITH RHEUMATOID ARTHRITIS IN A 10-YEAR PERSPECTIVE
Abstract	Atzeni Fabiola (Italy)	OP0006	INFLUENCE OF AUTONOMIC NERVOUS SYSTEM DYSFUNCTION IN THE GENESIS OF SLEEP DISORDERS IN FIBROMYALGIA PATIENTS

Basic and Translational Science Session - South Auditorium

Chondrocyte Channels (Role in Mechanotransduction) or “Channeling the chondrocyte”

Chair	Malfait Anne-Marie (United States)		
Chair	Appleton Tom (Canada)		
Speaker	Beier Frank (Canada)		Pannexins in Cartilage
Speaker	Mobasheri Ali (United Kingdom)		The chondrocyte channelome
Speaker	Moilanen Eeva (Finland)	SP0022	TRPA1 in osteoarthritis
Abstract	Latourte Augustin (France)	OP0007	CCR2 INHIBITION ABROGATES IL-6-INDUCED ACTIVATION OF MATRIX METALLOPROTEINASES IN CARTILAGE
Abstract	López de Figueroa Paloma (Spain)	OP0008	DEFICIENT AUTOPHAGY INDUCES CHONDROCYTE DYSFUNCTION THROUGH LAMIN A/C ACCUMULATION IN AGING AND OSTEOARTHRITIS

Health Professionals Session - N101 / N102

Wearable technologies in 21st century healthcare

Chair	Swinnen Thijs (Belgium)		
Chair	Primdahl Jette (Denmark)		
Speaker	Clarke-Cornwell Alex (United Kingdom)	SP0023	Review of wearable technologies – the state of the art
Speaker	McCarthy Marie (Ireland)	SP0024	Wearable technologies in research and clinical trials
Speaker	Culén Alma Leora (Norway)		Ethics and politics of the use and the design of technology in health care
Speaker	Silva Mitchell (Belgium)		Patients perspective on wearables
Abstract	Bayraktar Deniz (Turkey)	OP0009-HPR	THE EFFECT OF AN 8-WEEK WATER EXERCISE PROGRAM ON ANAEROBIC EXERCISE CAPACITY IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS

Clinical Science Session - N105 / N106

Assessment and management of osteoporosis

Chair	Tam Lai-Shan (China, People's Republic of)		
Chair	Lems Willem F. (Netherlands)		
Speaker	Åkesson Kristina (Sweden)	SP0025	The use of biomarkers for osteoporosis in clinics
Speaker	Chapurlat Roland D. (France)	SP0026	Novel imaging techniques for assessing osteoporotic fracture risk
Speaker	Geusens Piet (Netherlands)	SP0027	Emerging therapies for osteoporosis
Abstract	Lems Willem (Netherlands)	OP0010	EFFECT OF DENOSUMAB COMPARED WITH RISEDRONATE IN GLUCOCORTICOID-TREATED INDIVIDUALS: RESULTS FROM THE 12-MONTH PRIMARY ANALYSIS OF A RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED STUDY

The Young Rheumatologist - N111 / N112

Systematic literature review: the link from science to clinical practice

Chair	Rivellese Felice (Italy)		
-------	-----------------------------	--	--

Chair	Gossec Laure (France)		
Speaker	Ramiro Sofia (Netherlands)	SP0028	Systematic literature review: where to start
Speaker	Landewé Robert B.M. (Netherlands)	SP0029	Linking science to clinical practice: from the systematic literature review to the formulation of recommendations
Speaker	Visser Karen (Netherlands)	SP0030	Beyond the recommendations: examples of systematic literature review in daily clinical practice
Abstract	HILLIQUIN Stéphane (France)	OP0011	DOES A VERY EARLY THERAPEUTIC INTERVENTION IN VERY EARLY ARTHRITIS / PRE-RHEUMATOID ARTHRITIS PATIENTS PREVENT THE ONSET OF RHEUMATOID ARTHRITIS: A SYSTEMATIC REVIEW AND METANALYSIS.

Joint Session Clinical / HPR / PARE Session - N115 / N116

EULAR Campaign: Don't Delay, Connect Today

Chair	Burmester Gerd Rüdiger (Germany)		
Chair	Bosworth Ailsa (United Kingdom)		
Speaker	Schwarting Andreas (Germany)		Ways to improve early diagnosis despite limited rheumatologists resources
Speaker	Mallen Christian D. (United Kingdom)	SP0031	How could GPs enhance the early diagnosis of rheumatic diseases
Speaker	Kirwan Paul (Ireland)	SP0032	The contribution of physiotherapists to early detection of inflammatory arthritis
Speaker	Church John (Ireland)	SP0033	The EULAR campaign and how organisations can get involved
Abstract	Bennett Louise (United Kingdom)	OP0012-PARE	RHEUMATOSPHERE: REACH NEW HEIGHTS IN DIAGNOSIS AND TREATMENT OF ARTHRITIS BY ENGAGING, EMPOWERING AND INSPIRING.

EULAR Projects in Paediatric Rheumatology - N117 / N118

Standing Committee Session on Paediatric Rheumatology

Chair	Avcin Tadej (Slovenia)		
Chair	Wouters Carine (Belgium)		

Speaker	Beresford Michael (United Kingdom)	SP0034	SHARE recommendations on systemic vasculitides
Speaker	Zulian Francesco (Italy)	SP0035	SHARE recommendations on juvenile scleroderma
Speaker	van Royen Annet (Netherlands)	SP0036	SHARE recommendations on juvenile dermatomyositis
Abstract	Hetlevik Siri (Norway)	OP0013	PULMONARY MANIFESTATIONS IN JUVENILE ONSET MIXED CONNECTIVE TISSUE DISEASE AFTER LONG-TERM DISEASE DURATION – A NORWEGIAN CASE-CONTROL STUDY
Abstract	Marteau Pauline (France)	OP0014	CONVENTIONAL RADIOGRAPHY IN JUVENILE IDIOPATHIC ARTHRITIS: JOINED RECOMMENDATIONS FROM THE FRENCH SOCIETIES FOR RHEUMATOLOGY, RADIOLOGY AND PEDIATRIC RHEUMATOLOGY

Practical Skills Session - N107 / N108

Crystals I

Chair	Pascual Eliseo (Spain)		
Chair	Tausche Anne Kathrin (Germany)		
Tutor	Norkuviene Eleonora (Lithuania)		
Tutor	Sivera Francisca (Spain)		
Tutor	Pimentao José (Portugal)		
Tutor	Oliviero Francesca (Italy)		

Practical Skills Session - N109 / N110

Ultrasound Basic I

Chair	Bruyn George A. W. (Netherlands)		
Chair	Kortekaas Marion (Netherlands)		
Speaker	Filippou Georgios (Italy)	SP0037	How to assess US elementary lessons in CPPD + demo
Speaker	Mandl Peter (Austria)	SP0038	How to assess cartilage in RA and pitfalls + demo

Speaker	Iagnocco Annamaria (Italy)	SP0039	How to evaluate the subtalar joint + demo
Speaker	Möller Ingrid (Spain)	SP0040	How to scan the hip - new approaches + demo
Tutor	Midtboell Oernbjerg Lykke (Denmark)		

🕒 Wednesday 14.06.2017 17:00 - 18:30

🏠 Abstract Session - Hall 8

🏠 Abstract Session: Still breaking news on TNF inhibitors in rheumatoid arthritis

Chair	Combe Bernard (France)		
Chair	Nam Jackie (United Kingdom)		
Abstract	Caporali R (-)	OP0015	INDUCTION OF REMISSION AND MAINTENANCE IN EARLY, AGGRESSIVE RHEUMATOID ARTHRITIS USING ADALIMUMAB IN COMBINATION WITH METHOTREXATE WITH OR WITHOUT SHORT-TERM HIGH-DOSE GLUCOCORTICOIDS: RESULTS OF A PHASE IV MULTICENTER, RANDOMIZED, DOUBLE BLIND STUDY (CLINTRIAL.GOV: NCT00480272)
Abstract	Turesson Carl (Sweden)	OP0016	COMPARATIVE EFFECTIVENESS AT 1 YEAR OF DIFFERENT ANTI-TNF DRUGS AS FIRST BIOLOGIC DMARD IN PATIENTS WITH RHEUMATOID ARTHRITIS – RESULTS FROM THE NATIONWIDE SWEDISH REGISTER
Abstract	Mariette Xavier (France)	OP0017	LACK OF PLACENTAL TRANSFER OF CERTOLIZUMAB PEGOL DURING PREGNANCY: RESULTS FROM CRIB, A PROSPECTIVE, POSTMARKETING, MULTICENTER, PHARMACOKINETIC STUDY
Abstract	Pham Thao (France)	OP0018	TOOL AND THRESHOLD PREDICTING A SUCCESSFUL BIOLOGICAL DMARDS TAPERING IN PATIENTS WITH RA REMISSION DETERMINATION
Abstract	Pope Janet (Canada)	OP0019	DMARD WITHDRAWAL IN RA PATIENTS ACHIEVING THERAPEUTIC RESPONSE WITH

CERTOLIZUMAB PEGOL COMBINED WITH DMARDS: INTERIM RESULTS FROM A CANADIAN OBSERVATIONAL RANDOMIZED STUDY

Abstract	Shimizu Tomohiro (United States)	OP0020	ASSESSMENT OF 3-MONTH CHANGES IN BONE MICROSTRUCTURE UNDER ANTI-TNFA THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS USING HR-PQCT
Abstract	Alten R (United Kingdom)	OP0021	EFFICACY AND SAFETY RESULTS OF A PHASE III STUDY COMPARING FKB327, AN ADALIMUMAB BIOSIMILAR, WITH HUMIRA®, THE ADALIMUMAB REFERENCE PRODUCT, IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS
Abstract	Reed George (United States)	OP0022	TNFI AND TOFACITINIB MONOTHERAPY AND COMPARATIVE EFFECTIVENESS IN CLINICAL PRACTICE: RESULTS FROM CORRONA REGISTRY

 **Abstract Session - Hall 7A**

 **Abstract Session: Progress in management of SpA**

Chair	Baraliakos Xenophon (Germany)		
Chair	de Hooge Manouk (Belgium)		
Abstract	van der Heijde Desiree (Netherlands)	OP0023	FOUR-YEAR IMAGING OUTCOMES IN AXIAL SPONDYLOARTHRITIS PATIENTS TREATED WITH CERTOLIZUMAB PEGOL, INCLUDING PATIENTS WITH ANKYLOSING SPONDYLITIS AND NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS
Abstract	Eklund Kari (Finland)	OP0024	DRUG TROUGH LEVELS AND ANTIDRUG ANTIBODIES IN NONSELECTED ANKYLOSING SPONDYLITIS PATIENTS USING SELF-INJECTED ANTITNF DRUGS
Abstract	Ruwaard Jill (Netherlands)	OP0025	ANTIDRUG ANTIBODIES DETECTION IS STRONGLY INFLUENCED BY THE TYPE OF ASSAY USED.
Abstract	Carron Philippe	OP0026	HIGH DRUG-FREE REMISSION IN

(Belgium)

EARLY PERIPHERAL
SPONDYLOARTHRITIS AFTER
INDUCTION THERAPY WITH
GOLIMUMAB.

Abstract	Devauchelle Agathe OP0029 (France)		EVALUATION OF THE EFFICIENCY OF SACROILIAC JOINTS CORTICOID INJECTIONS UNDER SCAN CONTROL AND ITS RELATIONSHIP WITH THE PRESENCE OR ABSENCE OF SACROILIITIS LESIONS SEEN ON MRI OF PATIENTS WITH SPONDYLOARTHRITIS
Abstract	Xu Dan (China)	OP0028	LOW DOSE IL-2 THERAPY CAN RECOVERY TH17/TREG CELL BALANCE IN PATIENTS WITH ANKYLOSING SPONDYLITIS
Abstract	Nikiphorou Elena (United Kingdom)	OP0030	INEQUITY IN BIOLOGIC DMARD PRESCRIPTION FOR SPA ACROSS THE GLOBE. RESULTS FROM THE ASAS COMOSPA STUDY.

Abstract Session - Hall 7B

Abstract Session: Early diagnosis of systemic sclerosis and myositis: Biomarkers and diagnostic tool

Chair	Denton Christopher (United Kingdom)		
Chair	Smith Vanessa (Belgium)		
Abstract	Moroncini Gianluca (Italy)	OP0031	DEVELOPMENT OF A NOVEL EPITOPE-BASED DIAGNOSTIC ASSAY FOR SYSTEMIC SCLEROSIS
Abstract	Fernandes Susana (Portugal)	OP0032	IS IMMUNOHISTOCHEMISTRY USEFUL TO PREDICT RESPONSE TO TREATMENT IN NECROTIZING MYOPATHIES?
Abstract	Diederichsen Louise (Denmark)	OP0033	SPECT- AND PET/CT IMAGING IN NEWLY ONSET IDIOPATHIC INFLAMMATORY MYOPATHY
Abstract	Mihai Carina (Romania)	OP0034	FACTORS ASSOCIATED WITH DISEASE PROGRESSION IN EARLY-DIAGNOSED PULMONARY ARTERIAL HYPERTENSION ASSOCIATED WITH SYSTEMIC SCLEROSIS: LONGITUDINAL DATA FROM THE DETECT COHORT
Abstract	Smith Vanessa (Belgium)	OP0035	PRELIMINARY ANALYSIS OF NAILFOLD CAPILLAROSCOPY IN THE VERY EARLY DIAGNOSIS OF

SYSTEMIC SCLEROSIS (VEDOSS):
THE CAPI-VEDOSS EXPERIENCE

Abstract	Kubo Satoshi (Japan)	OP0036	SEROLOGICAL BIOMARKERS OF ECM TURNOVER ARE ASSOCIATED WITH SKIN FIBROSIS AND LUNG INVOLVEMENT IN SYSTEMIC SCLEROSIS
Abstract	Ruaro Barbara (Italy)	OP0037	EVALUATION OF SKIN INVOLVEMENT IN SYSTEMIC SCLEROSIS PATIENTS BY USING TWO ULTRASOUND TRANSDUCERS WITH DIFFERENT FREQUENCY
Abstract	Pinal-Fernandez Iago (United States)	OP0038	MYOSITIS AUTOANTIBODIES OUTPERFORM CLINICAL SUBGROUP CLASSIFICATION IN PREDICTING MUSCLE WEAKNESS IN MYOSITIS PATIENTS

 **Abstract Session - N103 / N104**

 **Abstract Session: SLE, Sjögren's APS - clinical aspects**

Chair	Svenungsson Elisabet (Sweden)		
Chair	Bertsias Georges (Greece)		
Abstract	Bultink Irene (Netherlands)	OP0039	A POPULATION-BASED STUDY ON MORTALITY AND THE INFLUENCE OF MEDICATION USE IN 4356 PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND 21845 MATCHED CONTROLS FROM THE UNITED KINGDOM
Abstract	Devauchelle- Pensec Valérie (France)	OP0040	INTEGRATION OF SALIVARY-GLAND ULTRASONOGRAPHY IN CLASSIFICATION CRITERIA FOR PRIMARY SJÖGREN'S SYNDROME: AN INTERNATIONAL VIGNETTE-BASED STUDY.
Abstract	Moghaddam Bahar (Canada)	OP0041	ALL-CAUSE, CARDIOVASCULAR AND MALIGNANCY RELATED MORTALITY IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): A POPULATION-BASED STUDY
Abstract	Galindo-Izquierdo Maria (Spain)	OP0042	BACTEREMIA IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS FROM RELESSER REGISTRY: RISK FACTORS, CLINICAL AND MICROBIOLOGICAL CHARACTERISTICS AND OUTCOMES

Abstract	Liu Xiaoqing (China)	OP0043	THE NUMBER OF CIRCULATING REGULATORY T CELLS IS REDUCED AND LOW-DOSE IL-2 SELECTIVELY STIMULATES ITS PROLIFERATION IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
Abstract	Alunno Alessia (Italy)	OP0044	ANTIBODIES ANTI-SACCHAROMYCES CEREVISIAE IN PRIMARY SJÖGREN'S SYNDROME: PREVALENCE, CLINICAL ASSOCIATIONS AND POSSIBLE CROSS-REACTIVITY WITH DISEASE SPECIFIC AUTOANTIGENS
Abstract	Giannakou Ioanna (Sweden)	OP0045	PREDICTORS OF PERSISTENT DISEASE ACTIVITY AND PERSISTENT LONG QUIESCENCE IN SYSTEMIC LUPUS ERYTHEMATOSUS – RESULTS FROM THE HOPKINS LUPUS COHORT
Abstract	Lazzaroni Maria Grazia (Italy)	OP0046	RISK FACTORS FOR ADVERSE PREGNANCY OUTCOME IN ANTIPHOSPHOLIPID ANTIBODIES CARRIERS: RESULTS FROM A MULTICENTER ITALIAN COHORT OVER 20 YEARS OF EXPERIENCE

Abstract Session - South Auditorium

Abstract Session: Osteoporosis treatment gap, new options and new strategies

Chair	Chapurlat Roland D. (France)		
Chair	Lems Willem F. (Netherlands)		
Abstract	Sehgal Maanek (United States)	OP0047	OSTEOPOROTIC HIP FRACTURE PREVENTION: ARE WE IN A CRISIS ?
Abstract	Geusens Piet (Netherlands)	OP0048	ROMOSOZUMAB RAPIDLY REDUCES CLINICAL VERTEBRAL FRACTURE INCIDENCE: RESULTS FROM THE FRAME STUDY
Abstract	Makhzoum Anas (Canada)	OP0049	SYSTEMATIC REVIEW OF RANDOMIZED CONTROLLED TRIALS EVALUATING BISPHOSPHONATES FOR THE PREVENTION AND TREATMENT OF GLUCOCORTICOID- INDUCED OSTEOPOROSIS
Abstract	Spángéus Anna	OP0050	THE TREATMENT GAP AFTER

	(Sweden)		FRACTURE IN OSTEOPOROSIS PATIENTS IN SWEDEN
Abstract	Danila Maria (United States)	OP0051	THE ACTIVATING PATIENTS AT RISK FOR OSTEOPOROSIS STUDY: A RANDOMIZED TRIAL WITHIN THE GLOBAL LONGITUDINAL STUDY OF OSTEOPOROSIS IN WOMEN COHORT
Abstract	Haschka Judith (Austria)	OP0052	CORTICAL BONE LOSS IS AN EARLY FEATURE OF AXIAL SPONDYLOARTHRITIS
Abstract	Ruzickova Olga (Czech Republic)	OP0053	BONE LOSS AND CARDIOVASCULAR RISK IN PATIENTS WITH EROSION AND NON-EROSIVE HAND OSTEOARTHRITIS
Abstract	Sahuguet Julie (France)	OP0054	INCIDENCE OF VERTEBRAL FRACTURES IN EARLY SPONDYLOARTHRITIS : 5-YEAR PROSPECTIVE DATA OF THE DESIR COHORT

Health Professionals Session - N101 / N102

Rehabilitation and modern drug treatment – needs and challenges

Chair	Kennedy Norelee (Ireland)		
Chair	Smucrova Hana (Czech Republic)		
Speaker	Björk Mathilda (Sweden)	SP0041	Current needs for rehabilitation
Speaker	Catrina Florin (Romania)	SP0042	The art of juggling - a patient's perspective
Speaker	Brodin Nina (Sweden)		Physical activity: subjective and objective outcome
Speaker	Prior Yeliz (United Kingdom)	SP0043	Work retention rehabilitation in practice
Abstract	Esbensen Bente (Denmark)	OP0055-HPR	PREFERENCES FOR SELF-MANAGEMENT AND SUPPORT SERVICES IN PATIENTS WITH INFLAMMATORY ARTHRITIS: A DANISH NATIONWIDE CROSS-SECTIONAL STUDY

Abstract Session - N105 / N106

Abstract Session: Basic and clinical science in paediatric rheumatology

Chair	Beresford Michael		
-------	-------------------	--	--

(United Kingdom)

Chair	Koné-Paut Isabelle (France)		
Abstract	Fisher Corinne (United Kingdom)	OP0056	IL-23P19 IS UP-REGULATED IN MONOCYTE-DERIVED MACROPHAGES FROM HLA B27 POSITIVE PATIENTS WITH ENTHEISITIS RELATED ARTHRITIS
Abstract	Horneff Gerd (Germany)	OP0057	FLUORESCENCE OPTICAL IMAGING IN JUVENILE IDIOPATHIC POLYARTICULAR DISEASE BEFORE AND DURING ANTIRHEUMATIC TREATMENT
Abstract	Ruperto N (Italy)	OP0058	IMPROVEMENT IN PATIENT-REPORTED OUTCOMES IN PATIENTS WITH POLYARTICULAR-COURSE JUVENILE IDIOPATHIC ARTHRITIS AND INADEQUATE RESPONSE TO BIOLOGIC OR NON-BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS TREATED WITH SC ABATACEPT
Abstract	Domínguez Casas LC (Spain)	OP0059	GOLIMUMAB VERSUS TOCILIZUMAB FOR SEVERE AND REFRACTORY JUVENILE IDIOPATHIC ARTHRITIS-UVEITIS. MULTICENTER STUDY OF 33 PATIENTS
Abstract	Listing Miriam (Germany)	OP0060	HEALTH BEHAVIOR IN ADOLESCENTS WITH JUVENILE IDIOPATHIC ARTHRITIS- RESULTS OF THE INCEPTION COHORT OF NEWLY DIAGNOSED PATIENTS (ICON)
Abstract	Blay Gabriela (Brazil)	OP0061	DIFFUSE ALVEOLAR HEMORRHAGE: A MULTICENTER STUDY IN 847 CHILDHOOD-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS
Abstract	Fogel Olivier (France)	OP0062	ASSESSMENT OF BIOTHERAPIES' EFFICACY IN BLAU SYNDROME: DATA FROM AN INTERNATIONAL RETROSPECTIVE COHORT OF 23 CASES
Abstract	De Benedetti Fabrizio (Italy)	OP0063	CANAKINUMAB TREATMENT IN PATIENTS WITH COLCHICINE-RESISTANT FMF (CRFMF), HIDS/MKD AND TRAPS: EFFICACY IN THE 16 WEEKS RANDOMISED

Abstract Session - N111 / N112**Abstract Session: Impact of rheumatic diseases**

Chair	Boonen Annelies (Netherlands)		
Chair	Visser Karen (Netherlands)		
Abstract	Beauvais Catherine (France)	OP0064	CLEFS DE DOS: A UNIQUE PARE- LED VIDEO PROGRAM TO IMPROVE COPING SKILLS OF PEOPLE LIVING WITH AXIAL SPONDYLOARTHRITIS
Abstract	Goulenok Tiphaine (France)	OP0065	NURSE-LED VACCINATION PROGRAM DRAMATICALLY IMPROVES PNEUMOCOCCAL VACCINATION COVERAGE AMONG PATIENTS WITH CHRONIC INFLAMMATORY RHEUMATIC DISEASES: A PROSPECTIVE PILOT STUDY
Abstract	Guillen-Astete Carlos (Spain)	OP0066	THE PROBLEM BASED LEARNING APPLIED TO TEACHING RHEUMATOLOGICAL TOPICS AMONG NON RHEUMATOLOGY RESIDENTS
Abstract	van Dijk Bastiaan (Netherlands)	OP0067	DEVELOPMENT AND VALIDATION OF A MODEL TO FACILITATE RECOGNITION OF ARTHRITIS BY GENERAL PRACTITIONERS
Abstract	Yazdany Jinoos (United States)	OP0068	PRACTICES PARTICIPATING IN THE ACR'S RHEUMATOLOGY INFORMATICS SYSTEM FOR EFFECTIVENESS (RISE) NATIONAL REGISTRY SHOW IMPROVEMENTS IN QUALITY OF CARE
Abstract	Lee Jeong Seok (Korea, Republic Of)	OP0069	THE BURDEN OF ANKYLOSING SPONDYLITIS: A POPULATION BASED STUDY
Abstract	Rodrigues Manica Santiago (Portugal)	OP0070	THE ROLE OF INDIVIDUAL AND COUNTRY-LEVEL SOCIO- ECONOMIC FACTORS IN WORK PARTICIPATION IN PATIENTS WITH SPONDYLOARTHRITIS ACROSS 22 COUNTRIES WORLDWIDE: RESULTS FROM THE COMOSPA STUDY

Abstract	Norli Ellen Sauar (Norway)	OP0071	SICK LEAVE AFTER SIX MONTHS IN 664 PATIENTS WITH RECENT- ONSET INFLAMMATORY ARTHRITIS
----------	-------------------------------	--------	---

PARE Session - N115 / N116

Co-morbidities: Having one RMD is enough – we don't need anything else

Chair	Andersen Jeanette (United Kingdom)		
Chair	Mazuras Kristijonas (Lithuania)		
Speaker	Rusthoven Cindy (Netherlands)		The patient experience on comorbidities
Speaker	Gossec Laure (France)	SP0044	Screening for comorbidities in daily practice: who and how?
Speaker	Bosworth Ailsa (United Kingdom)	SP0045	Do patient organisations have a role to play in preventing co-morbidities?
Speaker	Garcia-Diaz Silvia (Spain)	SP0046	Prevention and the protective role of exercise and lifestyle interventions on comorbidities
Abstract	Proulx Laurie (Canada)	OP0072-PARE	PREGNANCY AND PARENTING WITH ARTHRITIS – DEVELOPING AN EDUCATIONAL RESOURCE FOR PATIENT BY PATIENTS

Abstract Session - N117 / N118

Abstract Session: Risk factors for developing diseases or comorbidities

Chair	Symmons Deborah (United Kingdom)		
Chair	Courvoisier Delphine (Switzerland)		
Abstract	van der Helm-van Mil Annette H.M. (Netherlands)	OP0073	PERFORMANCE OF THE EULAR DEFINITION OF ARTHRALGIA SUSPICIOUS FOR PROGRESSION TO RHEUMATOID ARTHRITIS – A LONGITUDINAL STUDY
Abstract	Chen Hsin-Hua (Taiwan, Province of China)	OP0074	ASSOCIATION BETWEEN A HISTORY OF MYCOBACTERIAL INFECTION AND THE RISK OF SJÖGREN'S SYNDROME: A NATIONWIDE, POPULATION-BASED CASE-CONTROL STUDY
Abstract	Lu Huifang (United States)	OP0075	OSTEOPOROTIC FRACTURE RISK ASSESSMENT USING FRAX FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION

Abstract	Aletaha Daniel (Austria)	OP0076	RISK OF DEVELOPING ADDITIONAL IMMUNE MEDIATED MANIFESTATIONS FOR PATIENTS WITH SYSTEMIC ARTHRITIDES
Abstract	Park Jun Won (Korea, Republic Of)	OP0077	PRIMARY PROPHYLAXIS FOR PNEUMOCYSTIS PNEUMONIA IN PATIENTS WITH RHEUMATIC DISEASE AND TREATED WITH PROLONGED, HIGH-DOSE STEROID: A RETROSPECTIVE COHORT STUDY WITH 12-YEAR OBSERVATION
Abstract	Tiosano Shmuel (Israel)	OP0078	THE LONG TERM PROGNOSTIC SIGNIFICANCE OF PULMONARY HYPERTENSION IN SARCOIDOSIS - A BIG DATA ANALYSIS
Abstract	Linauskas Asta (Denmark)	OP0079	BODY FAT PERCENTAGE AND WAIST CIRCUMFERENCE WERE ASSOCIATED WITH THE DEVELOPMENT OF RHEUMATOID ARTHRITIS – A DANISH FOLLOW-UP STUDY
Abstract	Kuo Chang-Fu (Taiwan, Province of China)	OP0080	RISK OF AUTISM SPECTRUM DISORDER IN CHILDREN BORN TO MOTHERS WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND RHEUMATOID ARTHRITIS IN TAIWAN

Abstract Session - N107 / N108

Abstract Session: Scleroderma, myositis and related syndromes, etiology, pathogenesis

Chair	Müller-Ladner Ulf (Germany)		
Chair	Siegert Elise (Germany)		
Abstract	Avouac Jérôme (France)	OP0081	PAN-PPAR AGONIST IVA337 IS EFFECTIVE IN THE PREVENTION OF EXPERIMENTAL LUNG FIBROSIS AND PULMONARY HYPERTENSION
Abstract	Corallo Claudio (Italy)	OP0082	FIBROSIS AND MICROANGIOPATHY ARE THE MAIN HISTOPATHOLOGICAL HALLMARKS OF SCLERODERMA-RELATED MYOPATHY
Abstract	Schnierer Janine (Switzerland)	OP0083	MOLECULAR TARGETED IMAGING BIOMARKERS FOR PERSONALIZED MEDICINE STRATEGIES IN SYSTEMIC SCLEROSIS-RELATED INTERSTITIAL LUNG DISEASE

Abstract	Stellato Mara (Switzerland)	OP0084	RESCUE FROM THE FAILING HEART IN SYSTEMIC SCLEROSIS, A NOVEL INSIGHT: TARGETING TGF- β /FRA2-DEPENDENT AUTOPHAGY
Abstract	Volkman Elizabeth (United States)	OP0085	LONGITUDINAL ANALYSIS OF THE GASTROINTESTINAL MICROBIOTA IN SYSTEMIC SCLEROSIS
Abstract	Pachera Elena (Switzerland)	OP0086	LONG NONCODING RNA H19X AS A NEW THERAPEUTIC TARGET FOR FIBROSIS
Abstract	Hirabayashi Megumi (Japan)	OP0087	PLATELET-SPECIFIC FLI1-KNOCKOUT MICE SHOW ACCELERATED WOUND CLOSURE ASSOCIATED WITH INCREASED MYOFIBROBLAST FORMATION IN THE INFLAMMATORY PHASE.
Abstract	Rudnik Michal (Switzerland)	OP0088	THE ROLE AND FUNCTION OF MONOCYTE-DERIVED FIBROBLAST-LIKE CELLS IN MULTI-ORGAN FIBROSIS IN SYSTEMIC SCLEROSIS

Abstract Session - N109 / N110

Abstract Session: Novel insights in inflammatory mediators

Chair	McInnes Iain (United Kingdom)		
Chair	Rodriguez -Carrio Javier (Spain)		
Abstract	Kim Sunhwa (United States)	OP0089	COMBINATION THERAPY OF SELECTIVE MMP9 AND TNF INHIBITORS ARE EFFICACIOUS IN THE MOUSE CIA MODEL OF RHEUMATOID ARTHRITIS
Abstract	Marchetti Carlo (United States)	OP0090	THE HUMAN SAFE NLRP3 INFLAMMASOME INHIBITOR OLT1177 SUPPRESSES JOINT INFLAMMATION IN MURINE MODELS OF EXPERIMENTAL ARTHRITIS
Abstract	Popp David (Germany)	OP0091	S100A8 TRIGGERS A NOVEL IMMUNE-REGULATORY MECHANISM IN DEVELOPING DENDRITIC CELLS
Abstract	Cavalli Giulio (Italy)	OP0092	INTERLEUKIN 37 REVERSES THE METABOLIC COST OF INFLAMMATION, INCREASES OXIDATIVE RESPIRATION AND IMPROVES EXERCISE TOLERANCE

Abstract	Le Goff Benoît (France)	OP0093	IL-38 OVEREXPRESSION INDUCES ANTI-INFLAMMATORY EFFECTS IN MICE ARTHRITIS MODELS AND IN HUMAN MACROPHAGES IN VITRO
Abstract	Mulhearn Ben (United Kingdom)	OP0094	DEVELOPMENT OF A 37-CHANNEL MASS CYTOMETRY (CYTOF) PANEL TO PREDICT TREATMENT RESPONSE IN RHEUMATOID ARTHRITIS
Abstract	Md Yusof Md Yuzairul (United Kingdom)	OP0095	PREDICTION OF CONNECTIVE TISSUE DISEASE IN AN AT-RISK COHORT USING A NOVEL INTERFERON STIMULATED GENE EXPRESSION SCORE
Abstract	Mendoza Fabian (United States)	OP0096	INTERFERON SIGNATURE IN SYSTEMIC SCLEROSIS LUNG MICROVASCULAR ENDOTHELIAL CELLS.

🕒 Thursday 15.06.2017 08:15 - 09:45

🏠 Basic and Translational Science Session - South Auditorium

🏠 Cytokines and chemokines

Chair	Rovere-Querini Patrizia (Italy)		
Chair	Straub Rainer H. (Germany)		
Speaker	Rönblom Lars (Sweden)	SP0047	Type I interferon system in autoimmunity
Speaker	Tas Sander W. (Netherlands)	SP0048	Targeting of angiogenic molecules
Speaker	Pisetsky David S. (United States)	SP0049	DNA aggregates as alarmins
Abstract	Bodewes Iris (Netherlands)	OP0097	SYSTEMIC IFN TYPE I AND TYPE II SIGNATURES IN PRIMARY SJÖGREN'S SYNDROME REVEAL DIFFERENCES IN DISEASE SEVERITY

🕒 Thursday 15.06.2017 10:15 - 11:45

🏠 WIN & HOT Session - Hall 6

🏠 WIN & HOT Session

Chair	Branco Jaime C. (Portugal)		
-------	-------------------------------	--	--

Chair	Studenic Paul (Austria)	
Speaker	Martinoli Carlo (Italy)	WIN Session: What is the use of imaging for regional pain syndromes
Speaker	Hasset Afton (United States)	WIN Session: Fibromyalgia

Abstract Session - Hall 8

Abstract Session: Progress in biological treatment of RA

Chair	Fleischmann Roy (United States)		
Chair	Emery Paul (United Kingdom)		
Abstract	Dörner Thomas (Belgium)	OP0098	REMISSION AND MAINTENANCE OF EFFICACY IN A PHASE 2B STUDY OF VOBARILIZUMAB, AN ANTI-INTERLEUKIN 6 RECEPTOR NANOBODY, IN PATIENTS WITH MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS DESPITE TREATMENT WITH METHOTREXATE
Abstract	Galeazzi Mauro (Switzerland)	OP0099	SAFETY, TOLERABILITY AND INITIAL SIGNS OF EFFICACY OF THE FULLY HUMAN IMMUNOCYTOKINE DEKAVIL (F8IL10): A NOVEL THERAPEUTIC APPROACH FOR RHEUMATOID ARTHRITIS
Abstract	Wadström Hjalmar (Sweden)	OP0100	OVERALL CANCER RISK IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH TNF INHIBITORS, TOCILIZUMAB, ABATACEPT, OR RITUXIMAB
Abstract	Simon TA (United States)	OP0101	RISK OF OPPORTUNISTIC INFECTIONS IN PATIENTS WITH RHEUMATOID ARTHRITIS INITIATING ABATACEPT: ANALYSIS OF ALL AVAILABLE CLINICAL TRIAL DATA
Abstract	Strand Vibeke (United States)	OP0102	PATIENT REPORTED BENEFITS OF SARILUMAB MONOTHERAPY VERSUS ADALIMUMAB MONOTHERAPY IN ADULT PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS
Abstract	Dasgupta Bidisha (United States)	OP0103	THE EFFECT OF SIRUKUMAB PLUS METHOTREXATE ON CIRCULATING BIOMARKERS OF JOINT DESTRUCTION IN MODERATE TO

SEVERE RHEUMATOID ARTHRITIS PATIENTS FROM THE SIRROUND-D PHASE 3 STUDY

Abstract	URATA Yukitomo (Japan)	OP0104	TOCILIZUMAB: DOSE REDUCTION OR INTERVAL SPACING – WHICH PROVES A BETTER TAPERING STRATEGY FOR RHEUMATOID ARTHRITIS IN CLINICAL REMISSION?
----------	---------------------------	--------	---

Abstract	Mohan Shalini (United States)	OP0105	LONG-TERM SAFETY OF TOCILIZUMAB FROM LARGE CLINICAL TRIAL AND POSTMARKETING POPULATIONS
----------	----------------------------------	--------	---

Abstract Session - Hall 7A

Abstract Session: PsA: A fascinating disease

Chair	Siebert Stefan (United Kingdom)
-------	------------------------------------

Chair	Carubbi Francesco (Italy)
-------	------------------------------

Abstract	Kristensen Lars Erik (Denmark)	OP0106	THE IMPACT OF COMORBIDITIES ON EFFECT AND DISCONTINUATION OF TUMOUR NECROSIS FACTOR INHIBITOR THERAPY IN PSORIATIC ARTHRITIS: A POPULATION-BASED COHORT STUDY
----------	-----------------------------------	--------	---

Abstract	Conaghan Philip (United Kingdom)	OP0107	PAIN STILL REMAINS A HIGH UNMET NEED AMONG PSORIATIC ARTHRITIS PATIENTS RECEIVING EXISTING BIOLOGIC TREATMENT: RESULTS FROM A MULTI NATIONAL REAL-WORLD SURVEY
----------	-------------------------------------	--------	--

Abstract	Landewé Robert (Netherlands)	OP0108	INHIBITION OF RADIOGRAPHIC PROGRESSION IN PSORIATIC ARTHRITIS BY ADALIMUMAB INDEPENDENT OF THE CONTROL OF CLINICAL DISEASE ACTIVITY
----------	---------------------------------	--------	---

Abstract	Michelsen Brigitte (Norway)	OP0109	IS MENTAL HEALTH COMPARABLE IN RHEUMATOID AND PSORIATIC ARTHRITIS PATIENTS? A COMPARATIVE ANALYSIS OF REAL LIFE LONGITUDINAL DATA FROM THE NOR-DMARD STUDY
----------	--------------------------------	--------	--

Abstract	Jani Meghna (United Kingdom)	OP0110	ASSOCIATION OF PHARMACOLOGICAL BIOMARKERS WITH TREATMENT RESPONSE AND LONG-TERM DISABILITY IN PATIENTS WITH PSORIATIC
----------	---------------------------------	--------	---

ARTHRITIS: RESULTS FROM
OUTPASS

Abstract	Eder Lihi (Canada)	OP0111	THE ASSOCIATION BETWEEN SONOGRAPHIC ENTHESITIS AND RADIOGRAPHIC JOINT DAMAGE IN PSORIATIC ARTHRITIS
Abstract	Jørgensen Tanja (Denmark)	OP0112	IN PSORIATIC ARTHRITIS FATIGUE IS DRIVEN BY INFLAMMATION, DISEASE DURATION, AND CHRONIC PAIN: AN OBSERVATIONAL DANBIO REGISTRY STUDY
Abstract	Ortolan Augusta (Italy)	OP0113	METABOLIC SYNDROME AND LIVER STIFFNESS IN PSORIATIC ARTHRITIS AND PSORIASIS PATIENTS: A CASE-CONTROL STUDY.

 **Abstract Session - Hall 7B** **Abstract Session: More or less imaging in axial SpA?**

Chair	Sampaio-Barros Percival D. (Brazil)		
Chair	Marzo-Ortega Helena (United Kingdom)		
Abstract	de Koning Anoek (Netherlands)	OP0114	LOW DOSE COMPUTED TOMOGRAPHY DETECTS MORE PROGRESSION OF BONE FORMATION IN COMPARISON TO CONVENTIONAL RADIOGRAPHY IN PATIENTS WITH ANKYLOSING SPONDYLITIS: RESULTS FROM THE SIAS COHORT
Abstract	dougados maxime (France)	OP0115	EVALUATION OF THE CHANGES IN STRUCTURAL DAMAGE IN AXIAL SPONDYLOARTHRITIS ON PLAIN PELVIC RADIOGRAPHS: THE 5 YEARS DATA OF THE DESIR COHORT.
Abstract	Dougados Maxime (France)	OP0116	SWITCH FROM NON-RADIOGRAPHIC TO RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS IS HIGHLY DEPENDENT OF BASELINE OBJECTIVE SIGNS OF INFLAMMATION: 5 YEAR DATA OF THE DESIR COHORT
Abstract	Weber Ulrich (Denmark)	OP0117	BONE MARROW OEDEMA IN SACROILIAC JOINTS OF YOUNG

ATHLETES SHOWS MOST
FREQUENTLY IN THE POSTERIOR
INFERIOR ILIUM

Abstract Protopopov Mikhail OP0118
(Germany)

IMPACT OF RADIOGRAPHIC
DAMAGE IN THE SACROILIAC
JOINTS ON FUNCTION AND SPINAL
MOBILITY IN PATIENTS WITH AXIAL
SPONDYLOARTHRITIS: RESULTS
FROM THE GERMAN
SPONDYLOARTHRITIS INCEPTION
COHORT

Abstract Meghnathi Bhowmik OP0119
(France)

EVALUATION OF THE PREDICTIVE
VALIDITY OF THE ASAS AXIAL
SPONDYLOARTHRITIS CRITERIA IN
THE DESIR COHORT

Abstract Akar Servet OP0120
(Turkey)

THE ROLE OF SMOKING IN THE
DEVELOPMENT AND
PROGRESSION OF STRUCTURAL
DAMAGE IN PATIENTS WITH
ANKYLOSING SPONDYLITIS: THE
PRELIMINARY RESULTS OF A
SYSTEMATIC REVIEW AND META-
ANALYSIS.

Abstract Maksymowych OP0121
Walter (Canada)

VALIDATION OF MRI STRUCTURAL
LESIONS USING COMPUTED
TOMOGRAPHY IN PATIENTS WITH
AXIAL SPONDYLOARTHRITIS

Abstract Session - N103 / N104

Abstract Session: Clinical and therapeutical news in systemic sclerosis

Chair Gabrielli Armando
(Italy)

Chair Radstake Timothy
R. (Netherlands)

Abstract Johnson Sindhu OP0122
(Canada)

VENOUS THROMBOEMBOLISM IN
SYSTEMIC SCLEROSIS:
PREVALENCE, RISK FACTORS AND
IMPACT ON SURVIVAL

Abstract Herrick Ariane OP0123
(United Kingdom)

PREDICTION OF PROGRESSIVE
SKIN THICKENING IN EARLY
DIFFUSE SYSTEMIC SCLEROSIS
USING THREE-MONTHLY SKIN
SCORES FROM THE EUROPEAN
SCLERODERMA OBSERVATIONAL
STUDY (ESOS)

Abstract Volkmann Elizabeth OP0124
(United States)

TREATMENT WITH
CYCLOPHOSPHAMIDE FOR
SYSTEMIC SCLEROSIS-RELATED
INTERSTITIAL LUNG DISEASE

			DOES NOT IMPROVE SURVIVAL AFTER 12 YEARS OF FOLLOW UP
Abstract	Yang Xinlei (China)	OP0125	MORTALITY IN PATIENTS WITH DERMATOMYOSITIS/POLYMYOSITIS IN A CHINESE MEDICAL CENTRE
Abstract	Spiera Robert (United States)	OP0126	A PHASE 2 STUDY OF SAFETY AND EFFICACY OF ANABASUM (JBT-101) IN SYSTEMIC SCLEROSIS
Abstract	Hashimoto Naoaki (Japan)	OP0127	TEN YEARS FOLLOW-UP OF GASTROINTESTINAL INVOLVEMENT BY THE SMALL INTESTINAL CLEARANCE IN PATIENTS WITH SYSTEMIC SCLEROSIS
Abstract	Poindron Vincent (France)	OP0128	DETECTION OF SUB-CLINICAL DIFFUSE MYOCARDIAL FIBROSIS BY NATIVE T1 MAPPING MAGNETIC RESONANCE IMAGING IN A PROSPECTIVE SYSTEMIC SCLEROSIS COHORT
Abstract	Fretheim Håvard (Norway)	OP0129	MYCOPHENOLATE MOFETIL VERSUS CYCLOPHOSPHAMIDE IN SCLERODERMA-RELATED INTERSTITIAL LUNG DISEASE IN A REAL LIFE SCENARIO

Abstract Session - South Auditorium

Abstract Session: Vasculitis Clinical and Pathogenic Highlights

Chair	Luqmani Raashid (United Kingdom)		
Chair	Molloy Eamonn S. (Ireland)		
Abstract	Wechsler Michael (United States)	OP0130	MEPOLIZUMAB FOR THE TREATMENT OF PATIENTS WITH EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS: A PHASE III RANDOMISED, PLACEBO-CONTROLLED TRIAL
Abstract	Stone J (United States)	OP0131	OPTIMAL DOSE OF TOCILIZUMAB FOR THE TREATMENT OF GIANT CELL ARTERITIS: EFFICACY, SAFETY, AND EXPOSURE-EFFICACY ANALYSIS FROM GIACTA
Abstract	Fu Xiaolan (China)	OP0132	LOW-DOSE INTERLEUKIN-2 SELECTIVELY RESTORE REGULATORY T CELL NUMBERS IN PATIENTS WITH BD
Abstract	Jese Rok (Slovenia)	OP0133	COLOUR DOPPLER ULTRASONOGRAPHY OF FACIAL

AND OCCIPITAL ARTERIES IN PATIENTS WITH GIANT CELL ARTERITIS: THE FREQUENCY OF INVOLVEMENT AND THE ROLE OF THEIR ASSESSMENT IN DAILY PRACTICE: A PROSPECTIVE STUDY

Abstract Comarmond Cloé (France) OP0134

LONG TERM OUTCOME AND PROGNOSIS FACTORS OF COMPLICATIONS IN TAKAYASU'S ARTERITIS: MULTICENTER STUDY OF 318 PATIENTS

Abstract Vegas Revenga Nuria (Spain) OP0135

TOCILIZUMAB IN GIANT CELL ARTERITIS: GIAC TA TRIAL VERSUS A SERIES OF PATIENTS FROM CLINICAL PRACTISE

Abstract Hocevar Alojzija (Slovenia) OP0136

MICRORNA-223-3P EXPRESSION IN AFFECTED SKIN OF ADULT IGA VASCULITIS CORRELATES WITH THE SEVERITY OF SKIN INVOLVEMENT

Abstract Cornec Divi (United States) OP0137

AUTO-REACTIVE B CELLS ESCAPE PERIPHERAL TOLERANCE CHECKPOINTS IN PATIENTS WITH PR3-ANCA ASSOCIATED VASCULITIS

Abstract Session - N101 / N102

HPR Abstract Session: Mind over matter - patients perspectives

Chair Prior Yeliz (United Kingdom)

Chair Domjan Andrea (Hungary)

Abstract Selten Ellen (Netherlands) OP0138-HPR

DO PATIENTS' TREATMENT BELIEFS AFFECT TREATMENT CHOICES IN KNEE AND HIP OSTEOARTHRITIS?

Abstract Hewlett Sarah (United Kingdom) OP0139-HPR

REDUCING ARTHRITIS FATIGUE - CLINICAL TEAMS (RAFT) USING COGNITIVE-BEHAVIOURAL APPROACHES: AN RCT

Abstract Nealon Lennox Noirin (Ireland) OP0140-HPR

ACCEPTANCE AND COMMITMENT THERAPY: A RETROSPECTIVE STUDY OF OUTCOMES FROM A HOSPITAL-BASED, GROUP, PAIN REHABILITATION PROGRAMME IN RHEUMATOLOGY SERVICES IN THE SOUTH EAST OF IRELAND

Abstract Peter Wilfred (Netherlands) OP0141-HPR

AN INNOVATE MEASUREMENT INSTRUMENT TO ASSESS ACTIVITY

LIMITATIONS IN HIP AND KNEE OSTEOARTHRITIS: THE COMPUTERIZED ANIMATED ACTIVITY QUESTIONNAIRE (AAQ) AND ITS PSYCHOMETRIC PROPERTIES.

Abstract	Geenen Rinie (Netherlands)	OP0142-HPR	THE POTENTIAL BUFFERING ROLE OF SELF-EFFICACY AND PAIN ACCEPTANCE AGAINST INVALIDATION IN RHEUMATIC DISEASES
Abstract	Björk Mathilda (Sweden)	OP0143-HPR	DISABILITY IN THE FEET RELATED TO PARTICIPATION IN DAILY LIFE IN PATIENTS WITH EARLY RA – AN INTERVIEW STUDY IN THE SWEDISH TIRA PROJECT.
Abstract	Henriques Marta (Portugal)	OP0144-HPR	“IT CAN’T BE ZERO”: A QUALITATIVE STUDY OF PATIENTS’ PERSPECTIVE ON PATIENT GLOBAL ASSESSMENT IN RHEUMATOID ARTHRITIS
Abstract	Mathijssen Elke (Netherlands)	OP0145-HPR	RHEUMATOID ARTHRITIS PATIENTS’ SUPPORT NEEDS REGARDING MEDICATION USE AND THEIR PERSPECTIVES ON THE APPLICABILITY OF EHEALTH INTERVENTIONS TO ADDRESS THOSE NEEDS: A FOCUS GROUP STUDY

Abstract Session - N105 / N106

Abstract Session: RA: really a systemic disease?

Chair	Nurmohamed Michael (Netherlands)		
Chair	Atzeni Fabiola (Italy)		
Abstract	Filhol Elisabeth (France)	OP0146	DECREASE IN CARDIOVASCULAR EVENT EXCESS RISK IN RHEUMATOID ARTHRITIS SINCE 2000': A META- ANALYSIS OF CONTROLLED STUDIES.
Abstract	Skielta Mattias (Sweden)	OP0147	TRENDS IN MORTALITY, CO-MORBIDITY AND TREATMENT AFTER ACUTE MYOCARDIAL INFARCTION IN PATIENTS WITH RHEUMATOID ARTHRITIS 1998-2013
Abstract	Sparks Jeffrey (United States)	OP0148	IMPACT OF A CARDIOVASCULAR EVENT ON DMARD TREATMENT

AMONG PATIENTS WITH
RHEUMATOID ARTHRITIS,
PSORIATIC ARTHRITIS, OR
PSORIASIS

Abstract	Holmqvist Marie (Sweden)	OP0149	MORTALITY IN NEW-ONSET RHEUMATOID ARTHRITIS - HAS MODERN RHEUMATOLOGY HAD AN IMPACT?
Abstract	Jonge A.V. de Jonge (Netherlands)	OP0150	PARADOXICAL EFFECT OF BIOLOGICAL DMARDS IN RHEUMATOID ARTHRITIS PATIENTS WITH OVERWEIGHT AND OBESITY: LESS OFTEN CLINICAL REMISSION, BUT ALSO LESS RADIOLOGICAL DAMAGE
Abstract	Neumann Thomas (Germany)	OP0151	DOCOSAHEXAENOIC ACID TREATMENT OF RHEUMATOID ARTHRITIS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED, CROSS-OVER STUDY
Abstract	Onishi Akira (Japan)	OP0152	A LONGITUDINAL STUDY OF THE EFFECTS OF DISEASE ACTIVITY ON RENAL FUNCTION IN PATIENTS WITH RHEUMATOID ARTHRITIS UTILIZING LINEAR MIXED EFFECT MODELS - ANSWER COHORT STUDY -
Abstract	Subesinghe Sujith (United Kingdom)	OP0153	RECURRENT INFECTIONS IN RHEUMATOID ARTHRITIS PATIENTS, RESULTS FROM THE BSRBR

Abstract Session - N111 / N112

Abstract Session: Advances in RA and SpA pathophysiology

Chair	Ciccia Francesco (Italy)		
Chair	Hasseli Rebecca (Germany)		
Abstract	Ospelt Caroline (Switzerland)	OP0154	ALTERED LYMPH NODE STROMAL CELLS DURING THE EARLIEST PHASES OF RHEUMATOID ARTHRITIS
Abstract	Shi Maohua (China)	OP0155	MDM2-MEDIATED SUMOYLATION OF P53 CONTRIBUTES TO THE MIGRATION AND INVASION OF FIBROBLAST-LIKE SYNOVIOCYTES FROM PATIENTS WITH RHEUMATOID ARTHRITIS

Abstract	Bergström Beatrice (Sweden)	OP0156	METHOTREXATE INCREASES EXPRESSION OF THE CELL CYCLE REGULATORS LBH AND P21 AND REDUCES FIBROBLAST-LIKE SYNOVIOCYTE PROLIFERATION AFTER MITOGEN STIMULATION
Abstract	Pajak Agnieszka (Switzerland)	OP0157	APOPTOSIS RESISTANCE OF SYNOVIAL FIBROBLASTS OF PATIENTS WITH RHEUMATOID ARTHRITIS IS REGULATED BY THE LONG NON-CODING RNA FAS-AS1
Abstract	Arellano-Martinez Adolfo (Mexico)	OP0158	PREVALENCE OF IMMUNIZATION OF PATIENTS WITH AUTOIMMUNE DISEASE IN MEXICO
Abstract	Van Tok Melissa (Netherlands)	OP0159	THE INITIATION, BUT NOT THE PERSISTENCE, OF EXPERIMENTAL SPONDYLOARTHRITIS IN HLA- B27/HUB2M TRANSGENIC RATS IS CRUCIALLY DEPENDENT ON THE IL-23 AXIS
Abstract	Jacques Peggy (Belgium)	OP0160	GUT-DERIVED TNF AS RISK FACTOR FOR THE DEVELOPMENT OF SACROILIAC INFLAMMATION
Abstract	Robin-Jagerschmidt Catherine (France)	OP0161	THE JAK1 SELECTIVE INHIBITOR FILGOTINIB REGULATES BOTH ENTHESIS AND COLON INFLAMMATION IN A MOUSE MODEL OF PSORIATIC ARTHRITIS

PARE Session - N115 / N116

Bringing rheumatology research to the next level: Addressing the main challenges of patient partnerships in research and health care service design

Chair	Horonjeff Jennifer (United States)		
Chair	Clausen Jürgen (Germany)		
Speaker	Orbai Ana-Maria (United States)	SP0050	Ensuring representativeness of the patients' perspectives in the final results generated from clinical research – challenges from the perspective of researchers
Speaker	Mateus Elsa (Portugal)	SP0051	Becoming a patient research partner in the field of rheumatology. My expectations and the challenges of being educated and taken seriously
Speaker	Lempp Heidi (United Kingdom)	SP0052	Building patient partnerships in health care service design and delivery
Abstract	Stones Simon	OP0162-PARE	AN EXPLORATION OF LIVED

(United Kingdom)

EXPERIENCES AMONGST ADULTS WITH RHEUMATOID ARTHRITIS USING AN ONLINE RESEARCH COMMUNITY PLATFORM: A PILOT STUDY.

Abstract	Clausen Jürgen (Germany)	OP0163-PARE	INVIGORATING THE PRINCIPLE OF PARTICIPATORY RESEARCH IN GERMANY - SETUP OF A TRAINING COURSE FOR PATIENT REPRESENTATIVES
----------	-----------------------------	-------------	--

Abstract Session - N117 / N118

Abstract Session: Osteoarthritis: new horizons for treatment

Chair	Zhang Weiya (United Kingdom)		
Chair	not confirmed yet		
Abstract	Bowes Michael (United Kingdom)	OP0164	OPTIMIZING RECRUITMENT CRITERIA FOR AN OSTEOARTHRITIS STRUCTURE MODIFICATION TRIAL: DATA FROM THE OAI
Abstract	Bay-Jensen Anne (Denmark)	OP0165	A NEOEPIOTOPE FRAGMENT OF C-REACTIVE PROTEIN IS PROGNOSTIC OF RADIOGRAPHIC KNEE OA
Abstract	Yazici Y. (United States)	OP0166	RADIOGRAPHIC OUTCOMES FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY OF A NOVEL, INTRA-ARTICULAR, INJECTABLE, WNT PATHWAY INHIBITOR (SM04690) IN THE TREATMENT OF OSTEOARTHRITIS OF THE KNEE: WEEK 26 INTERIM ANALYSIS
Abstract	Stevens Randall (United States)	OP0167	EFFICACY AND SAFETY OF CNTX-4975 IN SUBJECTS WITH MODERATE TO SEVERE OSTEOARTHRITIS KNEE PAIN: 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY
Abstract	Kloppenburg Margreet (Netherlands)	OP0168	A PHASE 2A, PLACEBO-CONTROLLED, RANDOMIZED STUDY OF ABT-981, AN ANTI-INTERLEUKIN-1ALPHA AND -1BETA DUAL VARIABLE DOMAIN IMMUNOGLOBULIN, TO TREAT EROSIIVE HAND OSTEOARTHRITIS (EHOA)

Abstract	Zhu Zhaohua (Australia)	OP0169	EARLY OSTEOPHYTES DETECTED BY MRI ARE ASSOCIATED WITH CHANGES IN KNEE PAIN AND STRUCTURES IN OLDER ADULTS: A POPULATION-BASED COHORT STUDY
Abstract	Veenbrink Anne (Netherlands)	OP0170	LEPTIN AND ADIPONECTIN MEDIATE THE ASSOCIATION BETWEEN BODY MASS INDEX AND HAND AND KNEE OSTEOARTHRITIS
Abstract	Wang Kang (Australia)	OP0171	SIGNAL INTENSITY ALTERATION WITHIN INFRAPATELLAR FAT PAD PREDICTS TOTAL KNEE ARTHROPLASTY WITHIN FOUR YEARS: DATA FROM THE OSTEOARTHRITIS INITIATIVE

Abstract Session - N107 / N108

Abstract Session: Cellular drivers of inflammation in rheumatic disease

Chair	Elewaut Dirk (Belgium)		
Chair	Fonseca Joao Eurico (Portugal)		
Abstract	Balzaretti Giulia (Netherlands)	OP0172	EXPANDED T-CELL CLONES PRESENT IN SYNOVIUM AT ONSET OF RHEUMATOID ARTHRITIS ARE ALREADY PRESENT IN THE SYNOVIUM IN THE SEROPOSITIVE "AT RISK" STAGE.
Abstract	Klarenbeek Paul (Netherlands)	OP0173	DOMINANT B-CELL RECEPTOR CLONES IN PERIPHERAL BLOOD PREDICT ONSET OF ARTHRITIS IN INDIVIDUALS AT RISK FOR RHEUMATOID ARTHRITIS
Abstract	Skriner Karl (Germany)	OP0174	NEW PROTEIN ARRAY TECHNOLOGY IDENTIFIES RITUXIMAB TREATED NON RESPONDER RHEUMATOID ARTHRITIS PATIENTS ARE GENERATING A NEW AUTOANTIBODY REPERTOIRE
Abstract	Corsiero Elisa (United Kingdom)	OP0175	CHARACTERIZATION OF NOVEL STROMAL-DERIVED AUTOANTIGENS RECOGNIZED BY RA SYNOVIAL MONOCLONAL ANTIBODIES.
Abstract	Elewaut Dirk (Belgium)	OP0176	THE PARACASPASE MALT1 PLAYS A CENTRAL ROLE IN THE PATHOGENESIS OF RHEUMATOID

ARTHRITIS

Abstract	Scherer Hans (Netherlands)	OP0177	N-GLYCOSYLATION SITES IN THE VARIABLE DOMAIN OF B CELL RECEPTORS SPECIFIC FOR CITRULLINATED ANTIGENS
Abstract	Crowley Thomas (United Kingdom)	OP0178	FIBROBLAST PRIMING IS COMMON TO MANY SITES, AND PSORIATIC SKIN FIBROBLASTS MAY ACQUIRE INFLAMMATORY MEMORY
Abstract	Biavasco Riccardo (Italy)	OP0179	BRAFV600E PROMOTES MYELOID SKEWING IN MULTISYSTEMIC LANGERHANS CELL HISTIOCYTOSIS HUMANIZED MOUSE MODEL

Abstract Session - N109 / N110

Abstract Session: Joint health & joint damage: a tale of three tissues

Chair	Beier Frank (Canada)		
Chair	Ioan-Facsinay Andreea (Netherlands)		
Abstract	Amantini David (France)	OP0180	PHARMACOLOGICAL CHARACTERIZATION OF THE ADAMTS-5 INHIBITOR GLPG1972: AN ORAL ANTI-CATABOLIC AGENT FOR THE TREATMENT OF OSTEOARTHRITIS
Abstract	Fahmi Hassan (Canada)	OP0181	DELETION OF THE PROSTAGLANDIN D2 RECEPTOR DP1 EXACERBATES AGING-ASSOCIATED AND INSTABILITY-INDUCED OSTEOARTHRITIS
Abstract	McGonagle Dennis (United Kingdom)	OP0182	CONVERGENCE OF JOINT REPAIR AND PAIN PATHWAYS VIA NERVE GROWTH FACTOR AND P75 EXPRESSING MESENCHYMAL STEM CELLS- A NOVEL EXPLANATION FOR OSTEOARTHRITIS PROGRESSION WITH ANTI-NGF IN OSTEOARTHRITIS
Abstract	Ashraf Sadaf (United Kingdom)	OP0183	CORDYCEPIN, A NOVEL COMPOUND, REDUCES KNEE JOINT PATHOLOGY AND PAIN IN THE MONOSODIUM IODOACETATE (MIA) RAT MODEL OF OSTEOARTHRITIS

Abstract	Najm Aurelie (France)	OP0184	IMSYC IMMUNOLOGIC SYNOVITIS SCORE: A NEW HISTOLOGICAL SCORE FOR DISCRIMINATING INFLAMMATORY AND NON-INFLAMMATORY ARTHRITIS.
Abstract	Cuervo Aguilera Andrea (Spain)	OP0185	IMMUNOHISTOLOGIC STUDY OF SYNOVITIS FROM PATIENTS WITH UNDIFFERENTIATED ARTHRITIS WHO EVOLVED TO RHEUMATOID ARTHRITIS OR PSORIATIC ARTHRITIS AFTER FOLLOW-UP.
Abstract	Mediero Aranzazu (Spain)	OP0186	TENOFOVIR, A NUCLEOSIDE ANALOG REVERSE TRANSCRIPTASE INHIBITOR FOR TREATMENT OF HIV, PROMOTES OSTEOCLAST DIFFERENTIATION AND BONE LOSS IN VIVO IN A MECHANISM DEPENDING ON ATP RELEASE AND ADENOSINE, AND DIPYRIDAMOLE MAY BE A USEFUL TREATMENT TO REVERT THE EFFECTS
Abstract	Wiebe Edgar (Germany)	OP0187	TRANSGENIC DISRUPTION OF GLUCOCORTICOID-SIGNALING IN MATURE OSTEOBLASTS AND OSTEOCYTES ATTENUATES STRUCTURAL BONE DAMAGE IN A LONG-TERM MURINE K/BXN SERUM-INDUCED ARTHRITIS MODEL

Thursday 15.06.2017 11:45 - 13:30

Poster Tour - Poster Area

HPR Poster Tour: From top to toe; health professional practice

Chair	Moe Rikke Helene (Norway)		
Chair	Rimac Branka (Croatia)		
Abstract	Tenten-Diepenmaat Marloes (Netherlands)	THU0750-HPR	THE EFFECTIVENESS OF THERAPEUTIC FOOTWEAR IN PATIENTS WITH RHEUMATOID ARTHRITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS
Abstract	Gijon-Nogueron Gabriel (Spain)	THU0751-HPR	EFFECTIVENESS OF FOOT ORTHOSIS IN PATIENTS WITH RHEUMATOID ARTHRITIS RELATED TO QUALITY OF LIFE AND PAIN. A SYSTEMATIC REVIEW AND META-

			ANALYSIS.
Abstract	Selten Ellen (Netherlands)	THU0752-HPR	DEVELOPMENT OF THE "TREATMENT BELIEFS IN KNEE AND HIP OSTEOARTHRITIS (TOA)" QUESTIONNAIRE
Abstract	Haroon Muhammad (Ireland)	THU0753-HPR	PREDICTING THE FUTURE DEVELOPMENT OF SPONDYLOARTHRITIS AMONG PATIENTS WITH IDIOPATHIC ACUTE ANTERIOR UVEITIS USING REAL- WORLD DATA
Abstract	Johannesson Sofia (Sweden)	THU0754-HPR	WORK STATUS IN WOMEN WITH FIBROMYALGIA- A 12-YEAR FOLLOW UP STUDY
Abstract	de Zwart Arjan (Netherlands)	THU0755-HPR	DIETARY PROTEIN INTAKE AND UPPER LEG MUSCLE STRENGTH IN PATIENTS WITH KNEE OSTEOARTHRITIS: DATA FROM THE OSTEOARTHRITIS INITIATIVE
Abstract	Kinikli Gizem (Turkey)	THU0756-HPR	PREDICTORS OF FEAR OF MOVEMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS
Abstract	Van der Elst Kristien (Belgium)	THU0757-HPR	EUROPEAN QUALITATIVE RESEARCH PROJECT ON PATIENT- PREFERRED OUTCOMES IN EARLY RHEUMATOID ARTHRITIS (EQPERA): RATIONALE, DESIGN AND METHODS OF AN ONGOING MULTI-COUNTRY, MULTI-CENTER, MULTI-LANGUAGE, LONGITUDINAL QUALITATIVE STUDY
Abstract	Niedermann Karin (Switzerland)	THU0758-HPR	APPLICATION OF THE EULAR RECOMMENDATIONS FOR PATIENT EDUCATION FOR PEOPLE WITH INFLAMMATORY ARTHRITIS IN SWITZERLAND
Abstract	KARAPINAR Merve (Turkey)	THU0759-HPR	DOES PHYSIOTHERAPY AND REHABILITATION PROGRAM IMPROVE MOBILITY AND DAILY LIVING ACTIVITIES IN ELDERLY INPATIENT WITH OSTEOPOROSIS ?
 Poster Tour: A stroll among the crystals			
Chair	So Alexander (Switzerland)		
Chair	Andrés Mariano (Spain)		
Abstract	Forien Marine (France)	THU0401	ULTRASOUND EVALUATION IN FOLLOW-UP OF URATE-LOWERING THERAPY IN GOUTY PATIENTS:

			THE USEFUL STUDY.
Abstract	Pascart Tristan (France)	THU0402	ULTRASONOGRAPHY AND DUAL-ENERGY CT (DECT) DO NOT PROVIDE THE SAME QUANTIFICATION OF URATE DEPOSITION IN GOUT : RESULTS FROM A CROSS-SECTIONAL STUDY.
Abstract	Kuo Chang-Fu (Taiwan, Province of China)	THU0403	URATE-LOWERING TREATMENT AND RISK OF INCIDENT UROLITHIASIS IN PEOPLE WITH GOUT: A NESTED CASE-CONTROL STUDY
Abstract	Landgren Anton (Sweden)	THU0404	SELF-REPORTED SEVERITY OF GOUT IN A PRIMARY CARE SETTING AND ASSOCIATED FACTORS – RESULTS FROM A GOUT SURVEY IN PRIMARY CARE
Abstract	Rai Sharan (United States)	THU0405	KILLING TWO BIRDS WITH ONE STONE? THE DASH DIET AND THE RISK OF GOUT: 26-YEAR FOLLOW-UP OF A PROSPECTIVE COHORT
Abstract	Pascual Eliseo (Spain)	THU0406	SERUM URIC ACID LOWERING TREATMENT APPEARS UNNECESSARY DURING HEMODIALYSIS.
Abstract	Uhlig Till (Norway)	THU0407	HIGH GOUT CLASSIFICATION SCORE IS ASSOCIATED WITH ULTRASOUND FINDINGS IN PATIENTS WITH CRYSTAL-PROVEN GOUT
Abstract	Sigurdardottir Valgerdur (Sweden)	THU0408	GOUT IS AN IMPORTANT PREDICTOR OF WORK DISABILITY IN BOTH MEN AND WOMEN
Abstract	Singh Gurkirpal (United States)	THU0409	NOT JUST A SWOLLEN BIG TOE: INCREASING ALL-CAUSE HOSPITALIZATIONS IN PATIENTS WITH GOUT IN THE UNITED STATES: 1993–2014
Abstract	Schlesinger Naomi (United States)	THU0410	GOUT AND THE RISK OF INCIDENT ERECTILE DYSFUNCTION: A BODY MASS INDEX-MATCHED POPULATION-BASED STUDY
 Poster Tour: Clinical features and treatment of orphan diseases			
Chair	Ionescu Ruxandra (Romania)		
Chair	Balanescu Andra (Romania)		
Abstract	Lanzillotta Marco	THU0538	EFFECTS OF GLUCOCORTICOIDS

	(Italy)		AND METHOTREXATE-BASED THERAPEUTIC REGIMENS ON B CELL SUBPOPULATIONS IN PATIENTS WITH IGG4-RELATED DISEASE
Abstract	Pérez-Alvarez Roberto (Spain)	THU0539	SARCOIDOSIS IN SPAIN: CLINICAL AND EPIDEMIOLOGICAL CHARACTERISTICS AT DIAGNOSIS IN 1082 PATIENTS
Abstract	Fabiani Claudia (Italy)	THU0540	EFFICACY AND SAFETY OF ADALIMUMAB IN BEHÇET'S DISEASE RELATED UVEITIS: A MULTICENTER RETROSPECTIVE OBSERVATIONAL STUDY
Abstract	Colafrancesco Serena (Italy)	THU0541	ROLE OF IL-1 INHIBITION IN ADULT ONSET STILL'S DISEASE (AOSD): A RETROSPECTIVE, OBSERVATIONAL MULTICENTRIC STUDY FROM THE ITALIAN SOCIETY OF RHEUMATOLOGY STUDY GROUP ON AUTOINFLAMMATORY DISEASES
Abstract	Ugurlu Serdal (Turkey)	THU0542	ANTI-INTERLEUKIN 1 THERAPY IN FMF AMYLOIDOSIS: A SINGLE CENTER EXPERIENCE (CASE SERIES)
Abstract	Tang Chun (Hong Kong)	THU0543	A RETROSPECTIVE OVERVIEW OF THE TREATMENT MODALITY, OUTCOME AND RELAPSE RISK OF IGG4 RELATED DISEASE IN HONG KONG: A DATASET OF 108 PATIENTS FROM FOUR REGIONAL HOSPITALS
Abstract	Cinar Muhammet (Turkey)	THU0544	THE IMPORTANCE OF R202Q POLYMORPHISM IN CLINICAL EXPRESSION OF FMF: A SINGLE CENTER CROSS-SECTIONAL STUDY
Abstract	González García Andrés (Spain)	THU0545	COMPARISON OF THE CLINICAL AND LABORATORY FEATURES AT ONSET BETWEEN MULTICENTRIC CASTLEMAN'S DISEASE AND ADULT-ONSET STILL'S DISEASE
Abstract	Letarouilly Jean-Guillaume (France)	THU0546	IMPACT OF BONE LOCALISATION ON THE PROGNOSTIC OF LANGERHANS CELL HISTIOCYTOSIS: A MONOCENTRIC RETROSPECTIVE STUDY
Abstract	Kozlova Anna (Russian Federation)	THU0547	CHARACTERIZATION OF A GROUP OF 12 PATIENTS WITH MEVALONATE KINASE DEFICIENCY:

SYMPTOMS AND TREATMENT WITH
IL-1 INHIBITORS**Poster Tour: Economical impact of biosimilars and dicussing risks with patients**

Chair	van der Heijde Désirée (Netherlands)		
Chair	Putrik Polina (Netherlands)		
Abstract	Glintborg Bente (Denmark)	THU0648	USE OF OUTPATIENT RHEUMATOLOGIC HEALTH CARE SERVICES BEFORE AND AFTER SWITCH FROM ORIGINATOR TO BIOSIMILAR INFlixIMAB
Abstract	Grøn Kathrine (Denmark)	THU0649	MANDATORY CHOICE OF FIRST BDMARD IN DENMARK - AN OPPORTUNITY TO STUDY REAL- LIFE EFFECTIVENESS? RESULTS FROM THE DANBIO REGISTRY
Abstract	Zavada Jakub (Czech Republic)	THU0650	THE EFFECT OF ANTI-TNF THERAPY ON WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS, ANKYLOSING SPONDYLITIS AND PSORIATIC ARTHRITIS OVER ONE YEAR – REAL LIFE DATA FROM THE CZECH BIOLOGICS REGISTRY ATTRA
Abstract	Gonzalez-Alvaro Isidoro (Spain)	THU0651	SHOULD WE REDUCE THE DOSE OF BIOLOGICAL THERAPY TO ALL PATIENTS WITH INFLAMMATORY ARTHRITIS ACHIEVING SUSTAINED THERAPEUTIC GOAL?
Abstract	Di Giuseppe Daniela (Sweden)	THU0652	ASSESSMENT OF BIOSIMILARS USING REAL WORLD DATA: THE COMPLEXITY OF CHOOSING A COMPARATOR AND UNDERSTANDING UPTAKE
Abstract	Harrison Mark (Canada)	THU0653	PREVENTING RHEUMATOID ARTHRITIS: A GENERAL POPULATION PILOT STUDY ON PERSPECTIVES OF THE RISK OF DEVELOPING THE DISEASE AND POTENTIAL PREVENTATIVE INTERVENTIONS
Abstract	Cozmuta Raluca (United States)	THU0654	THE INFLUENCE OF RISK PRESENTATION FORMAT ON WILLINGNESS TO START A MEDICATION

Abstract	Cozmuta Raluca (United States)	THU0655	DO VISUAL DECISION AIDS HELP PATIENTS CORRECTLY DIFFERENTIATE BETWEEN A 2% AND A 0.2% RISK?
Abstract	Thakur Kunal (Switzerland)	THU0656	ETANERCEPT BIOSIMILAR USAGE AND ASSOCIATED COST SAVINGS IN GERMANY.
Abstract	Thurah Annette (Denmark)	THU0657	A TELE-HEALTH FOLLOW-UP STRATEGY FOR TIGHT CONTROL OF DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS: RESULTS OF THE NON-INFERIORITY RANDOMISED CONTROLLED TRAIL (THE TERA STUDY)

Poster Tour: Genetic basis, epigenetics and genomics in disease

Chair	Neumann Elena (Germany)		
Chair	Chang Hyun-Dong (Germany)		
Abstract	Nair Nisha (United Kingdom)	THU0001	DIFFERENTIAL METHYLATION AS A POTENTIAL BIOMARKER OF METHOTREXATE RESPONSE IN PATIENTS WITH RHEUMATOID ARTHRITIS
Abstract	Oliver James (United Kingdom)	THU0002	ETANERCEPT AND ADALIMUMAB EXHIBIT HETEROGENEOUS EARLY SIGNATURES OF RESPONSE IN RHEUMATOID ARTHRITIS THERAPY
Abstract	Thalayasingam Nishanthi (United Kingdom)	THU0003	CD4+ AND B LYMPHOCYTE EXPRESSION QUANTITATIVE TRAITS AT RHEUMATOID ARTHRITIS RISK LOCI IN UNTREATED EARLY ARTHRITIS: IMPLICATIONS FOR CAUSAL GENE IDENTIFICATION?
Abstract	Bowes John (United Kingdom)	THU0004	CROSS PHENOTYPE ASSOCIATION MAPPING OF THE MHC IDENTIFIES GENETIC VARIANTS THAT DIFFERENTIATE PSORIATIC ARTHRITIS FROM PSORIASIS
Abstract	Londono John (Colombia)	THU0005	ERAP POLYMORPHISMS AND ITS ASSOCIATION WITH HLA-B15 AND HLA-B27 POSITIVE SPONDYLARTHROSIS PATIENTS
Abstract	Terao Chikashi (Japan)	THU0006	TRANS-ETHNIC META-ANALYSIS OF GENOME-WIDE ASSOCIATION STUDIES IDENTIFIES GSDMA AND PRDM1 AS SUSCEPTIBILITY GENES TO SYSTEMIC SCLEROSIS.

Abstract	Mccaffrey Timothy (United States)	THU0007	DEEP SEQUENCING TRANSCRIPTOME ANALYSIS OF THE EFFECT OF TRAUMEEL VERSUS DICLOFENAC THERAPEUTIC ACTION IN WOUND HEALING
Abstract	Kurreeman Fina (Netherlands)	THU0008	MAST CELLS SHOW A REPROGRAMMED TRANSCRIPTIONAL SIGNATURE FOLLOWING REPEATED IGG STIMULATIONS.
Abstract	Fernández-Moreno Mercedes (Spain)	THU0009	IN VITRO STUDIES USING CYBRIDS, SHOW THAT MTDNA FROM HEALTHY AND OA PATIENTS HAVE DIFFERENT MITOCHONDRIAL ACTIVITY
Abstract	Huang Yukai (China)	THU0010	ALTERED MIRNAS PROFILES IN PLASMA-DERIVED EXOSOME OF PATIENTS WITH ANKYLOSING SPONDYLITIS BY SMALL RNA-SEQ ANALYSIS
Poster Tour: Inflammatory mediators in Rheumatic disease			
Chair	Herrmann Martin (Germany)		
Chair	Koenders Marije (Netherlands)		
Abstract	Davies Ruth (United Kingdom)	THU0025	IL-6 TRANS-SIGNALING CAUSES ACCELERATED ATHEROSCLEROSIS IN DISEASE PRONE ANIMALS
Abstract	Nevin Katherine (United Kingdom)	THU0026	OSM IS MORE EFFECTIVE THAN IL- 6 AT INDUCING ENDOMT OF HUMAN DERMAL MICROVASCULAR CELLS
Abstract	Lennerová Tereza (Czech Republic)	THU0027	CLUSTERIN IS ELEVATED IN SERUM AND MUSCLE TISSUE IN IDIOPATHIC INFLAMMATORY MYOPATHIES AND IS ASSOCIATED WITH DISEASE ACTIVITY
Abstract	Vlachogiannis Nikolaos (Greece)	THU0028	TYPE I INTERFERON SIGNATURE IN THE PERIPHERAL BLOOD AND CXCL4 PLASMA LEVELS IN PATIENTS WITH SYSTEMIC SCLEROSIS
Abstract	Scanu Anna (Italy)	THU0029	BACTERICIDAL/PERMEABILITY- INCREASING PROTEIN DOWNREGULATES THE INFLAMMATORY RESPONSE TO PATHOGENIC CRYSTALS IN VITRO

AND IN VIVO

Abstract	Yokoyama Yuichi (Japan)	THU0030	IL-2IC SUPPRESSES CIA IN MICE BY THE TH1/TH17 IMMUNE RESPONSES DUE TO ENHANCEMENT OF BOTH TREG NUMBERS AND TREG FUNCTIONS.
Abstract	Hoshino-Negishi Kana (Japan)	THU0031	THERAPEUTIC TREATMENT OF ANTI-FRACTALKINE MONOCLONAL ANTIBODY INHIBITS JOINT DESTRUCTION IN COLLAGEN-INDUCED ARTHRITIS MODEL
Abstract	Geven Edwin (Netherlands)	THU0032	THE ROLE OF S100A9 IN PAIN RESPONSE DURING EXPERIMENTALLY INDUCED ACUTE SYNOVITIS.
Abstract	van Dalen Stephanie (Netherlands)	THU0033	LOCAL INJECTION OF ADIPOSE-DERIVED MESENCHYMAL STROMAL CELLS IN EXPERIMENTAL INFLAMMATORY OA RESULTS IN INTERLEUKIN-1B-MEDIATED ATTRACTION OF PMNS AND REDUCED S100A8/A9 RELEASE
Abstract	Renaudin Félix (France)	THU0034	THE INFLAMMATORY POTENTIAL OF CALCIUM PYROPHOSPHATE CRYSTALS DEPENDS ON THEIR CAPACITY TO INDUCE NF-KB AND MAPK PATHWAYS.

 **Poster Tour: MTX, GCs and JAK inhibitors in RA**

Chair	Takeuchi Tsutomu (Japan)		
Chair	De Cock Diederik (United Kingdom)		
Abstract	Hope Holly (United Kingdom)	THU0168	PATIENTS' POSITIVE BELIEFS AND CERTAINTY PREDICT METHOTREXATE ADHERENCE IN A RHEUMATOID ARTHRITIS COHORT: THE RAMS STUDY
Abstract	Beauvais Catherine (France)	THU0169	ONE-THIRD OF PATIENTS WITH RHEUMATOID ARTHRITIS ELIGIBLE FOR A FIRST BIOLOGIC ARE NOT ADHERENT TO METHOTREXATE: RESULTS OF FORGET, A CROSS-SECTIONAL SURVEY OF 244 PATIENTS.
Abstract	Tsutsumino Michi (Japan)	THU0170	OUTCOMES OF THE RAPID DOSE ESCALATION OF METHOTREXATE IN JAPANESE PATIENTS WITH EARLY RHEUMATOID ARTHRITIS;

RESULTS FROM A RANDOMIZED CONTROLLED TRIAL

Abstract	Avdeeva Anastasia (Russian Federation)	THU0171	INCREASED FUNCTIONAL ACTIVITY OF FOXP3+REGULATORY T CELLS IN THE PERIPHERAL BLOOD OF DMARDS-NAÏVE METHOTREXATE-TREATED PATIENTS WITH EARLY RA USING
Abstract	Santos-Moreno Pedro (Colombia)	THU0172	IMPROVEMENT OF DISEASE ACTIVITY IN A 5-YEAR COHORT OF RHEUMATOID ARTHRITIS PATIENTS TREATED UNDER TREAT TO TARGET RECOMMENDATIONS AND A MULTISPECIALITY CARE MODEL RECEIVING CONVENTIONAL DMARD THERAPY
Abstract	Alten Rieke (Germany)	THU0173	LONG TERM SAFETY AND EFFICACY OF FILGOTINIB IN A PHASE 2B OPEN LABEL EXTENSION STUDY IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS UP TO 144 WEEKS
Abstract	Finckh Axel (Switzerland)	THU0174	DRUG RETENTION OF TOFACITINIB VERSUS BIOLOGIC ANTIRHEUMATIC AGENTS IN RHEUMATOID ARTHRITIS: OBSERVATIONAL DATA FROM THE SWISS SCQM REGISTRY
Abstract	Conaghan Philip G (United Kingdom)	THU0175	INFLAMMATION DETECTED WITH MODERN SENSITIVE MRI ANALYSIS DEMONSTRATES THAT THERAPEUTIC RESPONSE AS EARLY AS ONE MONTH PREDICTS 12-MONTH RADIOGRAPHIC PROGRESSION: DATA FROM A STUDY USING TOFACITINIB AND METHOTREXATE IN METHOTREXATE-NAÏVE PATIENTS WITH EARLY RA
Abstract	Li Zhaohua (China)	THU0176	EFFICIENCY AND SAFETY OF RAPAMYCIN COMBINED WITH LOW-DOSE IL-2 TREATMENT COMPARED WITH METHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS

 **Poster Tour: Novelty in the clinical approach to SLE, Sjögren's and APS I**

Chair	Tincani Angela (Italy)		
Chair	Lazzaroni Maria Grazia (Italy)		
Abstract	Gergianaki Irini	THU0246	THE IMPACT OF CLASSIFYING SLE

(Greece)

PATIENTS WITH THE SLICC-2012 VERSUS THE ACR-1997 CLASSIFICATION CRITERIA ON EARLY DIAGNOSIS, SEVERITY, AND DAMAGE: DATA FROM THE COMMUNITY-BASED CRETAN LUPUS REGISTRY

Abstract	Londono Jimenez Alejandra (United States)	THU0247	THE PRESENCE OF ANTI-RO AND ANTI-LA ANTIBODIES IS ASSOCIATED WITH TUBULOINTERSTITIAL DAMAGE IN LUPUS NEPHRITIS
Abstract	Tiosano Shmuel (Israel)	THU0248	THE ASSOCIATION BETWEEN SYSTEMIC LUPUS ERYTHEMATOSUS TO BIPOLAR DISORDER – A REAL-LIFE STUDY
Abstract	Guillen-Astete Carlos (Spain)	THU0249	SUBCLINICAL HAND ARTHROPATHY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
Abstract	Zhan Zhongping (China)	THU0250	EFFECT OF FETAL UMBILICAL ARTERY DOPPLER ON PREDICTION OF ADVERSE PREGNANCY OUTCOMES IN WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS
Abstract	Nakano Masahiro (Japan)	THU0251	DIFFERENT RESPONSES TO INDUCTION THERAPY IN TWO ONSET CATEGORIES OF LUPUS NEPHRITIS
Abstract	Melsens Karin (Belgium)	THU0252	NAILFOLD CAPILLAROSCOPY IN SYSTEMIC LUPUS ERYTHEMATOSUS: A SYSTEMATIC REVIEW AND CRITICAL APPRAISAL
Abstract	Levy Roger (Brazil)	THU0253	TRIPLE POSITIVITY TO ANTIPHOSPHOLIPID ANTIBODIES IN PRIMARY ANTIPHOSPHOLIPID SYNDROME: INCREASED RISK OF ARTERIAL THROMBOSES AND ABORTIONS
Abstract	Gergianaki Irini (Greece)	THU0254	COMPARISON OF URBAN VERSUS RURAL ENVIRONMENT ASSOCIATED SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): RISK AND CLINICAL FEATURES
Abstract	Petri Michelle (United States)	THU0255	COMPARISON OF REMISSION AND LUPUS LOW ACTIVITY STATE AS PREDICTORS OF ORGAN DAMAGE
Abstract	Tejera Segura Beatriz (Spain)	THU0256	DEVELOPMENT AND VALIDATION OF A SCORE TO PREDICT THE RISK OF SEVERE INFECTION IN SLE

Abstract	Choe Jung-Yoon (Korea, Republic Of)	THU0257	ENHANCED ACTIVATION OF NLRP3 INFLAMMASOMES IN PATIENTS WITH SJÖGREN'S SYNDROME
----------	---	---------	--

 **Poster Tour: Outcomes across all rheumatology**

Chair	Landewé Robert B.M. (Netherlands)		
-------	--------------------------------------	--	--

Chair	Mahler Elien (Netherlands)		
-------	-------------------------------	--	--

Abstract	Bartlett Susan (Canada)	THU0695	THE RA FLARE QUESTIONNAIRE (RA-FQ) IS RESPONSIVE TO CHANGE IN RA SYMPTOMS AND IMPACTS IN CLINICAL AND OBSERVATIONAL TRIALS
----------	----------------------------	---------	--

Abstract	Ceccarelli Fulvia (Italy)	THU0696	ANTI-CARBAMYLATED PROTEINS ANTIBODIES IN SLE PATIENTS WITH JOINT INVOLVEMENT: A POSSIBLE NEW BIOMARKER FOR EROSIVE DAMAGE
----------	------------------------------	---------	---

Abstract	Maksymowych Walter (Canada)	THU0697	FEASIBILITY AND RELIABILITY OF THE SPARCC SACROILIAC JOINT STRUCTURAL SCORE FOR CHILDREN WITH SPONDYLOARTHRITIS
----------	--------------------------------	---------	---

Abstract	Donaldson Mira (Canada)	THU0698	MEASUREMENT PROPERTIES OF PRESENTEEISM MEASURES WITH DUAL ANSWER KEYS IN INFLAMMATORY ARTHRITIS
----------	----------------------------	---------	--

Abstract	Pan Feng (Australia)	THU0699	CHARACTERIZING AND VALIDATING THE PHENOTYPE OF KNEE PAIN: A LATENT CLASS ANALYSIS
----------	-------------------------	---------	--

Abstract	Goll Guro (Norway)	THU0700	IMMUNOGENICITY IN PATIENTS SWITCHING FROM STABLE ORIGINATOR INFLIXIMAB TREATMENT TO CT-P13: ANALYSES ACROSS SIX DISEASES FROM THE 52-WEEK RANDOMIZED NOR- SWITCH STUDY
----------	--------------------	---------	--

Abstract	Kerschbaumer Andreas (Austria)	THU0701	THE EFFECTS OF STRUCTURAL DAMAGE ON FUNCTIONAL DISABILITY IN PSORIATIC ARTHRITIS.
----------	-----------------------------------	---------	--

Abstract	Boeters Debbie (Netherlands)	THU0702	ARE MRI-DETECTED EROSIONS SPECIFIC FOR RA? A LARGE EXPLORATIVE CROSS-SECTIONAL STUDY
----------	---------------------------------	---------	---

Abstract	Mahmood Sehrash (Netherlands)	THU0703	SYSTEMATIC REVIEW OF RHEUMATOID ARTHRITIS CLINICAL STUDIES: SUBOPTIMAL
----------	----------------------------------	---------	--

STATISTICAL ANALYSIS OF
RADIOLOGICAL DATA

Abstract	Boer Aleid (Netherlands)	THU0704	EVALUATION OF THE ACCURACY OF HAND AND FOOT MRI IN THE EARLY IDENTIFICATION OF RA: USING THE PREVALENCE OF LOW-GRADED INFLAMMATION IN THE SYMPTOM-FREE POPULATION AS REFERENCE REDUCES FALSE-POSITIVE MRI RESULTS
----------	-----------------------------	---------	---

 **Poster Tour: Paediatric Rheumatology**

Chair	Avcin Tadej (Slovenia)		
Chair	Consolaro Alessandro (Italy)		
Abstract	Świdrowska-Jaros Joanna (Poland)	THU0486	ANGIOPOETIN-2 AS A NEW VALUABLE MARKER OF DISEASE ACTIVITY IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS
Abstract	Horneff Gerd (Germany)	THU0487	REAL-LIFE TREATMENT WITH CANAKINUMAB IN SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS – FIRST EXPERIENCE FROM THE BIKER REGISTRY
Abstract	Shoop-Worrall Stephanie (United Kingdom)	THU0488	THE IMPACT OF OLIGOARTICULAR AND POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS OVER THE FIRST FIVE YEARS FOLLOWING DIAGNOSIS
Abstract	Diaz-Cordoves Rego Gisela (Spain)	THU0489	ADIPOSIITY AND INFLAMMATORY ACTIVITY IN JUVENILE IDIOPATHIC ARTHRITIS COULD THEY BE RELATED?
Abstract	Costa Reis Patricia (Portugal)	THU0490	MULTICENTRE STUDY OF LUPUS NEPHRITIS URINARY BIOMARKERS IN ADULT AND PAEDIATRIC PATIENTS
Abstract	Garrote Corral Sandra (Spain)	THU0491	COMPARISON OF CLINICAL AND SEROLOGICAL FEATURES OF JUVENILE AND ADULT-ONSET NEUROPSYCHIATRIC LUPUS IN SPANISH PATIENTS
Abstract	Sato Stoshi (Japan)	THU0492	MACROPHAGE ACTIVATION SYNDROME AS THE INITIAL MANIFESTATION OF JUVENILE SYSTEMIC LUPUS ERYTHEMATOSUS
Abstract	Sharma Avinash	THU0493	STUDY OF LONG-TERM OUTCOME

(India)

OF CHILDREN WITH JUVENILE DERMATOMYOSITIS FROM A SINGLE-CENTRE IN NORTH INDIA

Abstract Shi Lianjie (China) THU0494

CLINICAL FEATURES OF CHILDREN WITH KAWASAKI DISEASE IN DIFFERENT AGE GROUPS IN SOUTHWEST CHINA

Abstract Brogan Paul (United Kingdom) THU0495

EFFECTIVENESS OF CHILDHOOD VACCINATIONS IN CAPS PATIENTS TREATED WITH CANAKINUMAB: RESULTS FROM AN OPEN-LABEL PHASE 3 EXTENSION STUDY

Poster Tour: Pathomechanism in SLE, SS, APS

Chair Dörner Thomas (Germany)

Chair Aringer Martin (Germany)

Abstract Solé-Marcé Cristina (Spain) THU0216

URINARY NEUROPILIN-1: A NEW BIOMARKER APPROACH IN THE PROGNOSIS OF LUPUS NEPHRITIS.

Abstract Ulf-Møller Constance (Denmark) THU0217

DNA METHYLATION ANALYSIS IN MULTIPLE CELLULAR COMPARTMENTS DEMONSTRATES A UNIVERSAL DNA METHYLATION INTERFERON SIGNATURE IN MULTIPLE CELLULAR COMPARTMENTS AND PREDOMINANT B-CELL HYPERMETHYLATION IN TWINS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

Abstract Perez-Sanchez Carlos (Spain) THU0218

CIRCULATING MICRORNAS AS BIOMARKERS FOR DIAGNOSIS AND TYPIFYING THE ATHEROTHROMBOTIC STATUS IN ANTIPHOSPHOLIPID SYNDROME

Abstract Guleria Sandesh (India) THU0219

AUTOANTIBODY PROFILE OF CHILDREN WITH JUVENILE DERMATOMYOSITIS FROM A TERTIARY CARE CENTRE IN NORTH INDIA

Abstract Payne Andrew (United Kingdom) THU0220

SELETALISIB, A NOVEL SELECTIVE PI3K α INHIBITOR WITH THERAPEUTIC POTENTIAL IN INFLAMMATION AND AUTOIMMUNITY

Abstract Kapsogeorgou Efstathia (Greece) THU0221

DOWNREGULATED EXPRESSION OF MIR200B-5P IN MINOR SALIVARY GLANDS (MSG) OF PATIENTS WITH

SJÖGREN'S SYNDROME (SS)
ASSOCIATED LYMPHOMA

Abstract	Clarke Stephen (United States)	THU0222	PROPHYLACTIC AND THERAPEUTIC ADMINISTRATION OF AN ANTI-CD40 ANTAGONIST ANTIBODY BLOCKS AND REVERSES PROTEINURIA AND NEPHRITIS IN NZB/W-F1 MICE.
Abstract	Blokland Sofie (Netherlands)	THU0223	ELEVATED MTORC1 SIGNATURE IN B CELLS FROM SJÖGREN'S SYNDROME PATIENTS CORRELATES WITH B CELL HYPERACTIVITY THAT IS ABROGATED BY MTOR INHIBITION: A NOVEL THERAPEUTIC STRATEGY TO HALT B CELL HYPERACTIVITY IN PSS?
Abstract	Sacre Sandra (United Kingdom)	THU0224	ASSOCIATION OF IRAK-M WITH NEUROPSYCHIATRIC SYMPTOMS IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS.
Abstract	Fogel Olivier (France)	THU0225	ROLE OF THE IL-12/IL-35 BALANCE IN SJÖGREN'S SYNDROME
 Poster Tour: Progress in management of spondyloarthritis			
Chair	Elewaut Dirk (Belgium)		
Chair	Barcelos Anabela (Portugal)		
Abstract	Kristianslund Eirik K (Norway)	THU0345	REAL-LIFE EFFECTIVENESS OF TNF INHIBITORS IN AXIAL SPONDYLARTHROSIS: ARE CHANGING NATIONAL POLICIES ON CHOICE OF TNF INHIBITOR REFLECTED IN RESPONSE TO TREATMENT?
Abstract	Moltó Anna (France)	THU0346	CONCOMITANT FIBROMYALGIA IN AXIAL SPONDYLOARTHROSIS HAS A NEGATIVE IMPACT ON TNF ALPHA BLOCKERS TREATMENT EFFECT IN REAL LIFE.
Abstract	Micheroli Raphael (Switzerland)	THU0347	IMPACT OF OBESITY ON THE RESPONSE TO TUMOUR NECROSIS FACTOR INHIBITORS IN AXIAL SPONDYLOARTHROSIS
Abstract	Deodhar Atul (United States)	THU0348	SAFETY AND EFFICACY OF INTRAVENOUS GOLIMUMAB IN ADULT PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: RESULTS THROUGH WEEK 28

Abstract	Mulleman Denis (France)	THU0349	METHOTREXATE REDUCES ADALIMUMAB IMMUNOGENICITY IN PATIENTS WITH SPONDYLOARTHRITIS: A RANDOMIZED CLINICAL TRIAL
Abstract	Rivière Elodie (France)	THU0350	EFFECT OF NSAID CONSUMPTION ON CARDIOVASCULAR EVENTS IN SPONDYLOARTHRITIS
Abstract	Lian Fan (China)	THU0351	ADALIMUMAB TAPERING WITH COMBINED METHOTREXATE CAN BE EFFECTIVE AS MAINTENANCE THERAPY IN SPA-RELATED UVEITIS
Abstract	Maksymowych Walter (Canada)	THU0352	TOFACITINIB TREATMENT IS ASSOCIATED WITH ATTAINMENT OF THE MINIMALLY IMPORTANT REDUCTION IN AXIAL MRI INFLAMMATION IN PATIENTS WITH ANKYLOSING SPONDYLITIS
Abstract	Maksymowych Walter P (Canada)	THU0353	CHANGE IN MRI STRUCTURAL LESIONS IN THE SACROILIAC JOINT AFTER TWO YEARS OF ETANERCEPT THERAPY IN COMPARISON TO A CONTEMPORARY CONTROL COHORT IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS
Abstract	Goll Guro (Norway)	THU0354	DISEASE WORSENING AND SAFETY IN PATIENTS SWITCHING FROM ORIGINATOR INFLIXIMAB TO BIOSIMILAR INFLIXIMAB (CT-P13) IN THE RANDOMIZED NOR-SWITCH-STUDY: EXPLORATIVE ANALYSIS IN SPA PATIENTS

Poster Tour: RA disease course and prognosis

Chair	Petersson Ingemar (Sweden)		
Chair	Kristensen Lars Erik (Denmark)		
Abstract	Ten Brinck Robin (Netherlands)	THU0068	THE RISK OF INDIVIDUAL AUTOANTIBODIES, AUTOANTIBODY COMBINATIONS AND AUTOANTIBODY LEVELS FOR ARTHRITIS DEVELOPMENT IN CLINICALLY SUSPECT ARTHRALGIA
Abstract	Torikai Eiji (Japan)	THU0069	HOW MANY RHEUMATOID ARTHRITIS PATIENTS IN REMISSION EXPERIENCE PAIN? WHAT TYPES AND WITH WHAT FREQUENCY WERE PAINKILLERS

RECEIVED? IS REACHING
REMISSION A REALISTIC GOAL?

Abstract	Norvang Vibeke (Norway)	THU0070	TREAT-TO-TARGET IN RA: WHAT LEVEL OF TREATMENT RESPONSE IS NECESSARY BY 3 MONTHS IN ORDER TO ACHIEVE THE TREATMENT TARGET BY 6 MONTHS? RESULTS FROM A REAL LIFE STUDY.
Abstract	Steunebrink Laura (Netherlands)	THU0071	RADIOGRAPHIC PROGRESSION IN EARLY RHEUMATOID ARTHRITIS PATIENTS FOLLOWING INITIAL COMBINATION VERSUS STEP-UP TREAT TO TARGET THERAPY IN DAILY CLINICAL PRACTICE: RESULTS FROM THE DREAM REGISTRY
Abstract	Dreyer Lene (Denmark)	THU0072	RISK OF REVISION, PROSTHETIC JOINT INFECTION AND DEATH FOLLOWING TOTAL HIP OR KNEE ARTHROPLASTY IN PATIENTS WITH RHEUMATOID ARTHRITIS – A NATIONWIDE COHORT STUDY FROM DENMARK
Abstract	Goh Ee Teng (United Kingdom)	THU0073	FACTORS ASSOCIATED WITH TREATMENT ADHERENCE IN RHEUMATOID ARTHRITIS: A SYSTEMATIC LITERATURE REVIEW
Abstract	Ajeganova Sofia (Netherlands)	THU0074	BODY MASS INDEX IN EARLY RHEUMATOID ARTHRITIS IN UNDERWEIGHT PATIENTS IS ASSOCIATED WITH MORE PROGRESSION OF EROSIONS OVER 15 YEARS AND IN OBESE PATIENTS WITH LESS PROGRESSION OF JOINT SPACE NARROWING
Abstract	Twigg Sarah (United Kingdom)	THU0075	THE RELATIONSHIP BETWEEN DISEASE ACTIVITY AND DISABILITY IS MEDIATED BY PAIN AND FATIGUE IN EARLY RHEUMATOID ARTHRITIS.
Abstract	Youngstein Taryn (United Kingdom)	THU0076	DISEASE-MODIFYING TREATMENT REGIMENS HAVE BEEN INSUFFICIENT TO REDUCE THE INCIDENCE OF SYSTEMIC AA AMYLOIDOSIS ASSOCIATED WITH RHEUMATOID ARTHRITIS IN CONTRAST TO A SIGNIFICANT REDUCTION IN THOSE WITH JUVENILE IDIOPATHIC ARTHRITIS

Abstract	Manivel Vivek Anand (Sweden)	THU0077	ANTI-COLLAGEN TYPE II ANTIBODIES ARE ASSOCIATED WITH AN ACUTE ONSET RHEUMATOID ARTHRITIS PHENOTYPE AND PROGNOSTICATE LOWER DEGREE OF INFLAMMATION
----------	---------------------------------	---------	---

Poster Tour: Rheumatology training and disease burden

Chair	Iagnocco Annamaria (Italy)		
Chair	Dobrota Rucsandra (Switzerland)		
Abstract	Cikes Nada (Croatia)	THU0596	RHEUMATOLOGY SPECIALTY TRAINING IN EUROPEAN UNION COUNTRIES
Abstract	El Miedany Yasser (United Kingdom)	THU0597	FLIPPED LEARNING: CAN RHEUMATOLOGY LEAD THE SHIFT IN MEDICAL EDUCATION?
Abstract	Kwok Fiona Yi Haan (United Kingdom)	THU0598	CAN YOU HEAR THE JOINTS CRYING? MUSCULOSKELETAL EXAMINATION IN JUNIOR DOCTORS' MEDICAL ADMISSION CLERKINGS
Abstract	Cabrera Natalia (France)	THU0599	BENEFIT RISK RATIO FOR BIOLOGICAL AGENTS IN JUVENILE IDIOPATHIC ARTHRITIS, A META- ANALYSIS OF RANDOMIZED CLINICAL TRIALS
Abstract	DeQuattro Kimberly (United States)	THU0600	CUMULATIVE ADVERSE CHILDHOOD EXPERIENCES ARE ASSOCIATED WITH POOR OUTCOMES IN ADULTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
Abstract	Kjeldgaard Anette (Denmark)	THU0601	CARDIOVASCULAR SCREENING AMONG PATIENTS WITH INFLAMMATORY ARTHRITIS: TO WHAT EXTENT DO PATIENTS FOLLOW RECOMMENDATIONS?
Abstract	Verstappen S (United Kingdom)	THU0602	WORKER PRODUCTIVITY LOSS REMAINS A MAJOR ISSUE FOR PATIENTS WITH INFLAMMATORY ARTHRITIS AND OSTEOARTHRITIS: RESULTS FROM THE INTERNATIONAL EULAR-PRO WORKER PRODUCTIVITY STUDY
Abstract	Nielen Johannes (Netherlands)	THU0603	DISEASE BURDEN OF KNEE OSTEOARTHRITIS PATIENTS UNDERGOING JOINT

REPLACEMENT COMPARED TO
MATCHED CONTROLS: A
POPULATION-BASED ANALYSIS OF
A DUTCH MEDICAL CLAIMS
DATABASE.

Abstract Mahmood Sehrash THU0604
(Netherlands)

THE ASSESSMENT OF THE DUTCH
QUALITY REGISTRY RHEUMATOID
ARTHRITIS QUALITY INDICATORS
IN THREE PILOT HOSPITALS

Abstract Belhassen Manon THU0605
(France)

IMPACT OF NON-PERSISTENCE TO
SUBCUTANEOUS TNF-ALPHA
INHIBITORS ON MEDICAL
RESOURCE UTILIZATION AND
COSTS

Poster Tour: Vasculities Clinical Aspects I

Chair Calabrese
Cassandra (United
States)

Chair Hernandez-
Rodriguez Jose
(Spain)

Abstract Kikuchi Hirotoishi THU0294
(Japan)

DIFFERENTIAL PATTERNS OF
ATROPHY IN HIPPOCAMPUS AND
BRAINSTEM BETWEEN CHRONIC
PROGRESSIVE NEURO-BEHCET'S
DISEASE AND ALZHEIMER'S
DISEASE

Abstract Alibaz-Oner Fatma THU0295
(Turkey)

CLINICAL FEATURES OF
TAKAYASU'S ARTERITIS FROM AN
INCEPTION COHORT: EARLY
DISEASE IS CHARACTERIZED BY
'SYSTEMIC INFLAMMATION'

Abstract Monti Sara (Italy) THU0296

THE ROLE OF ULTRASOUND IN THE
MANAGEMENT OF GIANT CELL
ARTERITIS (GCA) IN ROUTINE
CLINICAL PRACTICE

Abstract Monti Sara (Italy) THU0297

A NOVEL ULTRASOUND SCORING
SYSTEM FOR GIANT CELL
ARTERITIS

Abstract A Goel Ruchika THU0298
(India)

LONG TERM OUTCOME OF
PATIENTS WITH TAKAYASU
ARTERITIS- A SINGLE CENTRE
STUDY

Abstract Tombetti Enrico THU0299
(Italy)

UNDERSTANDING THE
HETEROGENEITY OF LARGE-
VESSEL VASCULITIDES

Abstract Solans-Laqué THU0300
Roser (Spain)

CENTRAL NERVOUS SYSTEM
INVOLVEMENT IN
GRANULOMATOSIS WITH

POLYANGIITIS (WEGENER) IN A
LARGE SERIES OF PATIENTS WITH
ANCA-ASSOCIATED VASCULITIDES
(AAV).REVAS STUDY-GEAS-SEMI

Abstract Niles John (United States) THU0301

SAFETY FOLLOWING INITIATION OF
RITUXIMAB IN GRANULOMATOSIS
WITH POLYANGIITIS (GPA) OR
MICROSCOPIC POLYANGIITIS
(MPA): INTERIM ANALYSIS OF THE
RITUXIMAB IN ANCA-ASSOCIATED
VASCULITIS REGISTRY (RAVER)

Abstract Ponte Cristina (Portugal) THU0302

HISTOLOGY FINDINGS IN GIANT
CELL ARTERITIS (GCA) AND THEIR
RELATIONSHIP WITH THE
ULTRASOUND RESULTS: ANALYSIS
OF DATA FROM THE TABUL STUDY
(TEMPORAL ARTERY BIOPSY VS
ULTRASOUND IN DIAGNOSIS OF
GIANT CELL ARTERITIS)

Abstract Fukui Shoichi (Japan) THU0303

CLINICAL FEATURES AND
PROGNOSIS OF ANCA-
ASSOCIATED VASCULITIS WITH
RENAL INVOLVEMENT AT
DIAGNOSIS

Thursday 15.06.2017 12:00 - 13:30

Poster Tour - Poster Area

PARE Poster Tour I

Chair de Wit Maarten (Netherlands)

Chair Mazuras Kristijonas (Lithuania)

Abstract Stones Simon (Switzerland) PARE0001

GROWING STRONGER TOGETHER:
IMPLEMENTING EULAR YOUNG
PARE'S STRATEGY

Abstract Higginbottom Adele (United Kingdom) PARE0002

CELEBRATING TEN YEARS OF
SUCCESSFUL PATIENT
INVOLVEMENT IN RESEARCH OF
INFLAMMATORY CONDITIONS

Abstract Jurisic Skevin Aleksandra (Serbia) PARE0003

ASSESSMENT OF PAIN AND
IMPORTANCE OF EXERCISE IN HIP
OSTEOARTHRITIS

Abstract Tekkatte Roopa (United Kingdom) PARE0004

PATIENT REPORTED LONG TERM
EFFECTS OF SIX WEEK
PROGRESSIVE RESISTANCE
TRAINING PROGRAMME FOR
RHEUMATOID ARTHRITIS

Abstract	Espanha Margarida (Portugal)	PARE0005	EDUCATIONAL PROGRAM FOR OLDER ADULTS WITH KNEE OSTEOARTHRITIS
Abstract	Neijland Yvette (Netherlands)	PARE0006	PATIENT INVOLVEMENT IN BASIC RESEARCH: A PILOT STUDY.
Abstract	Garrido-Cumbrera Marco (Spain)	PARE0007	HOPES AND FEARS OF PATIENTS WITH AXIAL SPONDYLOARTHRITIS IN SPAIN. THE VALUE OF PATIENT OPINION: RESULTS FROM THE SPANISH ATLAS
Abstract	Viora Ugo (Italy)	PARE0008	TRANSITION: PARTICULARLY DIFFICULT TIME FOR YOUNG PEOPLE WITH AR
Abstract	Visser-Noordegraaf Marianne (Netherlands)	PARE0009	A TAXONOMY OF DISEASE EXPERIENCES OF WOMEN WITH SJÖGREN'S SYNDROME FROM THE PERSPECTIVE OF THE PATIENT
Abstract	de Souza Savia (United Kingdom)	PARE0010	SIGNIFICANCE OF FOOT PROBLEMS FOR PATIENTS WITH RHEUMATOID ARTHRITIS: A PATIENT-LED QUALITATIVE STUDY
Abstract	Ziegler Connie (Denmark)	PARE0011	ASK THE USERS - ESTABLISHING A DIGITAL USER PANEL

Thursday 15.06.2017 13:30 - 15:00

WIN & HOT Session - Hall 6

WIN & HOT Session

Chair	Gonzalez-Gay Miguel Angel (Spain)		
Chair	Ponte Cristina (Portugal)		
Speaker	Khamashta Munther (United Kingdom)		WIN Session: Antiphospholipid Syndrome
Speaker	Luqmani Raashid (United Kingdom)	SP0053	HOT Session: Vasculitis treatment

Clinical Science Session - Hall 8

Treat-to-target in axSpA: reality or utopy?

Chair	Boonen Annelies (Netherlands)		
Chair	Gensler Lianne (United States)		
Speaker	Braun Jürgen	SP0054	The concept of treat-to-target

	(Germany)		
Speaker	Dougados Maxime (France)	SP0055	What are the challenges for applying T2T in axSpA?
Speaker	van der Heijde Désirée (Netherlands)	SP0056	Treat-to-target recommendations in axSpA - update of the recommendations T2T in axSpA
Abstract	Moltó Anna (France)	OP0188	DEFINING CLINICALLY IMPORTANT WORSENING BASED ON ASDAS-CRP FOR AXIAL SPONDYLOARTHRITIS: A DATA-BASED CONSENSUS BY THE ASSESSMENT IN SPONDYLOARTHRITIS INTERNATIONAL SOCIETY (ASAS)
Abstract	Ciurea Adrian (Switzerland)	OP0189	TUMOR NECROSIS FACTOR INHIBITOR TREATMENT REDUCES SPINAL RADIOGRAPHIC PROGRESSION IN ANKYLOSING SPONDYLITIS BY DECREASING DISEASE ACTIVITY: A LONGITUDINAL ANALYSIS IN A LARGE PROSPECTIVE COHORT

Challenges in Clinical Practice Session - Hall 7A

What choice after failure of the first anti-TNF

Chair	Smolen Josef S. (Austria)		
Chair	Gabay Cem (Switzerland)		
Presenter	Sharma Ena (United States)		Case 1 presentation: Primary anti-TNF failure
Discussant	Fleischmann Roy (United States)		Case 1 discussion: A second anti-TNF or another mode of action is the same
Presenter	Felten Renaud (France)		Case 2 presentation: Secondary anti-TNF failure
Discussant	Gottenberg Jacques-Eric (France)		Case 2 discussion: Another Mode of Action is better than a second anti-TNF

From Bench to Bedside - Hall 7B

Calcium crystal deposition in rheumatic diseases

Chair	Lioté Frederic (France)		
Chair	So Alexander (Switzerland)		

Speaker	Ea Hang-Korng (France)		Mechanisms of CPP and HA crystal deposition in man
Speaker	Bertrand Jessica (Germany)	SP0057	Calcium crystals and their link to osteoarthritis
Speaker	Omoumi Patrick (Switzerland)	SP0058	Review of the different imaging modalities to detect calcium deposition diseases
Abstract	Darrietort-Laffite Christelle (France)	OP0190	HISTOLOGICAL CHARACTERIZATION OF ROTATOR CUFF CALCIFIC TENDINOPATHY
Abstract	Combier Alice (France)	OP0191	COMPARISON OF ULTRASONOGRAPHY AND RADIOGRAPHY OF THE WRIST FOR DIAGNOSIS OF CALCIUM PYROPHOSPHATE DEPOSITION.

Clinical Science Session - N103 / N104

Fifty shades of remission in RA

Chair	Kay Jonathan (United States)		
Chair	Tas Sander W. (Netherlands)		
Speaker	Boers Maarten (Netherlands)	SP0059	Remission: More than clinical
Speaker	d'Agostino Maria- Antonietta (France)		Imaging is required for remission: PRO
Speaker	Haavardsholm Espen A. (Norway)		Imaging is required for remission: CON
Speaker	Aletaha Daniel (Austria)		Biomarkers are required for remission: CON
Speaker	van Vollenhoven Ronald (Netherlands)	SP0060	Biomarkers are required for remission: PRO
Abstract	Sepriano Alexandre (Portugal)	OP0192	ADDING ULTRASOUND TO THE TREAT-TO-TARGET STRATEGY SHOWS NO BENEFIT IN ACHIEVEMENT OF REMISSION: RESULTS FROM THE BIODAM COHORT

Basic and Translational Science Session - South Auditorium

Innate immunity

Chair	Voll Reinhard E. (Germany)		
Chair	Zhao Yi (China,		

	People's Republic of)		
Speaker	Hidalgo Andres (Spain)	SP0061	Neutrophils patrol healthy tissues
Speaker	Krönke Gerhard (Germany)	SP0062	Differential scavenging of apoptotic cells and bacteria
Speaker	Rovere-Querini Patrizia (Italy)	SP0063	The role of muscle in innate immune responses
Abstract	Ciccia Francesco (Italy)	OP0193	INFLAMMATION OF ADVENTITIAL NERVES OCCURS IN GIANT CELL ARTERITIS PATIENTS AND IT IS CHARACTERIZED BY INFLAMMASOMES, UPR AND AUTOPHAGY ACTIVATION
Abstract	Steiner Guenter (Austria)	OP0194	INVOLVEMENT OF TOLL-LIKE RECEPTOR 9 IN THE PATHOGENESIS OF EROSIVE AUTOIMMUNE ARTHRITIS AND DURING OSTEOCLASTOGENESIS

Joint Session HPR / PARE / Paediatric - N101 / N102

To be and to become: transition from paediatric to adult care

Chair	Avcin Tadej (Slovenia)		
Chair	Taal Erik (Netherlands)		
Speaker	Olster Wendy (Netherlands)	SP0064	To be and to become: reflections on my transition
Speaker	Minden Kirsten (Germany)	SP0065	Are we asking the right questions in transition research?
Speaker	Raunsbaek - Knudsen Line (Denmark)	SP0066	Implementation of a brief transition programme for adolescents with juvenile idiopathic arthritis
Speaker	van der Net Janjaap (Netherlands)		Growing into a healthy lifestyle
Abstract	Pontikaki Irene (Italy)	OP0195	WHAT IS THE IMPACT OF JUVENILE IDIOPATHIC ARTHRITIS IN ADULTHOOD? THE MONOCENTRIC EXPERIENCE OF 240 PATIENTS FOLLOWED IN A TRANSITION TERTIARY CLINIC OF RHEUMATOLOGY

Paediatric Rheumatology Session - N105 / N106

Heterogeneity in JIA

Chair	Swart Joost F.		
-------	----------------	--	--

	(Netherlands)		
Chair	de Benedetti Fabrizio (Italy)		
Speaker	Yeung Rae (Canada)		Biologic basis of heterogeneity in JIA
Speaker	de Jager Wilco (Netherlands)	SP0067	JIA cytokine profiling
Speaker	Consolaro Alessandro (Italy)	SP0068	Clinical insights into JIA heterogeneity
Abstract	Horneff Gerd (Germany)	OP0196	CHANGING PATTERNS OF JUVENILE IDIOPATHIC ARTHRITIS PATIENTS TREATED WITH ETANERCEPT FROM 2000 TO 2016 IN THE GERMAN BIKER REGISTRY POPULATION
Abstract	Mallalieu Navita L. (United States)	OP0197	EVALUATION OF A DOSING REGIMEN FOR TOCILIZUMAB IN PATIENTS YOUNGER THAN TWO YEARS OF AGE WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS

Clinical Science Session - N111 / N112

EULAR - EMA Session

Chair	Breedveld Ferdinand C. (Netherlands)		
Chair	Strand Vibeke (United States)		
Speaker	Vesely Richard (United Kingdom)	SP0069	Registries in musculoskeletal diseases and their regulatory use
Speaker	Behrens Frank (Germany)		Bureaucratic hurdles in performing clinical trials
Speaker	Strand Vibeke (United States)	SP0070	News from OMERACT – Imaging and more
Speaker	Chowdhury, Badrul A. (United States)		The FDA's view
Speaker	not confirmed yet		Discussion and Q&A with the Faculty

PARE Session - N115 / N116

Barrier free employment for young people with RMDs

Chair	Phoka Andri (Cyprus)		
Chair	Alunno Alessia (Italy)		
Speaker	Kullamaa Lembe	SP0071	Young Patients: Ready, brilliant and

	(Estonia)		able to work!
Speaker	Andersen Jeanette (United Kingdom)	SP0072	Challenges and potential solutions about staying in work as a young person with an RMD
Speaker	McAllister Maureen (United Kingdom)	SP0073	Practical employability support for young people with RMDs
Abstract	O Leary Grainne (Ireland)	OP0198-PARE	FIT FOR WORK ONLINE: SUPPORTING EMPLOYEES WITH RMDs, EMPLOYERS AND HEALTHCARE PROFESSIONALS
Abstract	Putrik Polina (Netherlands)	OP0199-PARE	SUPPORT TO STAY EMPLOYED AND SOCIAL SECURITY ARRANGEMENTS FOR WORK DISABILITY DUE TO RA – PERCEPTIONS OF PATIENTS WITH RA AND RHEUMATOLOGISTS IN 31 EUROPEAN COUNTRIES

EULAR Projects in Epidemiology and Health Services - N117 / N118

Epidemiology of rheumatic and musculoskeletal diseases - a critical appraisal

Chair	Carmona Loreto (Spain)		
Chair	Machado Pedro (United Kingdom)		
Speaker	Symmons Deborah (United Kingdom)		The impact of epidemiological research in rheumatic and musculoskeletal diseases over the past decade
Speaker	Petersson Ingemar (Sweden)		What to learn about strategies for successful development of epidemiological and public health research from other medical areas
Speaker	Gossec Laure (France)	SP0074	The future of epidemiological research in rheumatic and musculoskeletal disorders
Speaker	Dixon William G. (United Kingdom)		The future of public health and health services research in rheumatic and musculoskeletal disorders
Abstract	Frisell Thomas (Sweden)	OP0200	CONFOUNDING BY INDICATION WILL MAKE NON-TNFI BDMARDS APPEAR MORE HARMFUL THAN TNFI BDMARDS - A NATIONWIDE STUDY OF CHANNELING IN SWEDEN 2010-2014

Practical Skills Session - N107 / N108



Crystals II

Chair	Tausche Anne Kathrin (Germany)
Chair	Pascual Eliseo (Spain)
Tutor	Norkuviene Eleonora (Lithuania)
Tutor	Sivera Francisca (Spain)
Tutor	Pimentao José (Portugal)
Tutor	Oliviero Francesca (Italy)

Practical Skills Session - N109 / N110

Ultrasound Advanced I

Chair	Filippou Georgios (Italy)		
Chair	Naredo Esperanza (Spain)		
Speaker	Ohrndorf Sarah (Germany)		How to score synovitis quantitatively - validity and feasibility + demo
Speaker	Ammitzboll Mads (Denmark)	SP0075	How to use image fusion + demo
Speaker	Bong David (Spain)	SP0076	How and when to assess cervical facet joints + demo
Speaker	Vojinovic Jelena (Serbia)	SP0077	How to evaluate joints in JiA + patient cases
Tutor	Midtboell Oernbjerg Lykke (Denmark)		

Thursday 15.06.2017 15:30 - 17:00

WIN & HOT Session - Hall 6

WIN & HOT Session

Chair	Carmona Loreto (Spain)		
Chair	Nikiphorou Elena (United Kingdom)		
Speaker	Dixon William G. (United Kingdom)		WIN Session: Disease registers and electronic patient records for bench marking in rheumatological care
Speaker	Kvien Tore K.		WIN Session: Do published guidelines

(Norway)

and recommendations improve the quality of care in rheumatology?

Clinical Science Session - Hall 8**PsA: an integrated perspective**

Chair	Tam Lai-Shan (China, People's Republic of)		
Chair	Coates Laura (United Kingdom)		
Speaker	Ostergaard Mikkel (Denmark)	SP0078	Can imaging be a predictor of psoriatic disease?
Speaker	Lories Rik (Belgium)	SP0079	Pathologies across the tissues in PsA
Speaker	van den Bosch Filip (Belgium)		New and old agents: how to use our new toys?
Abstract	Nash Peter (Australia)	OP0201	A PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF IXEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR INHIBITOR(S)
Abstract	Gladman Dafna (Canada)	OP0202	EFFICACY AND SAFETY OF TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND AN INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR INHIBITORS: OPAL BEYOND, A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 TRIAL

Challenges in Clinical Practice Session - Hall 7A**Autoinflammatory diseases in children and adults**

Chair	Vojinovic Jelena (Serbia)		
Chair	Ionescu Ruxandra (Romania)		
Presenter	Blazina Stefan (Slovenia)		Case 1 presentation: Chronic nonbacterial osteomyelitis - a child with bone pain
Discussant	Girschick Hermann (Germany)		Case 1 discussion: Diagnosis and management of chronic nonbacterial osteomyelitis
Presenter	Deaconu Claudia	SP0080	Case 2 presentation: Recurrent

(Romania)

episodes of fever and arthritis in adult patient

Discussant
Cantarini Luca
(Italy)

Case 2 discussion: Diagnosis and management of autoinflammatory diseases in adults

From Bench to Bedside - Hall 7B

Immunogenicity of biologics; Myth or reality?

Chair
Wolbink Gert-Jan
(Netherlands)

Chair
Mauri Claudia
(United Kingdom)

Speaker
Maillere Bernard
(France) SP0081

The T-cell response against biologics

Speaker
Gils Ann (Belgium) SP0082

Immunogenicity of biologics in inflammatory bowel diseases

Speaker
Bijlsma Johannes
W.J. (Netherlands) SP0083

As a rheumatologist, does it have any consequence in my daily practice?

Abstract
Kay Jonathan
(United States) OP0203

IMPACT OF ADALIMUMAB SERUM CONCENTRATION ON EFFICACY AND ASSOCIATION BETWEEN ANTI-DRUG ANTIBODIES AND SERUM CONCENTRATION: 24 WEEK RESULTS FROM A PHASE III STUDY COMPARING SB5 (AN ADALIMUMAB BIOSIMILAR) WITH REFERENCE ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS

Abstract
Vencovsky Jiri
(Czech Republic) OP0204

IMPACT OF ANTI-DRUG ANTIBODY AND INJECTION SITE REACTION ON EFFICACY: 24-WEEK RESULTS FROM A PHASE III STUDY COMPARING SB4 (ETANERCEPT BIOSIMILAR) WITH REFERENCE ETANERCEPT IN PATIENTS WITH RHEUMATOID ARTHRITIS

Clinical Science Session - N103 / N104

Which target/outcome is more relevant in the management of SLE?

Chair
Tincani Angela
(Italy)

Chair
Bertsias Georges
(Greece)

Speaker
Doria Andrea (Italy)

Clinical targets

Speaker
Chizzolini Carlo
(Switzerland) SP0084

Biological targets

Speaker	Schneider Matthias (Germany)	SP0085	Patient reported outcomes
Abstract	Nakayamada Shingo (Japan)	OP0205	ASSOCIATION BETWEEN T FOLLICULAR HELPER CELL AND PLASMABLAST CORRELATES WITH DISEASE ACTIVITY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
Abstract	Jesus Diogo (Portugal)	OP0206	PERFORMANCE OF SLEDAI-2K TO DETECT A CLINICALLY MEANINGFUL CHANGE IN SLE DISEASE ACTIVITY: A 36-MONTH PROSPECTIVE COHORT STUDY OF 334 PATIENTS.

Basic and Translational Science Session - South Auditorium

Joint EULAR - EFIS session: Tilting the balance: from disease to tolerance induction

Chair	Toes Rene (Netherlands)		
Chair	Taams Leonie (United Kingdom)		
Speaker	Klatzmann David (France)		Low dose IL-2 and tolerance induction: the holy grail?
Speaker	Chang Hyun-Dong (Germany)	SP0086	Pathogenic memory cells: road blocks to tolerance induction?
Speaker	Isaacs John D. (United Kingdom)	SP0087	How antigen presenting cells can be tuned into tolerogenic cells
Abstract	Numajiri Hiroko (Japan)	OP0207	B CELL DEPLETION INCREASES REGULATORY T CELLS AND AMELIORATES SKIN AND LUNG FIBROSIS IN A BLEOMYCIN-INDUCED SYSTEMIC SCLEROSIS MODEL MOUSE.
Abstract	Kurowska-Stolarska Mariola (United Kingdom)	OP0208	SYNOVIAL TISSUE OF RA PATIENTS IN REMISSION CONTAINS A UNIQUE POPULATION OF REGULATORY MACROPHAGES

Health Professionals Session - N101 / N102

What to do about co-morbidity?

Chair	Moe Rikke Helene (Norway)		
Chair	Dekker Joost (Netherlands)		
Speaker	Häkkinen Arja Helena (Finland)	SP0088	New drugs, but still comorbidity

Speaker	Neovius Martin (Sweden)		Costs of comorbidity
Speaker	Dagfinrud Hanne (Norway)	SP0089	How to prevent and treat cardiovascular comorbidity with exercise?
Speaker	de Rooij Mariette (Netherlands)	SP0090	Co-morbidity-adapted exercise for patients with knee osteoarthritis
Abstract	MARTIN MARTINEZ MARIA AUXILIADORA (Spain)	OP0209-HPR	INCIDENCE OF FIRST CARDIOVASCULAR EVENT IN SPANISH PATIENTS WITH CHRONIC INFLAMMATORY RHEUMATIC DISEASES: PROSPECTIVE DATA FROM THE CARMA PROJECT

Practical Skills Session - N111 / N112

Data visualisation: tables and graphs for publication and presentation I

Speaker	Boers Maarten (Netherlands)	SP0091	Data visualisation: tables and graphs for publication and presentation
---------	--------------------------------	--------	--

PARE Session - N115 / N116

Difficult to reach patient groups

Chair	Boteva Boryana (Bulgaria)		
Chair	Betteridge Neil (United Kingdom)		
Speaker	Zänker Michael (Germany)	SP0092	The vicious circle of educational level of rheumatoid arthritis and risk of poverty - results of a cross-sectional multicentre study in Germany
Speaker	Kumar Kanta (United Kingdom)	SP0093	The challenges and solutions for engaging patients from ethnic backgrounds in rheumatology care
Speaker	Diao Tidiane (Sweden)	SP0094	The Swedish experience - how a patient organisation could reach out to immigrants and develop through integration
Abstract	Stones Simon (United Kingdom)	OP0210-PARE	THE DEVELOPMENT AND EVALUATION OF AN INTERACTIVE HEALTH COMMUNICATION APPLICATION TO EDUCATE AND EMPOWER YOUNG PEOPLE LIVING WITH JUVENILE IDIOPATHIC ARTHRITIS: A PILOT STUDY
Abstract	Bosworth Ailsa (United Kingdom)	OP0211-PARE	WHO CARES? AN INVESTIGATION OF THE HEALTH AND PERCEIVED SOCIAL CARE NEEDS OF PEOPLE

WITH RHEUMATOID ARTHRITIS
LIVING IN SCOTLAND.

 **EULAR Projects in Musculoskeletal Imaging - N117 / N118**

 **EULAR Projects in Musculoskeletal Imaging**

Chair	Naredo Esperanza (Spain)		
Chair	Baraliakos Xenophon (Germany)		
Speaker	Dejaco Christian (Austria)	SP0095	EULAR recommendations for the use of imaging in the diagnosis and management of large vessel vasculitis in clinical practice
Speaker	d'Agostino Maria- Antonietta (France)		Development of EULAR recommendations for the reporting of musculoskeletal ultrasound studies in rheumatology
Speaker	Collado Paz (Spain)	SP0096	EULAR-PRoS Standardised procedures for Ultrasound Imaging in Paediatric Rheumatology
Speaker	Gandjbakhch Frédérique (France)		Definition of Rheumatoid Arthritis bone erosion
Speaker	d'Agostino Maria- Antonietta (France)		EULAR Recommendation/criteria for the Appropriate Use of MSK US in Rheumatology Clinical Practice
Speaker	Möller Ingrid (Spain)	SP0097	EULAR Standardised procedures for Rheumatology Ultrasound Imaging

 **Practical Skills Session - N107 / N108**

 **Capillaroscopy I**

Chair	Ingegnoli Francesca (Italy)		
Chair	Sulli Alberto (Italy)		
Speaker	Smith Vanessa (Belgium)	SP0098	The importance to differentiate normal from abnormal capillaroscopic images for an early diagnosis of disease
Speaker	Sulli Alberto (Italy)		Scoring the capillaroscopic images: manual versus (semi)automatic systems
Speaker	Herrick Ariane L. (United Kingdom)		How to distinguish the major capillaroscopic patterns in connective tissue diseases
Speaker	Cutolo Maurizio (Italy)	SP0099	Why capillaroscopy can predict disease severity and prognosis

Speaker	Hermann Walter (Germany)	SP0100	How to select the most appropriate capillaroscopic device: pros and cons
Speaker	not confirmed yet		Live Practical sessions with patients and case discussion

Practical Skills Session - N109 / N110

Ultrasound, Clinical, diagnostic and therapeutic skills I

Chair	Damjanov Nemanja (Serbia)		
Chair	Roccatello Dario (Italy)		
Speaker	Mandl Peter (Austria)	SP0101	Diagnostic and therapeutic ultrasound- guided procedures
Speaker	Doherty Michael (United Kingdom)	SP0102	How to perform a quick and efficient physical examination
Speaker	Caporali Roberto (Italy)		How to read and interpret imaging tools: X-Ray
Speaker	Hammer Hilde Bernier (Norway)	SP0103	How to assess US competency skills
Speaker	not confirmed yet		Q&A

Thursday 15.06.2017 17:30 - 19:00

Basic and Translational Science Session - South Auditorium

Macrophage M2 polarization: implications in fibrotizing diseases

Chair	Distler Oliver (Switzerland)		
Chair	Müller-Ladner Ulf (Germany)		
Speaker	Sica Antonio (Italy)	SP0104	Molecular and epigenetic basis of macrophage polarized activation
Speaker	Camara Niels (Brazil)	SP0105	Macrophages during the fibrotic process: friend or foe
Speaker	Lafyatis Robert (United States)		Alternative activation of monocyte/macrophages in pathophysiology of fibrotizing diseases
Abstract	Soldano Stefano (Italy)	OP0212	ENDOTHELIN-1 INDUCES A PROFIBROTIC PHENOTYPE IN CULTURED HUMAN MICROVASCULAR ENDOTHELIAL AND CIRCULATING MONOCYTE/MACROPHAGE CELLS
Abstract	King Jamie (United Kingdom)	OP0213	MACROPHAGES FROM A SCLERODERMA SUBGROUP WITH

HIGHER SKIN SCORES EXPRESS
ACTIVATION MARKERS AND
INDUCE FIBROBLASTS IN CO-
CULTURE

🕒 Friday 16.06.2017 08:15 - 09:45

🏠 Basic and Translational Science Session - South Auditorium

🏠 Mucosal B cells: gatekeepers of immune function

Chair	Somers Veerle (Belgium)		
Chair	Jacques Peggy (Belgium)		
Speaker	Mauri Claudia (United Kingdom)		How microbiota shape regulatory B cells
Speaker	Catrina Anca (Sweden)	SP0106	The lung in RA as driver of ACPA: cause or consequence
Abstract	Chiba Asako (Japan)	OP0214	ACTIVATION STATUS OF MUCOSAL-ASSOCIATED INVARIANT T CELLS REFLECTS PATHOLOGY OF SYSTEMIC LUPUS ERYTHEMATOSUS.
Abstract	Hirose Sachiko (Japan)	OP0215	ROLE OF INHIBITORY IGG FC RECEPTOR IIB ON B CELLS AND MONOCYTES IN YAA-RELATED MURINE LUPUS

🕒 Friday 16.06.2017 10:15 - 11:45

🏠 WIN & HOT Session - Hall 6

🏠 WIN & HOT Session

Chair	Calvo Alén Jaime (Spain)		
Chair	Pisetsky David S. (United States)		
Speaker	Denton Christopher (United Kingdom)	SP0107	HOT Session: Scleroderma treatment
Speaker	Gottenberg Jacques-Eric (France)		WIN Session: Sjögren's Syndrome

🏠 Abstract Session - Hall 8

🏠 Abstract Session: PsA: The options grow!

Chair	Tam Lai-Shan (China, People's Republic of)		
Chair	Hueber Axel (Germany)		
Abstract	Mease Philip (United States)	OP0216	EFFICACY AND SAFETY OF TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, OR ADALIMUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND AN INADEQUATE RESPONSE TO CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (CSDMARDS): A RANDOMISED, PLACEBO-CONTROLLED, PHASE 3 TRIAL
Abstract	Araujo Elizabeth (Germany)	OP0217	USTEKINUMAB IS SUPERIOR TO TNF INHIBITOR TREATMENT IN RESOLVING ENTHESITIS IN PSA PATIENTS WITH ACTIVE ENTHESITIS- RESULTS FROM THE ENTHESIAL CLEARANCE IN PSORIATIC ARTHRITIS (ECLIPSA) STUDY
Abstract	Deodhar Atul (United States)	OP0218	EFFICACY AND SAFETY RESULTS OF GUSELKUMAB, AN ANTI-IL23 MONOCLONAL ANTIBODY, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS OVER 24 WEEKS: A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
Abstract	Nash Peter (Australia)	OP0219	EARLY ONSET OF EFFICACY WITH APREMILAST MONOTHERAPY IN BIOLOGIC-NAÏVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: A PHASE 3B, RANDOMIZED, CONTROLLED TRIAL
Abstract	O'Dell James (United States)	OP0220	RANDOMIZED, DOUBLE-BLIND, GLOBAL CLINICAL TRIAL TO EVALUATE EQUIVALENCE OF CHS-1420 TO ADALIMUMAB IN PATIENTS WITH PSORIASIS AND PSORIATIC ARTHRITIS
Abstract	van der Heijde Désirée (Netherlands)	OP0221	RADIOGRAPHIC PROGRESSION OF STRUCTURAL JOINT DAMAGE IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS TREATED WITH IXEKIZUMAB OVER 52 WEEKS
Abstract	McInnes Iain	OP0222	SECUKINUMAB PROVIDES

(United Kingdom)

SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS: 104 WEEKS RESULTS FROM A PHASE 3 TRIAL, FUTURE 2

Abstract	Mease P (United States)	OP0223	ABATACEPT IN THE TREATMENT OF ACTIVE PSORIATIC ARTHRITIS: 1-YEAR RESULTS FROM A PHASE III STUDY
----------	-------------------------	--------	---

Abstract Session - Hall 7A

Abstract Session: From classics to new: synthetic DMARDs in RA

Chair	Taylor Peter C. (United Kingdom)		
Chair	Mourão Ana Filipa (Portugal)		
Abstract	Bergstra Sytske Anne (Netherlands)	OP0224	SIMILAR SHORT TERM CLINICAL RESPONSE TO INITIAL TREATMENT WITH HIGH VERSUS LOW DOSE METHOTREXATE IN MONO- AND COMBINATION THERAPY IN EARLY RHEUMATOID ARTHRITIS PATIENTS
Abstract	Davies Rebecca (United Kingdom)	OP0225	THE EFFECT OF A LOW VERSUS HIGH FIRST PRESCRIBED DOSE OF METHOTREXATE ON EULAR RESPONSE AT SIX MONTHS USING DATA FROM THE RAMS STUDY
Abstract	Stouten Veerle (Belgium)	OP0226	SUSTAINED EFFECTIVENESS OF METHOTREXATE WITH STEP-DOWN GLUCOCORTICOID REMISSION INDUCTION (COBRA SLIM) FOR EARLY RHEUMATOID ARTHRITIS IN A TREAT-TO-TARGET SETTING: 2-YEAR RESULTS OF THE CARERA TRIAL
Abstract	Brunekreef Tammo (Netherlands)	OP0227	REMISSION INDUCTION WITH METHOTREXATE STEP-UP THERAPY VERSUS COMBINATION OF HYDROXYCHLOROQUINE, METHOTREXATE AND TRIAMCINOLONE: 3 YEAR RESULTS
Abstract	Westhovens René (Belgium)	OP0229	EFFECT OF BASELINE SERUM CRP LEVELS ON CLINICAL EFFICACY IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH FILGOTINIB: POST-HOC ANALYSIS FROM TWO PHASE 2B STUDIES
Abstract	Fleischmann Roy (United States)	LB0003	TOFACITINIB WITH AND WITHOUT METHOTREXATE VERSUS

ADALIMUMAB WITH
METHOTREXATE FOR THE
TREATMENT OF RHEUMATOID
ARTHRITIS: RESULTS FROM ORAL
STRATEGY, A PHASE 3B/4
RANDOMISED TRIAL

Abstract Winthrop Kevin
(United States) OP0230

THE EFFECTIVENESS OF ZOSTER
VACCINE IN RA PATIENTS
SUBSEQUENTLY TREATED WITH
TOFACITINIB

Abstract Session - Hall 7B

Abstract Session: New treatments in SLE, Sjögren's and APS

Chair Hiepe Falk
(Germany)

Chair Alunno Alessia
(Italy)

Abstract Rodríguez-Pintó
Ignasi (Spain) OP0231

THE EFFECT OF "TRIPLE THERAPY"
WITH ANTICOAGULATION PLUS
CORTICOSTEROIDS PLUS PLASMA
EXCHANGE AND/OR INTRAVENOUS
IMMUNOGLOBULINS ON THE
MORTALITY OF CATASTROPHIC
ANTIPHOSPHOLIPID SYNDROME
(CAPS) PATIENTS

Abstract Wallace Daniel
(United States) OP0232

SUSTAINED SAFETY AND
EFFICACY OVER 10 YEARS WITH
BELIMUMAB (BEL) PLUS STANDARD
SYSTEMIC LUPUS
ERYTHEMATOSUS (SLE) THERAPY
(SOC) IN PATIENTS WITH SLE

Abstract Fasano Serena
(Italy) OP0233

PRIMARY PROPHYLAXIS OF
CARDIOVASCULAR EVENTS IN
SYSTEMIC LUPUS
ERYTHEMATOSUS: A
RETROSPECTIVE ANALYSIS OF 291
PATIENTS FROM TWO ITALIAN
CENTERS

Abstract Cheng Laurence
(United States) OP0234

CLINICAL AND BIOLOGIC EFFECTS
OF ICOSL BLOCKADE BY AMG 557
IN SUBJECTS WITH LUPUS
ARTHRITIS

Abstract El-Sherbiny Yasser
(United Kingdom) OP0235

A NOVEL B CELL SPECIFIC IFN-I
BIOMARKER IS ASSOCIATED WITH
PLASMA BLAST NUMBERS
FOLLOWING B CELL DEPLETION
THERAPY IN SLE

Abstract Yelnik Cécile
(France) OP0236

BENEFIT AND SAFETY OF
ANTITHROMBOTIC TREATMENT IN

264 PREGNANCIES IN PATIENTS
WITH ANTIPHOSPHOLIPID
SYNDROME

Abstract	Dobronravov Vladimir (Russian Federation)	LB0002	48 WEEK COMPLETE REMISSION OF ACTIVE LUPUS NEPHRITIS WITH VOCLOSPORIN
Abstract	Shojaei Amir (United States)	OP0237	LIFITEGRAST OPHTHALMIC SOLUTION 5.0% FOR TREATMENT OF DRY EYE DISEASE: COMBINED EVIDENCE FROM 5 RANDOMIZED CONTROLLED TRIALS.

Abstract Session - N103 / N104

Abstract Session: Axial Spondyloarthritis from risk factor to clinical outcomes

Chair	van Gaalen Floris A. (Netherlands)		
Chair	van Onna Marloes (Netherlands)		
Abstract	Garrido-Castro Juan (Spain)	OP0238	MEASUREMENT OF SPINAL MOBILITY IN AXIAL SPONDYLOARTHRITIS USING INERTIAL SENSORS: RELIABILITY AND VALIDATION PRELIMINARY RESULTS.
Abstract	Alivernini Stefano (Italy)	OP0239	HISTOLOGICAL FEATURES OF JOINT AND COLONIC INFLAMMATION IN INFLAMMATORY BOWEL DISEASE PATIENTS TREATED WITH ANTI-TNF
Abstract	Bengtsson Karin (Sweden)	OP0240	HOW STRONG ARE THE ASSOCIATIONS OF SPONDYLOARTHRITIS-RELATED COMORBIDITIES WITH ANKYLOSING SPONDYLITIS, PSORIATIC ARTHRITIS AND UNDIFFERENTIATED SPONDYLOARTHRITIS? – A REGISTER-BASED STUDY FROM SWEDEN
Abstract	de Koning Anoek (Netherlands)	OP0241	ERAP1 IS A SUSCEPTIBILITY FACTOR FOR EARLY AXIAL SPONDYLOARTHRITIS MEETING THE ASAS CLASSIFICATION CRITERIA: RESULTS FROM THE DESIR AND SPACE COHORTS
Abstract	Puyraimond- Zemmour Deborah (France)	OP0242	HEALTH-RELATED QUALITY OF LIFE IMPROVED ONLY SLIGHTLY ALTHOUGH DISEASE ACTIVITY DECREASED OVER 3 YEARS IN

EARLY AXIAL
SPONDYLOARTHRITIS: 442
PATIENTS FROM THE DESIR
COHORT.

Abstract	Sieper Joachim (Germany)	OP0243	PREDICTORS OF REMISSION AT WEEK 12 IN PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS RECEIVING OPEN-LABEL ADALIMUMAB TREATMENT IN THE ABILITY-3 STUDY
Abstract	van Gaalen Floris (Netherlands)	OP0244	FAMILY MATTERS: VALUE OF FAMILY HISTORY OF SPONDYLOARTHRITIS IN THE DIAGNOSTIC WORK-UP OF PATIENTS WITH CHRONIC BACK PAIN: RESULTS FROM THE SPACE AND DESIR COHORTS.
Abstract	Webers Casper (Netherlands)	OP0245	EMPLOYMENT PERSPECTIVES OF PATIENTS WITH ANKYLOSING SPONDYLITIS IN THE BIOLOGICS ERA

Abstract Session - South Auditorium

Abstract Session: RA - causes and courses

Chair	Turesson Carl (Sweden)		
Chair	Verstappen Suzanne (United Kingdom)		
Abstract	Wallman Johan (Sweden)	OP0246	IMPACT OF DISEASE ACTIVITY MEASURES ON SICK LEAVE IN BIOLOGICS-TREATED PATIENTS WITH RHEUMATOID ARTHRITIS: OBSERVATIONAL DATA FROM SOUTHERN SWEDEN
Abstract	Vanier Antoine (France)	OP0247	AN IMPROVED MATRIX TO PREDICT RAPID RADIOGRAPHIC PROGRESSION OF EARLY RHEUMATOID ARTHRITIS PATIENTS: POOLED ANALYSES FROM SEVERAL DATABASES
Abstract	Winthrop Kevin (United States)	OP0248	SERIOUS INFECTION AND ASSOCIATED RISK FACTORS IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS TREATED WITH BARICITINIB
Abstract	Hagen Melanie (Germany)	OP0249	MULTI-BIOMARKER DISEASE ACTIVITY AND AUTOANTIBODY

STATUS LEAD TO COST EFFECTIVE
TAPERING ALGORITHMS IN
RHEUMATOID ARTHRITIS PATIENTS
IN SUSTAINED REMISSION

Abstract Freeston Jane
(United Kingdom) OP0250

CAN RANKL SERUM LEVELS
PREDICT FUTURE PROGRESSION
TO RHEUMATOID ARTHRITIS IN
ACPA NEGATIVE PATIENTS?

Abstract Dreyer Lene
(Denmark) OP0251

INCIDENCE OF KNEE AND HIP
REPLACEMENTS IN RHEUMATOID
ARTHRITIS PATIENTS FOLLOWING
INTRODUCTION OF BIOLOGICAL
DMARDS: AN INTERRUPTED TIME
SERIES ANALYSIS USING
NATIONWIDE HEALTH CARE
REGISTERS

Abstract Bergstra Sytske
Anne (Netherlands) OP0252

RHEUMATOID ARTHRITIS PATIENTS
WITH CONTINUED LOW DISEASE
ACTIVITY HAVE SIMILAR
OUTCOMES OVER 10 YEARS,
REGARDLESS OF INITIAL THERAPY.

Abstract Seror Raphaële
(France) OP0253

PASSIVE SMOKING IN CHILDHOOD
AND HISTORY OF CHRONIC
DIARRHEA INCREASES THE RISK
OF DEVELOPING RHEUMATOID
ARTHRITIS (RA).

Abstract Session - N101 / N102

HPR Abstract Session: Move to improve

Chair Oesch Peter
(Switzerland)

Chair Alliot Françoise
(France)

Abstract Ellegaard Karen
(Denmark) OP0254-HPR

HAND EXERCISE FOR WOMEN
WITH RHEUMATOID ARTHRITIS
AND DECREASED ADL ABILITY: AN
EXPLORATORY RANDOMISED
CONTROLLED TRIAL

Abstract Berdal G. (Norway) OP0255-HPR

AN ADD-ON PROGRAMME
IMPROVED THE SHORT-TERM, BUT
NOT THE LONG-TERM EFFECT OF
REHABILITATION IN PATIENTS WITH
RHEUMATIC DISEASES: RESULTS
FROM A PRAGMATIC MULTI-
CENTRE STEPPED-WEDGE
CLUSTER RANDOMIZED
CONTROLLED TRIAL

Abstract Boström Carina
OP0256-HPR

PHYSICAL ACTIVITY AND

	(Sweden)		INACTIVITY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
Abstract	Villarreal Laura (Colombia)	OP0257-HPR	RELATIONSHIP BETWEEN SLEEP DISORDERS AND DISEASE ACTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS
Abstract	Lange Elvira (Sweden)	OP0258-HPR	INTENSIVE PHYSICAL EXERCISE FOR ELDERLY PERSONS WITH RHEUMATOID ARTHRITIS IMPROVES PHYSICAL CAPACITY
Abstract	Miyamoto Samira (Brazil)	OP0259-HPR	SUPERVISED WALKING IMPROVES AEROBIC CAPACITY, EXERCISE TOLERANCE, FATIGUE AND PERCEIVED IMPROVEMENT IN WOMEN WITH PRIMARY SJÖGREN'S SYNDROME: A RANDOMIZED CONTROLLED TRIAL
Abstract	Mannerkorpi Kaisa (Sweden)	OP0260-HPR	HIGHER SATISFACTION WITH ACTIVITY-RELATED SYMPTOMS AFTER 15-WEEK RESISTANCE EXERCISE IN WOMEN WITH FIBROMYALGIA
Abstract	Risum Kristine (Norway)	OP0261-HPR	PHYSICAL ACTIVITY LEVEL MEASURED BY ACCELEROMETER IS COMPARABLE BETWEEN JUVENILE IDIOPATHIC ARTHRITIS PATIENTS AND CONTROLS, BUT PATIENTS SPEND LESS TIME IN VIGOROUS PHYSICAL ACTIVITY

Abstract Session - N105 / N106

Abstract Session: Gout: advances in diagnosis and management

Chair	Pascual Eliseo (Spain)		
Chair	Dalbeth Nicola (New Zealand)		
Abstract	Dehlin Mats (Sweden)	OP0262	TRENDS AND COSTS FOR GOUT HOSPITALIZATION IN SWEDEN
Abstract	Merriman Tony (New Zealand)	OP0263	TRANS-ANCESTRAL META-ANALYSIS IDENTIFIES 13 NEW LOCI ASSOCIATED WITH SERUM URATE LEVELS
Abstract	Choi Hyon (United States)	OP0264	CAN MODERATE ALCOHOL INTAKE LOWER THE RISK OF MYOCARDIAL INFARCTION AND MORTALITY EVEN AMONG GOUT PATIENTS?
Abstract	Gaffo Angelo	OP0265	VALIDATION OF A DEFINITION FOR

	(United States)		ATTACK (FLARE) IN PATIENTS WITH ESTABLISHED GOUT
Abstract	Dalbeth Nicola (New Zealand)	OP0266	PRESENCE OF MONOSODIUM URATE CRYSTALS BY DUAL-ENERGY COMPUTED TOMOGRAPHY IN GOUT PATIENTS TREATED WITH ALLOPURINOL
Abstract	Stamp Lisa (New Zealand)	OP0267	SERUM URATE AS A SURROGATE ENDPOINT FOR GOUT FLARES: RESULTS OF A SYSTEMATIC REVIEW AND META-REGRESSION ANALYSIS OF RANDOMIZED TRIALS
Abstract	Doherty Michael (United Kingdom)	OP0268	NURSE-LED CARE VERSUS GENERAL PRACTITIONER CARE OF PEOPLE WITH GOUT: A UK COMMUNITY-BASED RANDOMISED CONTROLLED TRIAL
Abstract	Bredemeier Markus (Brazil)	OP0269	EFFECT OF XANTHINE OXIDASE INHIBITORS ON THE INCIDENCE OF CARDIOVASCULAR EVENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS

Abstract Session - N111 / N112

Abstract Session: Low back pain and fibromyalgia

Chair	Hider Samantha (United Kingdom)		
Chair	Prior James (United Kingdom)		
Abstract	Nguyen Christelle (France)	LB0001	INTRADISCAL GLUCOCORTICOID INJECTION FOR PATIENTS WITH CHRONIC LOW BACK PAIN ASSOCIATED WITH ACTIVE DISCOPATHY: A RANDOMIZED TRIAL
Abstract	Hansen Liselotte (Denmark)	OP0270	LONG-TERM PROGNOSIS IN CHRONIC PLANTAR FASCIITIS BASED ON DISEASE DURATION AND ULTRASONIC CHANGES
Abstract	Nissen Michael (Switzerland)	OP0271	CORTICOSTEROID INJECTIONS FOR GREATER TROCHANTERIC PAIN SYNDROME: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL
Abstract	Singh Gurkirpal (United States)	OP0272	CHRONIC LOW BACK PAIN AND ANXIETY: SIGNIFICANT DECREASE WITH GLUCOSAMINE-

CHONDROITIN SULFATE
TREATMENT IN A LARGE,
COMMUNITY-BASED, PILOT, OPEN
PROSPECTIVE INTERVENTIONAL
STUDY

Abstract	Weitzman Dahlia (Israel)	OP0273	A RETROSPECTIVE DATABASE STUDY OF ONE-YEAR ADEHERNCE AND PERSISTENCE WITH PHARMACOLOGICAL THERAPY AMONG FIBROMYALGIA PATIENTS IN ISRAEL
Abstract	Laroche Françoise (France)	OP0274	FIBROMYALGIA IN REAL LIFE A NATIONAL FRENCH WEB-BASED SURVEY IN 4516 PATIENTS
Abstract	Ghib Linda Jessica (Romania)	OP0275	FIBROMYALGIA PREVALENCE AND IMPACT ON DISEASE ACTIVITY SCORES IN RHEUMATOID ARTHRITIS PATIENTS WHO ARE UNRESPONSIVE TO BIOLOGICAL TREATMENT

Abstract Session - N115 / N116

PARE Abstract Session

Chair	O'Leary Gráinne (Ireland)		
Chair	Cattelaens Karl (Germany)		
Speaker	Hulst Stefanie (Netherlands)		Edgar Stene Prize 2017: Diagnosis from the perspective of a child
Abstract	Mateus Elsa (Portugal)	OP0276-PARE	MORE PARTICIPATION, BETTER HEALTH – PROMOTING PUBLIC INVOLVEMENT IN HEALTH
Abstract	Ekroth M. (Finland)	OP0277-PARE	INITIAL INFORMATION PACKAGE FOR CHILDREN DIAGNOSED WITH JIA
Abstract	Grange Laurent (France)	OP0278-PARE	THE FRENCH PATIENT'S ASSOCIATION (AFLAR: FRENCH LEAGUE AGAINST RHEUMATISM) HAS GENERATED THE FRENCH NATIONAL ALLIANCE AGAINST OSTEOARTHRITIS AND THE FIRST GENERAL CONVENTION OF OSTEOARTHRITIS IN FRANCE: A CAMPAIGN TO CREATE A NATIONAL LOBBYING TOOL TO IMPROVE THE MANAGEMENT OF OSTEOARTHRITIS.
Abstract	Jacklin Clare	OP0279-PARE	NRAS KNOW YOUR DAS APP SELF

	(United Kingdom)		ASSESSMENT TOOL EMPOWERING PATIENTS
Abstract	Andersen Jeanette (United Kingdom)	OP0280-PARE	PATIENT PANELS ON ACCESS AND ADHERENCE TO TREATMENT FOR SLE PATIENTS
Abstract	Phoka Charalambous Androulla (Cyprus)	OP0281-PARE	EDUCATING PATIENT EXPERTS/PATIENT PARTNERS - A NEW WAY
Abstract	Nordlund Kim (Sweden)	OP0282-PARE	#DOESNTSHOWDOESNTEXIST / #SYNSINTEFINNSINTE – A PHOTO CAMPAIGN BY UNGA REUMATIKER

Abstract Session - N117 / N118

Abstract Session: Imaging and treatment response in Rheumatology

Chair	Conaghan Philip (United Kingdom)		
Chair	Dale James (United Kingdom)		
Abstract	Stoenoiu Maria (Belgium)	OP0283	ULTRASONOGRAPHIC EVALUATION IN RHEUMATOID ARTHRITIS USING THE GLOBAL OMERACT/EULAR ULTRASOUND SYNOVITIS SCORE (GLOESS)
Abstract	Ahmad HA (United States)	OP0284	EVALUATION OF THE IMPACT OF BASELINE LEVELS OF MRI-DETECTED INFLAMMATION ON TREATMENT RESPONSE IN EARLY, SEROPOSITIVE, MTX-NAÏVE RA: DATA FROM THE AVERT TRIAL
Abstract	Nielsen Berit (Denmark)	OP0285	ATTENUATION OF FLUORINE-18-FLUORODEOXYGLUCOSE UPTAKE IN LARGE VESSEL GIANT CELL ARTERITIS AFTER SHORT-TERM HIGH-DOSE STEROID TREATMENT - A DIAGNOSTIC WINDOW OF OPPORTUNITY
Abstract	Ammitzbøll-Danielsen Mads (Denmark)	OP0286	THE UTILITY OF THE OMERACT ULTRASOUND TENOSYNOVITIS SCORING SYSTEM IN MULTICENTER CLINICAL TRIALS
Abstract	Seven Sengül (Denmark)	OP0287	ULTRASONOGRAPHY-DETECTED PERIPHERAL ENTHESITIS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS – ANATOMICAL DISTRIBUTION, MORPHOLOGY AND RESPONSE TO ANTI-TNF THERAPY
Abstract	Mandl Peter	OP0288	RELIABILITY OF A EULAR-

(Austria)

OMERACT SEMIQUANTITATIVE SCORING SYSTEM FOR THE ASSESSMENT OF CARTILAGE IN RHEUMATOID ARTHRITIS

Abstract	Sundlisater Nina (Norway)	OP0289	TREAT-TO-TARGET IN EARLY RHEUMATOID ARTHRITIS: ASSOCIATION BETWEEN SUSTAINED REMISSION AND JOINT DAMAGE
Abstract	Pimenta Emanuela (Brazil)	OP0290	CORRELATION OF CXCL13 AND ULTRASSONOGRAPHIC FINDINGS OF JACCOUD ARTHROPATHY IN SYSTEMIC LUPUS ERYTHEMATOSUS

Abstract Session - N107 / N108

Abstract Session: From genetics through epigenetics to proteomics: understanding disease mechanisms

Chair	Barton Anne (United Kingdom)		
Chair	Ospelt Caroline (Switzerland)		
Abstract	Smith Samantha (United Kingdom)	OP0291	IDENTIFICATION OF NOVEL SUSCEPTIBILITY LOCI IN A LARGE UK COHORT OF JUVENILE IDIOPATHIC ARTHRITIS (JIA) CASES
Abstract	Aterido Adrià (Spain)	OP0292	GENETIC VARIATION ASSOCIATED WITH CARDIOVASCULAR RISK IN AUTOIMMUNE DISEASES
Abstract	Teitsma Xavier (Netherlands)	OP0293	WEIGHTED GENE CO-EXPRESSION NETWORK ANALYSIS OF DMARD-NAÏVE EARLY RA PATIENTS ACHIEVING SUSTAINED DRUG-FREE REMISSION AFTER INITIATING TOCILIZUMAB THERAPY
Abstract	Ferrari Serge (Switzerland)	OP0294	FRACTURE PREDICTION USING A GENETIC MARKERS ALGORITHM COMPARED TO FRAX IN THREE EUROPEAN COHORTS
Abstract	Anaparti Vidyanand (Canada)	OP0295	UNIQUE WHOLE BLOOD MICRORNA BIOSIGNATURE FOR RHEUMATOID ARTHRITIS
Abstract	Purvis Harriet (United Kingdom)	OP0296	AUTOIMMUNE ASSOCIATED GENE PTPN22 NEGATIVELY REGULATES DECTIN-1 SIGNALLING IN DENDRITIC CELLS
Abstract	Stiburkova Blanka (Czech Republic)	OP0297	FUNCTIONAL POLYMORPHISMS OF THE ABCG2 GENE IN PRIMARY

GOUT

Abstract	Martin Paul (United Kingdom)	OP0298	CHROMATIN INTERACTIONS REVEAL NOVEL GENE TARGETS FOR DRUG REPOSITIONING IN RHEUMATIC DISEASES
----------	------------------------------	--------	---

Abstract Session - N109 / N110

Abstract Session: Innovative insights into mechanism of SLE, Sjögren's and APS

Chair	Isenberg David (United Kingdom)		
Chair	Peene Isabelle (Belgium)		
Abstract	Truglia Simona (Italy)	OP0299	SERUM AND GLOMERULAR EXPRESSION OF IL32 IN LUPUS NEPHRITIS
Abstract	Pontarini Elena (United Kingdom)	OP0300	ENRICHMENT OF T FOLLICULAR-HELPER CELLS (TFH) AND EXCLUSION OF T FOLLICULAR-REGULATORY CELLS (TFR) FROM ECTOPIC GERMINAL CENTERS IN SALIVARY GLANDS OF SJOGREN'S SYNDROME PATIENTS.
Abstract	Liu Hao (United States)	OP0301	TYPE I IFN GENE SIGNATURE TEST-HIGH AND -LOW PATIENTS WITH MODERATE TO SEVERE SLE DISEASE ACTIVITY HAVE DISTINCT GENE EXPRESSION SIGNATURES OF IMMUNOLOGIC PATHWAYS AND CELL TYPES
Abstract	Kraaij Tineke (Netherlands)	OP0302	SIGNIFICANT REDUCTIONS OF PATHOGENIC AUTOANTIBODIES BY SYNERGETIC RITUXIMAB AND BELIMUMAB TREATMENT EFFECTIVELY INHIBITS NEUTROPHIL EXTRACELLULAR TRAPS IN SEVERE, REFRACTORY SLE - THE SYNBIOSE STUDY
Abstract	Blokland Sofie (Netherlands)	OP0303	THE SALIVARY GLAND SECRETOME AS A POTENTIAL NEW TOOL TO IDENTIFY BIOMARKERS OF DRYNESS AND IMMUNOPATHOLOGY IN PRIMARY SJÖGREN'S SYNDROME AND NON-AUTOIMMUNE SICCA PATIENTS
Abstract	Rangel-Moreno Javier (United States)	OP0304	SELECTIVE INHIBITORS OF NUCLEAR EXPORT PREVENT LUPUS PROGRESSION BY TARGETING GERMINAL CENTER FORMATION AND AUTOREACTIVE

Abstract	Wahren Marie (Sweden)	OP0305	ANTIBODY SECRETING CELLS TYPE I IFN SYSTEM ACTIVATION IN NEWBORNS EXPOSED TO ANTI- RO/SSA AUTOANTIBODIES IN UTERO
Abstract	Van Den Hoogen Lucas (Netherlands)	OP0306	DOWNREGULATION OF MICRORNAS IN PLASMACYTOID DENDRITIC CELLS IS ASSOCIATED WITH A TYPE I INTERFERON SIGNATURE IN SYSTEMIC LUPUS ERYTHEMATOSUS AND ANTIPHOSPHOLIPID SYNDROME.

Friday 16.06.2017 11:45 - 13:30

Poster Tour - Poster Area

Poster Tour: Imaging advances in arthritis - what is new?

Chair	Terslev Lene (Denmark)		
Chair	Moeller-Bisgaard Signe (Denmark)		
Abstract	van der Laken CJ (Netherlands)	FRI0623	[18F]FLUORIDE PET-CT IMAGING OF BONE FORMATION IN ANKYLOSING SPONDYLITIS BEFORE AND AFTER 12 WEEKS OF ANTI-TNF TREATMENT.
Abstract	Ramirez Giuseppe A. (Italy)	FRI0624	STRUCTURAL MRI-BASED CONNECTOMICS IN SLE: A PILOT STUDY
Abstract	Kampylafka Eleni (Germany)	FRI0625	IMPROVEMENT OF JOINT INFLAMMATION AS ASSESSED BY MRI AND POWER DOPPLER ULTRASOUND (PDUS) IN AN OPEN LABEL STUDY IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS TREATED WITH SECUKINUMAB (PSARTROS)
Abstract	Rezaei Hamed (Sweden)	FRI0626	ANALYSIS OF CORRELATION AND CAUSES FOR DISCREPANCY BETWEEN QUANTITATIVE AND SEMI-QUANTITATIVE DOPPLER SCORES IN SYNOVITIS IN RHEUMATOID ARTHRITIS
Abstract	Hussain Sidra (United Kingdom)	FRI0627	ULTRASOUND HAND EXAMINATION IS MORE SENSITIVE IN DIAGNOSING HAND OSTEOARTHRITIS THAN CONVENTIONAL RADIOGRAPHY:

COMPARISON BETWEEN
DIFFERENT ULTRASONOGRAPHIC
SCORES

Abstract	Møller Døhn Uffe (Denmark)	FRI0628	ULTRASOUND SHOWS SIGNS OF INFLAMMATION IN MOST PATIENTS WITH RHEUMATOID ARTHRITIS IN LONGSTANDING CLINICAL REMISSION, IRRESPECTIVE OF CONVENTIONAL SYNTHETIC OR BIOLOGIC DMARD THERAPY
Abstract	Mathew Ashish Jacob (India)	FRI0629	MAGNETIC RESONANCE IMAGING (MRI) INFLAMMATION OF THE FEET DEMONSTRATES SUBCLINICAL INFLAMMATORY DISEASE IN CUTANEOUS PSORIASIS PATIENTS WITHOUT CLINICAL ARTHRITIS
Abstract	Freeston Jane (United Kingdom)	FRI0630	CAN WHOLE BODY MRI AT BASELINE IDENTIFY DEFINITE INFLAMMATORY ARTHRITIS PATTERNS IN UNDIFFERENTIATED ARTHRITIS?
Abstract	Mayordomo Lucia (Spain)	FRI0631	PREDICTIVE VALUE OF POWER DOPPLER ULTRASONOGRAPHY (PDUS) IN THE DIAGNOSIS OF EARLY RHEUMATOID ARTHRITIS
Abstract	Cimmino Marco (Italy)	FRI0632	MRI-US FUSION IMAGES FOR RHEUMATOID ARTHRITIS: CAN DOPPLER SUBSTITUTE FOR GADOLINIUM?

 **Poster Tour: Indexes and predictors in systemic sclerosis and myositis**

Chair	Cutolo Maurizio (Italy)		
Chair	Smith Vanessa (Belgium)		
Abstract	Salazar Gloria (United States)	FRI0363	KL6 AND NOT CCL-18 IS A PREDICTOR OF EARLY PROGRESSION IN SYSTEMIC SCLEROSIS RELATED INTERSTITIAL LUNG DISEASE
Abstract	Nakamura Hiroyuki (Japan)	FRI0364	USEFULNESS OF SERUM HAPTOGLOBIN LEVELS AS A NOVEL MARKER FOR PULMONARY ARTERIAL HYPERTENSION COMPLICATED WITH CONNECTIVE TISSUE DISEASE
Abstract	Dobrota Rucsandra (Switzerland)	FRI0365	NEW COLLAGEN BIOMARKERS PREDICT PROGRESSION OF FIBROSIS IN SYSTEMIC SCLEROSIS

Abstract	Van Roon Anniek (Netherlands)	FRI0366	A PILOT STUDY ON ISCHEMIA AND REPERFUSION INJURY DURING A RAYNAUD'S ATTACK: SEQUENTIAL ASSESSMENT OF REDOX STRESS PARAMETERS IN A UNIQUE COOLING AND REWARMING EXPERIMENT
Abstract	Notarnicola Antonella (Sweden)	FRI0367	NEW AUTOIMMUNE TARGETS IN IDIOPATHIC INFLAMMATORY MYOPATHIES - AN ANTIGEN BEAD ARRAY APPROACH
Abstract	Gheorghiu Ana Maria (Romania)	FRI0368	NAILFOLD CAPILLAROSCOPY CHANGES REFLECT ENDOTHELIAL ACTIVATION AND INJURY IN PATIENTS WITH SYSTEMIC SCLEROSIS
Abstract	Jaeger Veronika (Switzerland)	FRI0369	PROSPECTIVE EVALUATION OF THE CAPILLAROSCOPIC SKIN ULCER INDEX (CSURI) IN CLINICAL PRACTICE.
Abstract	Abignano Giuseppina (United Kingdom)	FRI0370	THREE-DIMENSIONAL NAILFOLD CAPILLARY IMAGING BY DYNAMIC OPTICAL COHERENCE TOMOGRAPHY IN SYSTEMIC SCLEROSIS: A VALIDATION STUDY USING NAILFOLD VIDEO-CAPILLAROSCOPY.
Abstract	Hax Vanessa (Brazil)	FRI0371	CLINICAL ALGORITHMS FOR THE DIAGNOSIS AND PROGNOSIS OF INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS
Abstract	Bruni Cosimo (Italy)	FRI0372	THE DUCAS: PROPOSAL FOR A DIGITAL ULCER ASSESSMENT SCORE IN SCLERODERMA
 Poster Tour: New drivers in RA and SPA pathophysiology			
Chair	Breban Maxime (France)		
Chair	Neumann Elena (Germany)		
Abstract	Sánchez Maria Alejandra (Spain)	FRI0420	ASSOCIATION OF SUPPRESSOR OF CYTOKINE SIGNALING -3 (SOCS-3) EXPRESSION WITH INTERLEUKIN-23 RECEPTOR (IL-23R) SINGLE NUCLEOTIDE POLYMORPHISMS (SNPS) IN ANKYLOSING SPONDYLITIS (AS).
Abstract	Wade Sarah (Ireland)	FRI0421	DYSREGULATED MIR-125 PROMOTES JOINT ANGIOGENESIS IN PSA THROUGH ALTERED

BIOENERGETICS.

Abstract	Jeong Hyemin (Korea, Republic Of)	FRI0422	ESTROGEN ATTENUATES THE DISEASE ACTIVITY OF SPONDYLOARTHRITIS IN SKG MICE
Abstract	Vinci Chiara (United Kingdom)	FRI0423	ANTIBODIES TO TYPE II COLLAGEN: A NOVEL TOOL FOR THE SPONDYLOARTHRITIS DIAGNOSIS?
Abstract	Sendo Sho (Japan)	FRI0080	CD11B+GR1DIM TOLEROGENIC DENDRITIC CELL-LIKE CELLS ARE EXPANDED IN INTERSTITIAL LUNG DISEASE IN SKG MICE
Abstract	Bitoun Samuel (France)	FRI0081	A MACAQUE MODEL OF RHEUMATOID ARTHRITIS BY IMMUNIZATION WITH CITRULLINATED PEPTIDES: LESSONS FOR THE HUMAN DISEASE
Abstract	Zayoud Morad (Israel)	FRI0082	RAS SIGNALING INHIBITORS ATTENUATE ARTHRITIS IN ANIMAL MODELS OF RHEUMATOID ARTHRITIS BY DOWN MODULATING THE PATHOGENIC TH17 CELL RESPONSE
Abstract	Bondt Albert (Netherlands)	FRI0083	REDUCED INCREASE OF ACPA IGG-FC GALACTOSYLATION DURING PREGNANCY IN COMPARISON TO TOTAL IGG: AN EXPLANATION WHY AUTOANTIBODY POSITIVE RA-PATIENTS IMPROVE LESS DURING PREGNANCY?
Abstract	Li Jing (China)	FRI0084	THE TONSIL MICROBIOME IS INVOLVED IN RHEUMATOID ARTHRITIS

Poster Tour: Novelty in the clinical approach to SLE, Sjögren's and APS II

Chair	Tincani Angela (Italy)		
Chair	Gatto Mariele (Italy)		
Abstract	Bortoluzzi Alessandra (Italy)	FRI0255	PATTERNS OF DISEASE ACTIVITY IMPACT ON ORGAN DAMAGE IN SYSTEMIC LUPUS ERYTHEMATOSUS
Abstract	Jousse-Joulin Sandrine (France)	FRI0256	ULTRASOUND CONSENSUS DEFINITIONS ON NORMAL AND ABNORMAL FINDINGS IN SALIVARY GLANDS IN SJÖGREN'S SYNDROME: RESULTS OF AN OMERACT DELPHI PROCESS.

Abstract	Mok Chi Chiu (Hong Kong)	FRI0257	URINARY ANGIOSTATIN, CXCL4 AND VCAM-1 AS BIOMARKERS FOR LUPUS NEPHRITIS
Abstract	Wang Qian (China)	FRI0258	LONG-TERM PROGNOSIS OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION: CSTAR-PAH COHORT STUDY
Abstract	Monov Simeon (Bulgaria)	FRI0259	LUPUS LOW DISEASE ACTIVITY STATE (LLDAS) IN PATIENTS WITH LUPUS NEPHRITIS (LN)
Abstract	Ferro Francesco (Italy)	FRI0260	ULTRASOUND STUDY OF PLEURAL PROFILE AND CHEST HIGH-RESOLUTION COMPUTED TOMOGRAPHY (HRCT): DIAGNOSTIC ROLE IN PRIMARY SJÖGREN'S SYNDROME-INDUCED LUNG INVOLVEMENT
Abstract	Taraborelli Mara (Italy)	FRI0261	SKIN CANCER IN A COHORT OF SYSTEMIC LUPUS ERYTHEMATOSUS
Abstract	Park Eun-Kyoung (Korea, Republic Of)	FRI0262	CLINICAL, LABORATORY AND IMMUNOLOGICAL CHARACTERISTICS OF 413 PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS IN SOUTH KOREA: A MULTICENTER RETROSPECTIVE COHORT STUDY
Abstract	Quartuccio Luca (Italy)	FRI0263	SYSTEMIC DISEASE ACTIVITY PROGRESSION IN A LARGE COHORT OF PRIMARY SJÖGREN'S SYNDROME: A LONG-TERM FOLLOW-UP DATA BASED ON THE ESSDAI SCORE
Abstract	Merayo-Chalico Javier (Mexico)	FRI0264	EPIDEMIOLOGIC PROFILE OF ERECTILE DYSFUNCTION IN SLE: A MULTI-CENTER STUDY IN LATIN AMERICAN PATIENTS
Abstract	Pettersson Susanne (Sweden)	FRI0265	CYTOKINES AND CORRELATIONS WITH PATIENT REPORTED OUTCOMES IN SYSTEMIC LUPUS ERYTHEMATOSUS AND POPULATION CONTROLS

Poster Tour: Osteoporosis risk assessment and treatment: new tools and new strategies

Chair
Tam Lai-Shan
(China, People's
Republic of)

Chair	Wong Priscilla (China, People's Republic of)		
Abstract	Cheng Tsz Ho (Hong Kong)	FRI0524	CAROTID ATHEROSCLEROSIS IS ASSOCIATED WITH COMPROMISED VOLUMETRIC BONE MINERAL DENSITY AND MICROSTRUCTURES IN PATIENTS WITH INFLAMMATORY ARTHRITIS
Abstract	Buehring Bjoern (Germany)	FRI0525	ASSOCIATION OF DYSMOBILITY SYNDROME WITH FRACTURE RISK IN THE MROS COHORT
Abstract	Chen Ying-Chou (Taiwan, Province of China)	FRI0526	ANTI-OSTEOPOROTIC THERAPY DECREASE CANCER RISK IN PATIENTS WITH OSTEOPOROTIC VERTEBRAL FRACTURES
Abstract	Zaia Annamaria (Italy)	FRI0527	LACUNARITY OF TRABECULAR BONE MICROARCHITECTURE, TBLB, AS A PREDICTOR OF BONE FRAGILITY FRACTURE AND POTENTIAL INDEX OF OSTEOPOROSIS TREATMENT EFFICACY. THE LOTO STUDY.
Abstract	Buehring Bjoern (Germany)	FRI0528	SUCCESSFUL IMPLEMENTATION OF A PHARMACIST-LED FRACTURE LIAISON SERVICE AT A US VETERAN AFFAIRS (VA) HOSPITAL
Abstract	Gifre Laia (Spain)	FRI0529	ANALYSIS OF THE EVOLUTION OF CORTICAL AND TRABECULAR BONE COMPARTMENTS IN THE PROXIMAL FEMUR AFTER SPINAL CORD INJURY BY 3D-DXA.
Abstract	Naranjo Antonio (Spain)	FRI0530	EFFECTIVENESS OF AN ORTHOGERIATRIC FRACTURE LIAISON SERVICE COMPARED WITH STANDARD CARE
Abstract	Suarez-Almazor Maria (United States)	FRI0531	DUAL ENERGY X-RAY ABSORPTIOMETRY TESTING IN ELDERLY MEN WITH PROSTATE CANCER INITIATING ANDROGEN DEPRIVATION THERAPY REDUCES SUBSEQUENT FRACTURE RISK
Abstract	Ursani Mohammad (United States)	FRI0532	DUAL ENERGY X-RAY ABSORPTIOMETRY TESTING IN WOMEN WITH BREAST CANCER INITIATING THERAPY WITH AROMATASE INHIBITORS REDUCES SUBSEQUENT FRACTURE RISK
Abstract	Choi Sang Tae (Korea, Republic)	FRI0533	INCIDENCE AND RISK FACTORS OF OSTEOPOROTIC FRACTURE IN

Of)

PATIENTS WITH RHEUMATOID ARTHRITIS: A MULTICENTER COMPARATIVE STUDY OF THE FRAX CRITERIA AND WHO CRITERIA

Poster Tour: Outcome in AxSpA: does it matter?

Chair	Ramiro Sofia (Netherlands)		
Chair	Sepriano Alexandre (Portugal)		
Abstract	Moltó Anna (France)	FRI0472	EXTRA-RHEUMATOLOGICAL FEATURES ARE FREQUENTLY ASSOCIATED WITH PERIPHERAL RHEUMATOLOGICAL FEATURES IN AXIAL SPONDYLOARTHRITIS AND INFLUENCE THE CHOICE OF THE ANTI-TNF IN DAILY PRACTICE. AN ANALYSIS OF 519 PATIENTS.
Abstract	Desthieux Carole (France)	FRI0473	PATIENT-PHYSICIAN DISCORDANCE IN GLOBAL ASSESSMENT IN 401 EARLY AXIAL SPONDYLOARTHRITIS (AXSPA) PATIENTS FROM THE DESIR COHORT: WHAT IS THE EFFECT ON OUTCOMES AT 3 YEARS?
Abstract	Baraliakos Xenofon (Germany)	FRI0474	DOES AXIAL SPONDYLOARTHRITIS PHENOTYPE CORRELATE WITH IMAGING MORPHOTYPE?
Abstract	de Winter Janneke (Netherlands)	FRI0475	ANTI-CD74 ANTIBODIES AS DIAGNOSTIC BIOMARKER FOR EARLY AXIAL SPONDYLOARTHRITIS: DATA FROM THE SPONDYLOARTHRITIS CAUGHT EARLY (SPACE) COHORT STUDY
Abstract	Ziade Nelly (Lebanon)	FRI0476	ANTI-CD74 ANTIBODIES: DIAGNOSTIC PROPERTIES IN LOW HLA-B27 EARLY AXIAL SPONDYLOARTHRITIS
Abstract	Chimenti Maria Sole (Italy)	FRI0477	PROSPECTIVE OBSERVATIONAL STUDY ON THE EVALUATION OF QUALITY OF LIFE IN PATIENTS AFFECTED BY ENTEROPATHIC SPONDYLOARTHRITIS
Abstract	Maksymowych Walter (Canada)	FRI0478	SUBCHONDRAL BONE SCLEROSIS ON COMPUTED TOMOGRAPHY – DOES IT HAVE ANY VALUE IN THE DIAGNOSIS OF INFLAMMATORY SACROILIITIS OR IS IT A NON-

SPECIFIC FINDING?

Abstract	Coates Laura (United Kingdom)	FRI0479	PREDICTORS OF LONG-TERM MODIFIED MINIMAL DISEASE ACTIVITY RESPONSE IN PERIPHERAL SPONDYLOARTHRITIS PATIENTS TREATED WITH ADALIMUMAB
Abstract	van der Heijde Désirée (Netherlands)	FRI0480	SCORING SYNDESMOPHYTES ON CT SPINE IMAGES OF PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS FROM THE SENSITIVE IMAGING OF AXIAL SPONDYLOARTHRITIS (SIAS) COHORT
Abstract	Madsen Ole Rintek (Denmark)	FRI0481	INTERPLAY BETWEEN PATIENT GLOBAL ASSESSMENT, PAIN AND FATIGUE AND INFLUENCE OF OTHER CLINICAL DISEASE ACTIVITY MEASURES IN PATIENTS WITH ACTIVE SPONDYLOARTHRITIS
 Poster Tour: RA all over the body			
Chair	Szekanecz Zoltán (Hungary)		
Chair	Szentpetery Agnes (Sweden)		
Abstract	Suissa Samy (Canada)	FRI0129	COMPARATIVE SAFETY OF BIOLOGIC DMARD INITIATION IN RA: A POPULATION-BASED OBSERVATIONAL STUDY OF MALIGNANCY RISK
Abstract	Strangfeld Anja (Germany)	FRI0130	RATES AND RISK FACTORS OF NEW-ONSET PSORIASIS UNDER DIFFERENT BIOLOGIC AGENTS AND CONVENTIONAL SYNTHETIC DMARD TREATMENT
Abstract	Boeters Debbie (Netherlands)	FRI0131	THE 2010 ACR/EULAR CRITERIA ARE INSUFFICIENTLY ACCURATE IN THE EARLY IDENTIFICATION OF AUTOANTIBODY-NEGATIVE RHEUMATOID ARTHRITIS: RESULTS FROM THE LEIDEN-EAC AND ESPOIR COHORTS
Abstract	Kuriya Bindee (Canada)	FRI0132	HIGH DISEASE ACTIVITY IS A PREDICTOR OF DEPRESSION AND PERSISTENT DEPRESSION IN EARLY RHEUMATOID ARTHRITIS: RESULTS FROM THE ONTARIO BEST PRACTICES RESEARCH

			INITIATIVE (OBRI)
Abstract	Ganguly Rita (United States)	FRI0133	IS THERE INCREMENTAL MENTAL HEALTH BURDEN ASSOCIATED WITH RHEUMATOID ARTHRITIS?
Abstract	Tanaka Ayae (Japan)	FRI0134	CLUSTER ANALYSIS OF PULMONARY LESIONS IN RHEUMATOID ARTHRITIS(RA); AIRWAY DISEASE IS SHARED AND CRITICAL PULMONARY ABNORMALITY IN RA
Abstract	Torikai Eiji (Japan)	FRI0135	TREATMENT OF JAPANESE EARLY RHEUMATOID ARTHRITIS PATIENTS WITH LOW-DOSE PREDNISOLONE FOR MAXIMUM 1 YEAR LEADS TO EARLIER IMPROVEMENT OF DISEASE ACTIVITY AND DOES NOT WORSEN BONE METABOLISM STATUS AND RATES OF NEW COMPLICATIONS
Abstract	Brouwer Jenny (Netherlands)	FRI0136	OVARIAN RESERVE, AS ASSESSED BY MEASURING SERUM ANTI-MÜLLERIAN HORMONE LEVELS, DECLINES MORE RAPIDLY OVER TIME IN RHEUMATOID ARTHRITIS PATIENTS COMPARED TO CONTROLS
Abstract	Emamifar Amir (Denmark)	FRI0137	PRESENCE OF THYROID DISEASE IN RHEUMATOID ARTHRITIS PATIENTS IS PREDICTOR OF WORSE INITIAL TREATMENT RESPONSE: AN OBSERVATIONAL, COHORT STUDY.
Abstract	Duarte Ana Catarina (Portugal)	FRI0138	LUNG INVOLVEMENT IN RHEUMATOID ARTHRITIS – A PORTUGUESE REALITY
 Poster Tour: RA stromal cells - reloaded			
Chair	Müller-Ladner Ulf (Germany)		
Chair	Richez Christophe (France)		
Abstract	Takahashi Soshi (Japan)	FRI0022	GLUTAMINE METABOLISM PLAYS A KEY ROLE IN THE CELL GROWTH OF FIBROBLAST-LIKE SYNOVIOCYTES IN RHEUMATOID ARTHRITIS
Abstract	Dai Lie (China)	FRI0023	ARTESUNATE CAN INHIBIT MIGRATION AND INVASION OF FIBROBLAST-LIKE SYNOVIOCYTES VIA SUPPRESSION OF MATRIX

METALLOPROTEINASE 9 IN
RHEUMATOID ARTHRITIS PATIENTS

Abstract	Saferding Victoria (Austria)	FRI0024	MICRORNA-146A CONTROLS LOCAL BONE DESTRUCTION BY REGULATING FIBROBLAST INDUCED OSTEOCLASTOGENESIS IN INFLAMMATORY ARTHRITIS
Abstract	Waterborg Claire (Netherlands)	FRI0025	THE TAM RECEPTORS AXL AND MER PLAY A PROTECTIVE ROLE IN A TEMPORAL AND SPATIAL MANNER IN INFLAMMATORY ARTHRITIS
Abstract	Kurowska Weronika (Poland)	FRI0026	IDENTIFICATION OF MICRORNAS CANDIDATES SPECIFICALLY EXPRESSED IN MONOCYTES OF UNDIFFERENTIATED ARTHRITIS PATIENTS WHO PROGRESSED TO RHEUMATOID ARTHRITIS.
Abstract	Barbati Cristiana (Italy)	FRI0027	TNF EXPRESSION ON MICROPARTICLES FROM RHEUMATOID ARTHRITIS PATIENTS MEDIATES ENDOTHELIAL CELL FATE IN VITRO
Abstract	Vomero Marta (Italy)	FRI0028	IN VITRO INHIBITORY EFFECT OF ETANERCEPT ON AUTOPHAGY: A NEW MECHANISM OF ACTION OF TNF INHIBITORS IN RHEUMATOID ARTHRITIS
Abstract	De Wilde Katelijne (Belgium)	FRI0029	THE OXYGEN SENSOR PHD1 IS AN INDISPENSABLE REGULATOR OF ARTHRITIS DEVELOPMENT
Abstract	Rivellese Felice (United Kingdom)	FRI0030	SYNOVIAL MAST CELLS IDENTIFY PATIENTS WITH A SEVERE PHENOTYPE IN A COHORT OF DMARD NAÏVE PATIENTS WITH EARLY RHEUMATOID ARTHRITIS
Abstract	Kawabe Akio (Japan)	FRI0031	DNA OXIDASE ENZYME TET3 EXACERBATES SYNOVIAL INFLAMMATION AND BONE DESTRUCTION

 **Poster Tour: Risk factors for RMDs or comorbid conditions**

Chair	Finckh Axel (Switzerland)		
Chair	Nikiphorou Elena (United Kingdom)		
Abstract	Ovalles-Bonilla Juan (Spain)	FRI0683	CAUSES OF DEATH IN 350 PATIENTS WITH SYSTEMIC AUTOIMMUNE RHEUMATIC

			DISEASES (SARD)
Abstract	Widdifield Jessica (Canada)	FRI0684	EARLY TREATMENT WITH METHOTREXATE IMPROVES ALL-CAUSE AND CARDIOVASCULAR SURVIVAL AMONG AN INCEPTION COHORT OF SENIORS WITH RHEUMATOID ARTHRITIS
Abstract	Eun Yeong Hee (Korea, Republic Of)	FRI0685	THE PRESENCE OF RHEUMATOID FACTOR IS ASSOCIATED WITH LOWER BONE MASS IN KOREAN HEALTH SCREENING MALE SUBJECTS WITHOUT CLINICALLY APPARENT ARTHRITIS
Abstract	Jakobsson Karin (Sweden)	FRI0686	NEGATIVE ASSOCIATIONS FOR FASTING BLOOD GLUCOSE, CHOLESTEROL AND TRIGLYCERIDE LEVELS WITH THE DEVELOPMENT OF GIANT CELL ARTERITIS
Abstract	Jakobsson Karin (Sweden)	FRI0687	BODY MASS INDEX, SMOKING, SOCIOECONOMIC STATUS AND THE RISK OF GIANT CELL ARTERITIS
Abstract	Mayr Michael (Austria)	FRI0688	PRERA (PREDICTING RHEUMATOID ARTHRITIS): PRELIMINARY FINDINGS FROM AN ON-GOING PROSPECTIVE STUDY OF SEROPOSITIVE AND SERONEGATIVE INDIVIDUALS AND THEIR RISK FOR DEVELOPING RA
Abstract	Stojanovich Ljudmila (Serbia)	FRI0689	LIPID PEROXIDATION AS RISK FACTOR FOR ENDOTHELIAL DYSFUNCTION IN ANTIPHOSPHOLIPID SYNDROME (APS) PATIENTS
Abstract	Abdul Sultan Alyshah (United Kingdom)	FRI0690	RISK OF FRACTURE AMONG PATIENTS WITH GOUT: A POPULATION-BASED COHORT STUDY
Abstract	Chen Hsin-Hua (Taiwan, Province of China)	FRI0691	ASSOCIATION BETWEEN PERIODONTITIS AND THE RISK OF PALINDROMIC RHEUMATISM: A NATIONWIDE, POPULATION-BASED, CASE-CONTROL STUDY
Abstract	Singh Jasvinder (United States)	FRI0692	ALLOPURINOL AND THE RISK OF VENTRICULAR ARRHYTHMIAS IN THE ELDERLY: A STUDY USING U.S. MEDICARE DATA

 **Poster Tour: Scleroderma and myositis: etiology**

Chair	Riemekasten Gabriela (Germany)		
Chair	Humrich Jens (Germany)		
Abstract	De Santis Maria (Italy)	FRI0353	SERUM PROTEOMICS PROFILE IN SYSTEMIC SCLEROSIS PATIENTS
Abstract	Sakata Komei (Japan)	FRI0354	CIRCULATING MICROPARTICLE SUBSETS ARE ASSOCIATED WITH PATIENTS WITH EXTENDED FIBROTIC PHENOTYPE IN SYSTEMIC SCLEROSIS
Abstract	Vettori Serena (Italy)	FRI0355	IL-17A UP-REGULATION IN PERIPHERAL BLOOD MONONUCLEAR CELLS CO- CULTURED WITH AUTOLOGOUS SKIN FIBROBLASTS IS ASSOCIATED WITH DOWN- REGULATION OF PRO-FIBROTIC MEDIATORS AND INCREASED FIBROBLAST APOPTOSIS
Abstract	Kurreeman Fina (Netherlands)	FRI0356	ANTISENSE LONG NONCODING RNAs ARE DEREGULATED IN SKIN TISSUE OF SSC PATIENTS.
Abstract	Manfredi Angelo (Italy)	FRI0357	MICROPARTICLES AS A BIOMARKER AND A REDOX- DEPENDENT REGULATOR OF NEUTROPHIL ACTIVATION AND PROTEOLYTIC ACTIVITY IN PATIENTS WITH SYSTEMIC SCLEROSIS
Abstract	Guo Li (China)	FRI0358	99MTC-RHANNEXIN V-128 AS A NOVEL EARLY DIAGNOSTIC MARKER FOR INTERSTITIAL LUNG DISEASE ASSOCIATED WITH SYSTEMIC SCLEROSIS
Abstract	Karpec Diana (Lithuania)	FRI0359	THE IMPACT OF NARROWBAND ULTRAVIOLET A1 ON PROLIFERATION AND APOPTOSIS MARKERS IN ANIMAL MODEL OF SCLERODERMA
Abstract	Perez-Sanchez Carlos (Spain)	FRI0360	ANALYSIS OF ENDOCANNABINOID SYSTEM ELEMENTS AND RELATED INFLAMMATORY MOLECULES IN PERIPHERAL BLOOD LEUKOCYTES OF PATIENTS WITH SYSTEMIC SCLEROSIS
Abstract	Akiyama Mitsuhiro (Japan)	FRI0361	INTERLEUKIN-4 INDUCES CLASS- SWITCHING TO IGG4 AND SYNERGISTICALLY CONTRIBUTES TO PLASMA BLASTS

DIFFERENTIATION WITH
INTERLEUKIN-21 THROUGH CD40
DEPENDENT MANNER IN IGG4-
RELATED DISEASE

Abstract Manetti Mirko (Italy) FRI0362

ANGIOGENIC T CELL EXPANSION
CORRELATES WITH SEVERITY OF
PERIPHERAL VASCULAR DAMAGE
IN SYSTEMIC SCLEROSIS

 **Poster Tour: TNF inhibitors in RA = always and again**

Chair Mariette Xavier
(France)

Chair van der Woude
Diane (Netherlands)

Abstract Clowse Megan FRI0179
(United States)

MINIMAL TO NO TRANSFER OF
CERTOLIZUMAB PEGOL INTO
BREAST MILK: RESULTS FROM
CRADLE, A PROSPECTIVE,
POSTMARKETING, MULTICENTER,
PHARMACOKINETIC STUDY

Abstract Bitoun Samuel FRI0180
(France)

MULTIPLE SCLEROSIS RISK-
ALLELES STUDY IN PATIENTS WITH
DEMYELINATING SIDE EFFECTS ON
ANTI TNF ALPHA THERAPY.

Abstract Ghang Byeongzu FRI0181
(Korea, Republic
Of)

TAPERING OR CESSATION OF
ANTIVIRAL AGENT IN HEPATITIS B
VIRUS-INFECTED PATIENTS
CONCOMITANTLY TREATED WITH
BIOLOGIC AGENTS

Abstract Goll Guro (Norway) FRI0182

DISEASE WORSENING AND
SAFETY IN PATIENTS SWITCHING
FROM ORIGINATOR INFLIXIMAB TO
BIOSIMILAR INFLIXIMAB (CT-P13) IN
THE NOR-SWITCH STUDY:
EXPLORATIVE ANALYSIS OF RA
PATIENTS

Abstract Vogelzang Erik FRI0183
(Netherlands)

ASSESSING ADHERENCE OF RA
PATIENTS TREATED WITH
ETANERCEPT USING ETANERCEPT
SERUM TROUGH
CONCENTRATIONS AND PATIENT
SELF-REPORT

Abstract Raya E. (Spain) FRI0184

THE PROFILES OF PATIENTS WITH
RHEUMATOID ARTHRITIS
ACCORDING TO THEIR BELIEFS IN
THEIR BIOLOGICAL DRUGS. ARCO
STUDY

Abstract Gavan Sean FRI0185
(United Kingdom)

A SYSTEMATIC REVIEW AND
BIVARIATE META-ANALYSIS OF
STUDIES THAT MEASURED

ADALIMUMAB DRUG LEVELS BY
ELISA TO DETECT TREATMENT
RESPONSE IN RHEUMATOID
ARTHRITIS

Abstract	Bogas Patricia (Spain)	FRI0186	INFLUENCE OF IMMUNOGENICITY TO THE FIRST TNF-I THERAPY ON RESPONSE TO THE SECOND BIOLOGIC AGENT IN RA PATIENTS
Abstract	Smolen Josef S. (Austria)	FRI0187	RADIOGRAPHIC PROGRESSION BY DISEASE ACTIVITY STATES IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH SB2 OR REFERENCE INFLIXIMAB
Abstract	Pappas Dimitrios (United States)	FRI0188	EFFECTIVENESS OF ADALIMUMAB COMBINATION THERAPY WITH METHOTREXATE AND NON- METHOTREXATE CSDMARDS: RESULTS FROM THE CORRONA RHEUMATOID ARTHRITIS REGISTRY
Abstract	Cohen Stanley (United States)	FRI0189	SIMILAR EFFICACY AND SAFETY OF BIOSIMILAR CANDIDATE BI 695501 AND HUMIRA® REFERENCE PRODUCT IN PATIENTS WITH MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS: 24 WEEK RESULTS FROM A PHASE III CLINICAL STUDY (VOLTAIRE®-RA)
Abstract	Glntborg Bente (Denmark)	FRI0190	CLINICAL OUTCOMES FROM A NATIONWIDE NON-MEDICAL SWITCH FROM ORIGINATOR TO BIOSIMILAR ETANERCEPT IN PATIENTS WITH INFLAMMATORY ARTHRITIS AFTER 5 MONTHS FOLLOW-UP. RESULTS FROM THE DANBIO REGISTRY

 **Poster Tour: Trends in non-TNF alpha biologicals for RA I**

Chair	Bijlsma Johannes W.J. (Netherlands)		
Chair	Teitsma Xavier M. (Netherlands)		
Abstract	Silvagni Ettore (Italy)	FRI0212	COMPARATIVE EFFECTIVENESS OF FIRST-LINE BIOLOGIC MONOTHERAPY IN RHEUMATOID ARTHRITIS
Abstract	Frisell Thomas (Sweden)	FRI0213	COMPARATIVE EFFECTIVENESS OF ABATACEPT, RITUXIMAB, TOCILIZUMAB AND ANTI-TNF BIOLOGICAL DMARDS IN RA:

RESULTS FROM THE NATIONWIDE SWEDISH REGISTER

Abstract	Tanaka Yoshiya (Japan)	FRI0214	LONG-TERM EFFICACY AND SAFETY OF SIRUKUMAB IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS DESPITE ANTI-TUMOR NECROSIS FACTOR THERAPY: RESULTS OF THE RANDOMIZED, PHASE 3 SIRROUND-T STUDY
Abstract	Favalli Ennio Giulio (Italy)	FRI0215	COMPARATIVE EFFICACY AND RETENTION RATE OF TOCILIZUMAB AND TNF INHIBITORS USED IN COMBINATION WITH METHOTREXATE AS FIRST-LINE BIOLOGIC THERAPY IN RHEUMATOID ARTHRITIS: DATA FROM A MULTICENTRE OBSERVATIONAL REGISTRY
Abstract	Burmester Gerd (Germany)	FRI0216	RESULTS OF A LONGITUDINAL REVIEW OF PULMONARY FUNCTION AND SAFETY DATA IN A PHASE IIB CLINICAL PROGRAMME TESTING GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF) RECEPTOR ANTAGONIST MAVRILIMUMAB FOR TREATMENT OF RHEUMATOID ARTHRITIS (RA)
Abstract	Köhm Michaela (Germany)	FRI0217	IMPACT OF RITUXIMAB IN COMBINATION WITH LEFLUNOMIDE AND RITUXIMAB RETREATMENT WITH TWO DIFFERENT DOSAGES ON PATIENT-REPORTED OUTCOMES: RESULTS FROM A MULTICENTER RANDOMIZED PLACEBO CONTROLLED INVESTIGATOR INITIATED CLINICAL TRIAL IN ACTIVE RHEUMATOID ARTHRITIS (AMARA-STUDY)
Abstract	Oryoji Kensuke (Japan)	FRI0218	SHARED EPITOPE POSITIVITY IS RELATED TO EFFICACY OF ABATACEPT IN RHEUMATOID ARTHRITIS.
Abstract	Huizinga TWJ (Netherlands)	FRI0219	ASSOCIATION BETWEEN CONVERSION TO ACPA/RF SERONEGATIVE STATUS AND CLINICAL OUTCOMES FOLLOWING TREATMENT WITH ABATACEPT IN COMBINATION WITH METHOTREXATE COMPARED WITH

METHOTREXATE ALONE IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS AND POOR PROGNOSTIC INDICATORS

Abstract Kafaja Suzanne (United States) FRI0220

ALLOGENEIC MESENCHYMAL PRECURSOR CELLS (MPCS): A NOVEL APPROACH TO TREATING BIOLOGIC REFRACTORY RHEUMATOID ARTHRITIS

Abstract Courvoisier Delphine (Switzerland) FRI0221

DOES SEROPOSITIVITY INFLUENCE DIFFERENTIALLY DRUG DISCONTINUATION OF BIOLOGIC ANTIRHEUMATIC AGENTS WITH NON-ANTI-TNF MODE OF ACTION?

Abstract Kremer Joel (United States) FRI0222

SUSTAINED RESPONSE FOLLOWING DISCONTINUATION OF METHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH SUBCUTANEOUS TOCILIZUMAB: RESULTS FROM A RANDOMIZED CONTROLLED TRIAL (COMP-ACT)

Abstract Yoo Dae Hyun (Korea, Republic Of) FRI0178

RITUXIMAB IS EFFECTIVE IN THE TREATMENT OF RHEUMATOID ARTHRITIS REGARDLESS OF BODY MASS INDEX

Poster Tour: Vasculities Clinical Aspects II

Chair Molloy Eamonn S. (Ireland)

Chair Soriano Alessandra (Italy)

Abstract Al-Soudi Aram (Netherlands) FRI0303

THE IGG4:IGG RNA RATIO IS A NEW AND PROMISING DISEASE ACTIVITY MARKER IN GRANULOMATOSIS WITH POLYANGIITIS.

Abstract Wang Yiwen (China) FRI0304

THE UTILITY OF 18F FDG-PET/CT IN DISTINGUISHING BENIGN FROM MALIGNANT RETROPERITONEAL FIBROSIS

Abstract Ihata Atsushi (Japan) FRI0305

RELATIVE FDG ACCUMULATION OF THE AORTIC WALL LESIONS TO AORTIC BLOOD POOL IN 18F-FDG-PET AND PET/CT COULD BE A USEFUL PARAMETER FOR THE PREDICTION OF DISEASE RELAPSE AFTER SUCCESSFUL TREATMENT IN TAKAYASU ARTERITIS

Abstract	Sfikakis Petros (Greece)	FRI0306	LONG TERM DRUG-FREE REMISSION IS FEASIBLE IN SEVERE BEHCET'S DISEASE AFTER CESSATION OF SUCCESSFUL ANTI-TNF TREATMENT: A SINGLE CENTER, RETROSPECTIVE LONGITUDINAL OUTCOME STUDY
Abstract	Ozguler Yesim (Turkey)	FRI0307	AN OUTCOME SURVEY OF 100 PATIENTS WITH CEREBRAL VENOUS SINUS THROMBOSIS DUE TO BEHCET'S SYNDROME FOLLOWED UP AT A SINGLE, DEDICATED CENTER
Abstract	Padoan Roberto (Italy)	FRI0308	PREDICTORS OF HYPOGAMMAGLOBULINAEMIA IN RITUXIMAB TREATED PATIENTS. A RETROSPECTIVE ANALYSIS ON A MONOCENTRIC COHORT.
Abstract	Houben Eline (Netherlands)	FRI0309	CARDIOVASCULAR EVENTS IN ANCA-ASSOCIATED VASCULITIS: A META-ANALYSIS OF OBSERVATIONAL STUDIES
Abstract	Berti Alvise (Italy)	FRI0310	LONG-TERM MORTALITY AND COMPLICATIONS IN YOUNG AND ELDERLY PATIENTS WITH ANCA-ASSOCIATED VASCULITIS
Abstract	Jung Jae Hyun (Korea, Republic Of)	FRI0311	ENDOVASCULAR INTERVENTION VERSUS SURGERY IN PATIENTS WITH TAKAYASU ARTERITIS: A META-ANALYSIS
Abstract	Monti Sara (Italy)	FRI0312	THE FREQUENCY AND SEVERITY OF PATIENT-REPORTED SYMPTOMS IN GIANT CELL ARTERITIS

Poster Tour: What's new in orphan diseases

Chair	Ionescu Ruxandra (Romania)		
Chair	Ostojic Predrag (Serbia)		
Abstract	Gabay Cem (Switzerland)	FRI0582	OPEN-LABEL, MULTICENTER, DOSE-ESCALATING PHASE II CLINICAL TRIAL ON THE SAFETY AND EFFICACY OF TADEKINIG ALPHA IN ADULT ONSET STILL'S DISEASE
Abstract	Lomborg Niels (Denmark)	FRI0583	IGG4-RELATED DISEASE AMONG PATIENTS PREVIOUSLY DIAGNOSED WITH IDIOPATHIC

			RETROPERITONEAL FIBROSIS. A NATIONWIDE DANISH STUDY.
Abstract	Marie Kostine (France)	FRI0584	RHEUMATIC AND MUSCULOSKELETAL DISORDERS RELATED TO IMMUNE CHECKPOINT INHIBITORS IN CANCER PATIENTS: A PROSPECTIVE SINGLE-INSTITUTION STUDY.
Abstract	Jaeger Veronika (Switzerland)	FRI0585	FREQUENT, UNUSUALLY SEVERE, LONG LASTING, LOCAL AND SYSTEMIC PNEUMOCOCCAL VACCINE REACTIONS IN PATIENTS WITH CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS): RESULTS OF A PROSPECTIVE REGISTRY BASED STUDY
Abstract	Fabiani Claudia (Italy)	FRI0586	INTERLEUKIN (IL)-1 INHIBITION WITH ANAKINRA AND CANAKINUMAB IN BEHÇET'S DISEASE RELATED UVEITIS: A MULTICENTER RETROSPECTIVE OBSERVATIONAL STUDY
Abstract	Mizushima Ichiro (Japan)	FRI0587	DIFFERENT FACTORS ARE RELATED TO RECURRENCE OF EXISTING ORGAN INVOLVEMENT AND NEW DEVELOPMENT OF ORGAN INVOLVEMENT IN IGG4-RELATED DISEASE
Abstract	Stone John (United States)	FRI0588	INTERIM RESULTS OF A PHASE 2 STUDY OF XMAB®5871, A REVERSIBLE B CELL INHIBITOR, IN IGG4-RELATED DISEASE
Abstract	Vázquez-Triñanes Caritina (Spain)	FRI0589	CANCER IS FREQUENT IN PATIENTS WITH ANTICENTROMERE PATTERN
Abstract	Akiyama Mitsuhiro (Japan)	FRI0590	SOLUBLE INTERLEUKIN-2 RECEPTOR LEVELS REFLECT DISEASE ACTIVITY IN IGG4-RELATED DISEASE AND PRIMARY SJÖGREN'S SYNDROME
Abstract	Sasaki Takanori (Japan)	FRI0591	RISK FACTORS FOR DISEASE RELAPSE IN IGG4-RELATED DISEASE FOLLOWING GLUCOCORTICOID TREATMENT

 **Friday 16.06.2017 12:00 - 13:30**

 **Poster Tour - Poster Area**

 **PARE Poster Tour II**

Chair	Wiek Dieter (Germany)		
Chair	Caeyers Nele (Belgium)		
Abstract	Egert Tsipora (Israel)	PARE0012	EDUCATING YOUNG CHILDREN, PARENTS AND DOCTORS THROUGH THE MEDIUM OF AN ILLUSTRATED CHILDREN'S BOOK
Abstract	Jacklin Clare (United Kingdom)	PARE0013	BEHIND THE SMILE - RA AWARENESS VIDEOS - RAISING AWARENESS OF THE HIDDEN IMPACT OF RHEUMATOID ARTHRITIS
Abstract	Olsder Wendy (Ireland)	PARE0015	THE IMPORTANCE OF FACE-TO- FACE NETWORKS: FINDINGS FROM THE 2ND EULAR YOUNG PARE CONFERENCE, 'CHANGE THE FUTURE'
Abstract	Viora Ugo Giuseppe (Italy)	PARE0016	KEEP CALM AND TELL ME YOUR STORY!: A NARRATIVE MEDICINE PILOT PROJECT FOR ITALIAN YOUNG PEOPLE LIVING WITH RHEUMATIC AND MUSCULOSKELETAL DISEASES
Abstract	Vergés Josep (Spain)	PARE0017	EMPOWERING PATIENTS WITH OSTEOARTHRITIS WITH NON- PHARMACOLOGICAL MEASURES
Abstract	Bankova Hristina (Bulgaria)	PARE0018	WE DO THE IMPOSSIBLE, BECAUSE THE POSSIBLE EVERYONE CAN DO WAD AWARENESS CAMPAIGN
Abstract	Viora Ugo (Italy)	PARE0019	ADHERENCE TO THERAPY: A COMPARISON BETWEEN THREE PATIENTS POPULATIONS WITH AUTOIMMUNE INFLAMMATORY DISEASES
Abstract	Garrido-Castro Juan (Spain)	PARE0020	25 YEARS OF PATIENTS' ASSOCIATIONS OF ANKYLOSING SPONDYLITIS IN SPAIN: ACEADE
Abstract	Macdonald Christopher (United Kingdom)	PARE0021	PUBLIC AND PATIENT INVOLVEMENT AT ARTHRITIS RESEARCH UK: ENSURING BENEFIT FOR ALL
Abstract	Van Der Giesen Florus (Netherlands)	PARE0022	ORGANIZATION OF GROUP EXERCISE THERAPY (GET) FOR PATIENTS WITH AXIAL SPONDYLOARTRITIS (AXSPA) IN THE NETHERLANDS; A NATIONWIDE SURVEY

🕒 Friday 16.06.2017 13:30 - 15:00

🏠 WIN & HOT Session - Hall 6

🏠 WIN & HOT Session

Chair	Blanco Francisco J. (Spain)	
Chair	Sivera Francisca (Spain)	
Speaker	Kloppenburg Margreet (Netherlands)	WIN Session: Osteoarthritis
Speaker	So Alexander (Switzerland)	HOT Session: Gout and other crystal induced arthritis treatment

🏠 Clinical Science Session - Hall 8

🏠 Co-morbidities in rheumatoid arthritis

Chair	Dougados Maxime (France)	
Chair	Strangfeld Anja (Germany)	
Speaker	Calabrese Leonard SP0108 (United States)	Herpes zoster: how to prevent, to diagnose and to treat
Speaker	Wells Athol (United Kingdom)	Interstitial lung disease in RA and its treatment: where are we ?
Speaker	Mariette Xavier (France)	Lymphomas in RA and its treatment: Where are we?
Abstract	Nocturne Gaetane OP0307 (France)	TREATMENT OF BAFF TRANSGENIC MICE WITH ANTI-TNF: MONOCLONAL ANTI-TNF ARE ASSOCIATED WITH A HIGHER RISK OF LYMPHOMA THAN ETANERCEPT
Abstract	Raaschou Pauline OP0308 (Sweden)	TNF INHIBITOR TREATMENT AND RISK OF CANCER RECURRENCE IN PATIENTS WITH RHEUMATOID ARTHRITIS: A NATIONWIDE COHORT STUDY FROM SWEDEN

🏠 Challenges in Clinical Practice Session - Hall 7A

🏠 Life-threatening presentation of rheumatic diseases

Chair	Riemekasten Gabriela (Germany)	
Chair	Anton Jordi (Spain)	
Presenter	Birolo Carolina SP0109	Case 1 presentation: Pediatric difficult

	(Italy)	case presentation
Discussant	Wouters Carine (Belgium)	Case 1 discussion: Life-threatening presentation of pediatric rheumatic diseases: an overview
Presenter	Siegert Elise (Germany)	Case 2 presentation: Adult difficult case presentation
Discussant	Cid Maria C (Spain) SP0110	Case 2 discussion: Life-threatening presentation of adult rheumatic diseases: an overview

From Bench to Bedside - Hall 7B

AxSpA: From bug to gut and to disease phenotype

Chair	Vereecke Lars (Belgium)	
Chair	Kiltz Uta (Germany)	
Speaker	Scher Jose U. (United States)	How microbiota shape the inflammatory response
Speaker	Elewaut Dirk (Belgium)	The gut and SpA: implication for disease phenotype
Speaker	Schett Georg (Germany)	What drives new bone formation in axSp? Progress from basic research
Speaker	Landewé Robert SP0111 B.M. (Netherlands)	Inhibiting bone formation in axSpA in the clinic: are we there yet?
Abstract	Ciccia Francesco OP0309 (Italy)	INTESTINAL SCLEROSTIN/SEROTONIN AXIS IS MODULATED BY DYSBIOSIS AND REGULATES ILC3 EXPANSION IN AS PATIENTS

Clinical Science Session - N103 / N104

Pregnancy meets Rheumatic Patients

Chair	Boumpas Dimitrios (Greece)	
Chair	Valesini Guido (Italy)	
Speaker	Østensen Monika SP0112 (Norway)	Which drugs in pregnant patients?
Speaker	Fischer-Betz SP0113 Rebecca (Germany)	Pregnancy in SLE: still challenging fetal and maternal issues
Speaker	Andreoli Laura SP0114 (Italy)	Children of patients with rheumatic diseases: disease and treatment related problems
Abstract	Blomjous Birgit OP0310 (Netherlands)	PREGNANCY OUTCOME IN WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS, A

MULTICENTER COHORT-STUDY

Abstract	Lisney Anna (Germany)	OP0311	HIGH MATERNAL EXPRESSION OF SIGLEC1 ON CD14+ MONOCYTES AS A SURROGATE MARKER OF A TYPE I INTERFERON SIGNATURE IS A RISK FACTOR FOR THE DEVELOPMENT OF AUTOIMMUNE CONGENITAL HEART BLOCK
----------	--------------------------	--------	---

Basic and Translational Science Session - South Auditorium

Neuronal and hormonal alterations in arthritis

Chair	Neumann Elena (Germany)		
Chair	Capellino Silvia (Germany)		
Speaker	Straub Rainer H. (Germany)	SP0115	Neurotransmitters and innervation in synovium
Speaker	da Silva José Antonio P. (Portugal)		Neurotransmitters and hormones as modulators in bone
Speaker	Cutolo Maurizio (Italy)	SP0116	How to target neuronal and hormonal alterations in arthritis
Abstract	Omdal Roald (Norway)	OP0312	A PROTEOMIC SIGNATURE OF FATIGUE IN PRIMARY SJÖGREN'S SYNDROME
Abstract	Welle Stefanie (Germany)	OP0313	P75 LOW AFFINITY RECEPTOR OF NERVE GROWTH FACTOR ON PERIPHERAL LEUKOCYTES AND CD11C-POSITIVE DENDRITIC CELLS ARE UPREGULATED IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

Health Professionals Session - N101 / N102

Fighting osteoporosis fragilities

Chair	Ferreira Ricardo (Portugal)		
Chair	Adams Jo (United Kingdom)		
Speaker	Kanis John (United Kingdom)	SP0117	Osteoporotic fractures in Europe: are we doing enough?
Speaker	Stephenson Sonya M. (United Kingdom)	SP0118	Establishing and implementing fracture liaison services
Speaker	Marques Andrea	SP0119	Predicting fracture risk: accuracy and

	(Portugal)		feasibility of tools
Speaker	Rose Debra J. (United States)	SP0120	Predicting the risk of falls and promoting balance in older adults
Abstract	Niedermann Karin (Switzerland)	OP0314-HPR	A HOME-BASED FALL PREVENTION PROGRAMME REDUCES FEAR OF FALLING IN SENIORS

Paediatric Rheumatology Session - N105 / N106

Biological agents in juvenile idiopathic arthritis: open issues

Chair	van Rossum Marion (Netherlands)		
Chair	Foell Dirk (Germany)		
Speaker	Swart Joost F. (Netherlands)	SP0121	Long term side effects of biological agents in JIA
Speaker	Quartier Pierre (France)	SP0122	Autoimmune phenomena associated with biological agents
Speaker	Horneff Gerd (Germany)		When and How to discontinue biological agents in JIA
Abstract	Mourão Ana (Portugal)	OP0315	REASONS FOR DISCONTINUATION OF BIOLOGICAL AGENTS IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS: DATA FROM THE PORTUGUESE REGISTER, REUMA.PT.
Abstract	Alexeeva Ekaterina (Russian Federation)	OP0316	DURATION OF CLINICAL REMISSION AND FLARE RATES IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS AFTER WITHDRAWAL OF BIOLOGICAL TREATMENT (PRELIMINARY DATA)

Practical Skills Session - N111 / N112

Data visualisation: tables and graphs for publication and presentation II

Speaker	Boers Maarten (Netherlands)	SP0091	Data visualisation: tables and graphs for publication and presentation
---------	--------------------------------	--------	--

PARE Session - N115 / N116

Health equity and economy – a vital relationship

Chair	Pchelnikova Polina (Russian Federation)		
Chair	Mateus Elsa (Portugal)		

Speaker	Betteridge Neil (United Kingdom)		Mind the gap! EULAR: campaigning for equity in Europe
Speaker	Putrik Polina (Netherlands)	SP0123	Uncovering the equity gap in rheumatic and musculoskeletal diseases
Speaker	Fautrel Bruno (France)	SP0124	Health economics and Health equity: two complementary disciplines
Abstract	Bosworth Ailsa (United Kingdom)	OP0317-PARE	AN INDEPENDENT REVIEW OF PEOPLE WITH RHEUMATOID ARTHRITIS (RA) AND THEIR CAREGIVER'S LOST WORK TIME
Abstract	Carreira Roca Francisco Javier (Spain)	OP0318-PARE	CONSULTING SERVICES TO EMPLOYERS OF PEOPLE WITH RMDs.

EULAR Projects in Clinical Affairs - N117 / N118

Biomarkers in cardiovascular rheumatology – state-of-the-art 2017

Chair	Müller-Ladner Ulf (Germany)		
Chair	Kurowska-Stolarska Mariola (United Kingdom)		
Speaker	Choy Ernest (United Kingdom)	SP0125	Inflammation and cardiovascular disease – Relevant metabolic biomarkers
Speaker	Ceglarek Uta (Germany)		Myths and facts about the lipidome and lipids in inflammatory rheumatic diseases
Speaker	Szekanecz Zoltán (Hungary)	SP0126	The vessel wall in IMIDs – new emerging vascular markers
Speaker	Nurmohamed Michael (Netherlands)	SP0127	Tapering biologics induces a pro-thrombotic state in rheumatoid arthritis
Abstract	Sacre Karim (France)	OP0319	HIGH SENSITIVITY CARDIAC TROPONIN T IS A BIOMARKER FOR ATHEROSCLEROSIS IN SYSTEMIC LUPUS ERYTHEMATOUS PATIENTS: A CROSS-SECTIONAL CONTROLLED STUDY

Practical Skills Session - N107 / N108

MRI I

Chair	Ostergaard Mikkel (Denmark)		
Chair	Hermann Kay-Geert		

	(Germany)		
Speaker	Eshed Iris (Israel)	SP0128	MRI of enthesitis – by conventional and wholebody MRI - including patient cases
Speaker	Glinatsi Daniel (Denmark)		Are MRI findings important to the rheumatoid arthritis patient – relation to patient reported outcomes - including patient cases
Speaker	Ostergaard Mikkel (Denmark)	SP0129	Classification, diagnosis and differential diagnosis of axial spondyloarthritis by MRI - including patient cases
Speaker	Hermann Kay-Geert (Germany)		MRI of the sacroiliac joint – lessons learnt from comparisons with CT - including patient cases

Practical Skills Session - N109 / N110

Ultrasound Basic II

Chair	Kortekaas Marion (Netherlands)		
Chair	Bruyn George A. W. (Netherlands)		
Speaker	Filippou Georgios (Italy)	SP0037	How to assess US elementary lessons in CPPD + demo
Speaker	Mandl Peter (Austria)	SP0038	How to assess cartilage in RA and pitfalls + demo
Speaker	Iagnocco Annamaria (Italy)	SP0039	How to evaluate the subtalar joint + demo
Speaker	Möller Ingrid (Spain)		How to scan the hip - new approaches + demo
Tutor	Midtboell Oernbjerg Lykke (Denmark)		

Friday 16.06.2017 15:30 - 17:00

WIN & HOT Session - Hall 6

WIN & HOT Session

Chair	Guanabens Nuria (Spain)		
Chair	Bours Sandrine (Netherlands)		
Speaker	Geusens Piet (Netherlands)	SP0130	WIN Session: Osteoporosis
Speaker	Jorgensen Christian		WIN Session: Regenerative medicine

(France)

Clinical Science Session - Hall 8**What is behind vasculitis?**

Chair	Fischer-Betz Rebecca (Germany)		
Chair	Dougados Maxime (France)		
Speaker	Szekanecz Zoltán (Hungary)	SP0131	Autoimmune atherosclerosis
Speaker	Calabrese Leonard (United States)	SP0132	Viruses driving vasculitis
Speaker	Luqmani Raashid (United Kingdom)	SP0133	ANCA and their environment
Abstract	Cornec Divi (United States)	OP0320	DETERMINANTS OF RITUXIMAB PHARMACOKINETICS AND CLINICAL OUTCOMES IN PATIENTS WITH ANCA-ASSOCIATED VASCULITIS
Abstract	Pugnet Grégory (France)	OP0321	RISK OF CORONARY ARTERY DISEASE AND ISCHEMIC STROKE IN PATIENTS WITH ANCA- ASSOCIATED VASCULITIS. A FRENCH POPULATION-BASED STUDY

Challenges in Clinical Practice Session - Hall 7A**Comorbidities in connective tissue diseases**

Chair	Tektonidou Maria (Greece)		
Chair	Galindo Izquierdo Maria (Spain)		
Presenter	Fredi Micaela (Italy)		Case 1 presentation: Infections in immunosuppressed patient
Discussant	Costedoat Nathalie (France)		Case 1 discussion: The challenge to prevent and manage simultaneously infections and autoimmunity
Presenter	Spinelli Francesca (Italy)		Case 2 presentation: Depression and mood disorders
Discussant	Mosca Marta (Italy)		Case 2 discussion: Improving the quality of life: how to recognize and manage the different presentations of mood disorders

From Bench to Bedside - Hall 7B

Cytokine taxonomy: reflection in the therapy of arthritides and other IMIDs

Chair	van Vollenhoven Ronald (Netherlands)		
Chair	Szentpetery Agnes (Sweden)		
Speaker	Crow Mary K. (United States)		What are the implication of our understanding of cytokine networks for the management of diseases such as RA and SLE?
Speaker	McInnes Iain (United Kingdom)		The exciting cytokine network: differences between RA, SpA and other IMIDs
Speaker	Schett Georg (Germany)		Reflection of the cytokine network in differential efficacy of various biologics in IMIDs
Speaker	Humrich Jens (Germany)	SP0134	Interleukin-2 therapy in SLE
Abstract	Sato Kojiro (Japan)	OP0322	A NOVEL HIERARCHICAL RELATIONSHIP BETWEEN INTERLEUKIN-17A AND INTERFERON-ALPHA IS INDICATED BY ANALYSIS OF MULTIPLE CYTOKINES IN THE SERUM OF ADULT-ONSET STILL'S DISEASE AND BEHÇET'S DISEASE

Clinical Science Session - N103 / N104

Personalised care for back pain

Chair	Bergman Stefan (Sweden)		
Chair	Sepriano Alexandre (Portugal)		
Speaker	Foster Nadine E. (United Kingdom)		Beyond stratification: whats next for back pain?
Speaker	Albert Hanne (Denmark)		New therapeutic options for back pain
Speaker	Al-Kaisy Adnan (United Kingdom)		Spinal cord stimulation for the treatment of back pain
Abstract	AHMED YAHIA Salim (France)	OP0323	DISCOPATHY ASSOCIATED WITH MODIC CHANGES IS NOT RELATED TO ANY INFECTIOUS PROCESS: A PROSPECTIVE MONOCENTRIC STUDY
Abstract	Karateev Andrey	OP0324	MANAGEMENT OF

(Russian
Federation)MUSCULOSKELETAL PAIN USING
AN ALGORITHM FOR SELECTION
OF ANALGESICS**Basic and Translational Science Session - South Auditorium****Regulatory molecules in connective tissue**

Chair	Gay Steffen (Switzerland)		
Chair	Senolt Ladislav (Czech Republic)		
Speaker	Pap Thomas (Germany)	SP0135	Myostatin, sclerostin, syndecan and more...
Speaker	Denton Christopher (United Kingdom)	SP0136	Multifactorial tissue growth factors
Speaker	Herrmann Martin (Germany)	SP0137	From glycosylation to inflammation
Abstract	Kragstrup Tue (Denmark)	OP0325	TGF-BETA-INDUCED ED-A FIBRONECTIN PRODUCTION BY FIBROBLAST-LIKE SYNOVIAL CELLS CONTRIBUTES TO INFLAMMATION IN OSTEOARTHRITIS
Abstract	Frank Bertoneclj Mojca (Switzerland)	OP0326	EPIGENETICALLY-DRIVEN DISTAL EXPRESSION OF THE LNCRNA HOTTIP SHAPES INFLAMMATORY, ADHESIVE AND PROLIFERATIVE CHARACTERISTICS OF HAND SYNOVIAL FIBROBLASTS IN ARTHRITIS

Health Professionals Session - N101 / N102**Patient Engagement in Research: Best Practices, Benefits, and Challenges**

Chair	Schlenk Elizabeth A. (United States)		
Chair	Vliet Vlieland Thea (Netherlands)		
Speaker	de Wit Maarten (Netherlands)	SP0138	The challenges of patient involvement in scientific research
Speaker	Redmond Anthony (United Kingdom)	SP0139	Meaningful patient and public involvement in planning research
Speaker	Poole Janet L. (United States)	SP0140	Patient engagement in research: A PCORI exemplar
Abstract	Cresswell Katharine (United Kingdom)	OP0327-PARE	YOUR RHEUM – GIVING YOUNG PEOPLE A VOICE IN RHEUMATOLOGY RESEARCH

The Young Rheumatologist - N111 / N112

RA treatment in patients wanting to become pregnant - interactive session

Chair	Schreiber Karen (United Kingdom)		
Chair	Alunno Alessia (Italy)		
Presenter	Willemze Annemiek (Netherlands)	SP0141	Case 1 presentation: New RA, but what about a new baby?
Discussant	Dolhain Radboud (Netherlands)		Case 1: interactive discussion
Presenter	Nero Patrícia (Portugal)	SP0142	Case 2 presentation: Foreplay and finale: factors affecting fertility, birth and lactation in RA patients
Discussant	Østensen Monika (Norway)		Case 2: interactive discussion

PARE Session - N115 / N116

Latest advances in the treatment and management of psoriatic arthritis and the latest news on the use of biosimilars in RMDs

Chair	Wiek Dieter (Germany)		
Chair	Stones Simon (United Kingdom)		
Speaker	Coates Laura (United Kingdom)	SP0143	A new day for people with Psoriatic Arthritis: a heterogeneous disease that can be treated well?
not confirmed yet		Q&A	
Abstract	Thomsen Lene Mandrup (Denmark)	OP0328-PARE	PATIENT SAFETY IN RELATION TO BIOSIMILARS – HOW CAN WE ACT AS A PATIENT ORGANIZATION?
Speaker	den Broeder Alfons (Netherlands)	SP0144	Biosimilars in rheumatic diseases: society chances versus patient concerns
Speaker	not confirmed yet		Q&A

EULAR Projects in Investigative Rheumatology - N117 / N118

From pre-RA to established RA

Chair	Mariette Xavier (France)		
Chair	Finckh Axel (Switzerland)		
Speaker	Toes Rene (Netherlands)	SP0145	Pathophysiologic processes leading to the development of autoimmunity

Speaker	van der Woude Diane (Netherlands)	SP0146	Can we predict who is going to develop rheumatoid arthritis?
Speaker	Deane Kevin (United States)	SP0147	Can we prevent the onset of rheumatoid arthritis in high risk individuals?
Speaker	Lauwerys Bernard (Belgium)	SP0148	Pathophysiology of established RA synovitis

Practical Skills Session - N107 / N108

Laboratory course – from the clinic to the lab and back I

Chair	Burmester Gerd Rüdiger (Germany)		
Chair	Dörner Thomas (Germany)		
Speaker	Dörner Thomas (Germany)		ANA diagnostic and antiphospholipid syndrome (APS) as inherited coagulation disorder
Speaker	Miossec Pierre (France)		Vasculitis, systemic autoimmunity
Speaker	Feist Eugen (Germany)	SP0149	New trends in biomarkers in inflammatory joint diseases

Practical Skills Session - N109 / N110

Ultrasound Advanced II

Chair	Naredo Esperanza (Spain)		
Chair	Filippou Georgios (Italy)		
Speaker	Ohrndorf Sarah (Germany)		How to score synovitis quantitatively - validity and feasibility + demo
Speaker	Ammitzboll Mads (Denmark)		How to use image fusion + demo
Speaker	Bong David (Spain)	SP0076	How and when to assess cervical facet joints + demo
Speaker	Vojinovic Jelena (Serbia)	SP0077	How to evaluate joints in JiA + patient cases
Tutor	Midtboell Oernbjerg Lykke (Denmark)		

Friday 16.06.2017 17:30 - 19:00

Basic and Translational Science Session - South Auditorium

Switching T on and off: how T cells drive and regulate chronic inflammation

Chair	Malmström Vivianne (Sweden)		
Chair	Taams Leonie (United Kingdom)		
Speaker	Kuchroo Vijay (United States)	SP0150	How T cells drive and regulate chronic inflammation: a story of mice and men
Speaker	Wraith David C. (United Kingdom)	SP0151	Learning from other fields: developing peptide immunotherapy for human autoimmune disease
Speaker	Klareskog Lars (Sweden)		Becoming more tolerant: can we induce T cell tolerance in RA?
Abstract	Abdollahi-Roodsaz Shahla (Netherlands)	OP0329	INVOLVEMENT OF T HELPER 17 CELLS IN INFLAMMATORY ARTHRITIS DEPENDS ON THE HOST INTESTINAL MICROBIOTA
Abstract	Renoux Florian (Switzerland)	OP0330	FRA2 OVEREXPRESSION LEADS TO SYSTEMIC AUTOIMMUNITY BY DECREASING IL-2 RESPONSIVENESS AND THYMIC TREG DEVELOPMENT.

🕒 Saturday 17.06.2017 08:30 - 10:00

🏠 WIN & HOT Session - Hall 6

🏠 WIN & HOT Session: The Lancet session - Pathogenesis and treatment of rheumatoid arthritis

Chair	Gomez-Reino Carnota Juan Jesus (Spain)		
Chair	Crow Mary K. (United States)		
Chair	Sargent Jennifer (United States)		
Speaker	McInnes Iain (United Kingdom)		WIN Session: Dissecting the pathogenesis of rheumatoid arthritis – what have therapeutics taught us
Speaker	Burmester Gerd Rüdiger (Germany)		WIN Session: Don't delay – new treatment concepts in rheumatoid arthritis

🏠 Clinical Science Session - Hall 8

🏠 Reverse translation - learning from clinical trials in SLE, Sjögren's and APS

Chair	Kalden Joachim R. (Germany)		
Chair	de Vita Salvatore (Italy)		

Speaker	Isenberg David (United Kingdom)	SP0152	The learnings from SLE trials
Speaker	Seror Raphaelae (France)		The learnings from Sjögren trials
Speaker	Rovin Brad (United States)		Lesson from Lupus Nephritis
Speaker	Khamashta Munther (United Kingdom)	SP0153	Lessons from APS trials
Abstract	Chen Bo (United States)	OP0331	A NOVEL HUMANIZED EFFECTOR-DEFICIENT FCYRIIA ANTIBODY INHIBITS IMMUNE COMPLEX MEDIATED PROINFLAMMATORY RESPONSES

Challenges in Clinical Practice Session - Hall 7A

Myositis

Chair	Doria Andrea (Italy)		
Chair	Vencovsky Jiri (Czech Republic)		
Presenter	Schneider Udo (Germany)		Case 1 presentation: Severe autoimmune myositis
Discussant	Cooper Robert (United Kingdom)		Case 1 discussion: Management of autoimmune myositis in 2017
Presenter	Gatto Mariele (Italy)		Case 2 presentation: Severe dermatomyositis with cardiac manifestations
Discussant	Diederichsen Louise (Denmark)		Case 2 discussion: Imaging on cardiac involvement in myositis

From Bench to Bedside - Hall 7B

Genomic imprinting and post-translational modifications

Chair	Herrmann Martin (Germany)		
Chair	Radbruch Andreas (Germany)		
Speaker	Chang Hyun-Dong (Germany)	SP0154	Rationale to target immune memory residing in inflamed tissues
Speaker	Toes Rene (Netherlands)	SP0155	The role of post-translational modification and autoreactivity
Speaker	Lipsky Peter (United States)	SP0156	How big data help us to understand new and old therapy targets
Abstract	Bertsias George (Greece)	OP0332	THE GENOMIC ARCHITECTURE OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) BY RNA-SEQ: DISTINCT DISEASE

SUSCEPTIBILITY, ACTIVITY AND SEVERITY SIGNATURES AND EXTENSIVE GENETIC EFFECTS ON WHOLE BLOOD GENE EXPRESSION

Abstract	Schulz-Knappe Peter (Germany)	OP0333	DISCOVERY AND VALIDATION OF NOVEL AUTOANTIGENS IN SJÖGREN'S SYNDROME WITH POTENTIAL FOR SUBGROUPING OF DISEASE
----------	----------------------------------	--------	--

Clinical Science Session - N103 / N104

Optimizing treatment for osteoarthritis. Take the phenotype in account "one size does not fit all"

Chair	Abishek Abishek (United Kingdom)		
Chair	Kroon Féline (Netherlands)		
Speaker	Berenbaum Francis (France)	SP0157	Metabolic phenotype: the two faces of obesity in OA
Speaker	Vincent Tonia (United Kingdom)		Post-traumatic phenotype: resulting in new insight's in OA pathogenesis
Speaker	Abishek Abishek (United Kingdom)	SP0158	Pain phenotype: can we take advantage of the placebo effect
Abstract	Pan Feng (Australia)	OP0334	PREDICTORS AND MRI-DETECTED STRUCTURAL PATHOLOGY WITH TRAJECTORIES OF KNEE PAIN SEVERITY: A 10.7-YEAR PROSPECTIVE STUDY
Abstract	Minten Michiel (Netherlands)	OP0335	EXPLORING ASSOCIATIONS BETWEEN HISTOLOGICALLY ASSESSED INFLAMMATION AND PAIN AND FATIGUE IN KNEE OSTEOARTHRITIS

Basic and Translational Science Session - South Auditorium

Targeting adipose tissue inflammation

Chair	Ioan-Facsinay Andreea (Netherlands)		
Chair	Bokarewa Maria (Sweden)		
Speaker	Bokarewa Maria (Sweden)	SP0159	Adipose tissue – bystander or therapeutical target?
Speaker	Schäffler Andreas (Germany)	SP0160	Is diabetes type 2 an inflammatory disease and should it be treated like that ?

Speaker	Ioan-Facsinay Andreea (Netherlands)	SP0161	Role of adipose tissue in osteoarthritis
Speaker	Gualillo Oreste (Spain)	SP0162	Adipokines in the pathophysiology of cartilage
Abstract	Arias de la Rosa Ivan (Spain)	OP0336	ROLE OF SYSTEMIC INFLAMMATION ASSOCIATED WITH RHEUMATOID ARTHRITIS IN THE GLUCOSE AND LIPID METABOLISM: HUMANS, CIA MOUSE MODEL AND IN VITRO STUDIES.

Health Professionals Session - N101 / N102

Trials and Tribulations of Medication Adherence

Chair	Prior Yeliz (United Kingdom)		
Chair	Sverker Annette (Sweden)		
Speaker	Adams Jo (United Kingdom)		Health literacy and its impact on accessing, understanding and using medication information
Speaker	Vriezolk Joke (Netherlands)	SP0163	Interventions to improve medication adherence in patients with inflammatory arthritis
Speaker	Koutsogianni Katerina (Greece)	SP0164	Barriers and facilitators to adherence to medication in patients with inflammatory arthritis
Speaker	Kumar Kanta (United Kingdom)	SP0165	Can Musculoskeletal Ultrasound inform health beliefs and play a role for medication adherence?
Abstract	Ahluwalia Vandana (Canada)	OP0337-HPR	PREDICTORS OF PATIENT REPORTED DECISION TO DISCONTINUE ANTI-RHEUMATIC MEDICATION IN RHEUMATOID ARTHRITIS PATIENTS: DATA FROM A RHEUMATOID ARTHRITIS COHORT

Paediatric Rheumatology Session - N105 / N106

Outcome in juvenile idiopathic arthritis

Chair	Zulian Francesco (Italy)		
Chair	Quartier Pierre (France)		
Speaker	van Rossum Marion (Netherlands)		Early predictors of juvenile Idiopathic arthritis outcome

Speaker	Foell Dirk (Germany)		Markers of remission in JIA
Speaker	Flato Berit (Norway)	SP0166	Long-term outcome of JIA into adulthood
Abstract	Minden Kirsten (Germany)	OP0338	FREQUENCY OF COMORBIDITIES IN JIA PATIENTS – RESULTS OF AN OBSERVATIONAL COHORT STUDY

Educational Session - N111 / N112

Getting financial support to research in RMDs through Horizon 2020: Opportunities, good practices, and successful experiences

Chair	Betteridge Neil (United Kingdom)		
Chair	Lories Rik (Belgium)		
Speaker	Haar Soeren (Belgium)		EULAR's service to the research community
Speaker	Riese Juan E. (Spain)	SP0167	Horizon 2020: Characteristics and opportunities for medical research and innovation
Speaker	Jorgensen Christian (France)		Successful experiences in applying for Horizon 2020 calls in the RMD scientific community: Dos and Don'ts
Speaker	McInnes Iain (United Kingdom)		RheuMap: A roadmap for research and innovation in RMDs for the next decade
Speaker	not confirmed yet		Q&A

EULAR Projects in Education and Training - N117 / N118

EULAR Projects - Challenging Projects in Education and Training

Chair	Iagnocco Annamaria (Italy)		
Chair	Damjanov Nemanja (Serbia)		
Speaker	Boers Maarten (Netherlands)	SP0168	Theory of poster design and presentation
Speaker	Bijlsma Johannes W.J. (Netherlands)	SP0169	The EULAR School of Rheumatology. A challenging Educational EULAR Project. Where are we now?
Speaker	Haines Catherine (United Kingdom)	SP0170	Assessing rheumatology skills

Practical Skills Session - N107 / N108

MRI II

Chair	Hermann Kay-Geert		
-------	-------------------	--	--

(Germany)

Chair	Ostergaard Mikkel (Denmark)		
Speaker	Eshed Iris (Israel)	SP0128	MRI of enthesitis – by conventional and wholebody MRI - including patient cases
Speaker	Glinatsi Daniel (Denmark)		Are MRI findings important to the rheumatoid arthritis patient – relation to patient reported outcomes - including patient cases
Speaker	Ostergaard Mikkel (Denmark)		Classification, diagnosis and differential diagnosis of axial spondyloarthritis by MRI - including patient cases
Speaker	Hermann Kay-Geert (Germany)		MRI of the sacroiliac joint – lessons learnt from comparisons with CT - including patient cases

Practical Skills Session - N109 / N110

Capillaroscopy II

Chair	Smith Vanessa (Belgium)		
Chair	Herrick Ariane L. (United Kingdom)		
Speaker	Smith Vanessa (Belgium)	SP0098	The importance to differentiate normal from abnormal capillaroscopic images for an early diagnosis of disease
Speaker	Sulli Alberto (Italy)		Scoring the capillaroscopic images: manual versus (semi)automatic systems”
Speaker	Herrick Ariane L. (United Kingdom)		How to distinguish the major capillaroscopic patterns in connective tissue diseases
Speaker	Cutolo Maurizio (Italy)	SP0099	Why capillaroscopy can predict disease severity and prognosis
Speaker	Ingegnoli Francesca (Italy)	SP0171	How to select the most appropriate capillaroscopic device: pros and cons
Speaker	not confirmed yet		Live practical sessions with patients and case discussion

Saturday 17.06.2017 10:15 - 11:45

PARE Session - N115 / N116

Workshop: Strengthening your organisation – How to manage volunteers

Speaker	Jacklin Clare (United Kingdom)	SP0172	How to manage volunteers – setting the scene
Speaker	Kosanovic Marija (Serbia)	SP0173	The challenges of a small organisation
Speaker	Ssymank Silke (Germany)	SP0174	Ways of supporting volunteers
Speaker	not confirmed yet		Group discussion and Q&A
Speaker	Jacklin Clare (United Kingdom)		Resume of the group discussions

Poster Tour - Poster Area

HPR Poster Tour: Nursing and daily practice

Chair	de Thurah Annette (Denmark)		
Chair	de la Torre-Aboki Jenny (Spain)		
Abstract	Zbinden Astrid (Switzerland)	SAT0717-HPR	PREGNANCY AND DELIVERY IN PATIENTS WITH RHEUMATOID ARTHRITIS AND SPONDYLOARTHRITIS
Abstract	Ferreira Ricardo (Portugal)	SAT0718-HPR	INFLUENCE OF PATIENT GLOBAL ASSESSMENT ON THE DISEASE ACTIVITY ASSESSMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS: A METEOR CROSS-SECTIONAL STUDY
Abstract	Mosor Erika (Austria)	SAT0719-HPR	'AND SUDDENLY YOU ARE A PERSON AT RISK OF DEVELOPING RHEUMATOID ARTHRITIS!' DIFFERENT PERSPECTIVES OF INDIVIDUALS ON PREDICTIVE TESTING – RESULTS OF AN INTERNATIONAL QUALITATIVE INTERVIEW STUDY
Abstract	Shi Qiang (China)	SAT0720-HPR	LONGITUDINAL ANALYSIS OF RESPONSE, COSTS AND RESOURCE USE OF PATIENTS WITH RHEUMATOID ARTHRITIS INITIATING BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (BDMARDS) IN TAIWAN USING THE NATIONAL HEALTH INSURANCE RESEARCH DATABASE
Abstract	Alfredsson Lars (Sweden)	SAT0721-HPR	EXPOSURE TO PASSIVE SMOKING AND RA RISK; RESULTS FROM THE SWEDISH EIRA STUDY
Abstract	Too Chun Lai (Malaysia)	SAT0722-HPR	FAMILIAL RISKS OF RHEUMATOID ARTHRITIS: EVIDENCE FROM THE

MALAYSIAN EPIDEMIOLOGICAL
INVESTIGATION OF RHEUMATOID
ARTHRITIS CASE-CONTROL STUDY

Abstract	Esbensen Bente (Denmark)	SAT0723-HPR	GENDER DIFFERENCES IN COPING STRATEGIES AND ILLNESS ACCEPTANCE IN PATIENTS WITH INFLAMMATORY ARTHRITIS – A NATIONWIDE CROSS-SECTIONAL STUDY
----------	-----------------------------	-------------	---

Abstract	Bergsten Ulrika (Sweden)	SAT0724-HPR	GOTHENBURG NURSE LED TIGHT CONTROL STUDY – GOTNET. PATIENTS' EXPERIENCES OF NURSE-LED CARE AND TIGHT CONTROL. A QUALITATIVE STUDY OF PATIENTS WITH RHEUMATOID ARTHRITIS.
----------	-----------------------------	-------------	--

Abstract	Bergsten Ulrika (Sweden)	SAT0725-HPR	GOTHENBURG NURSE LED TIGHT CONTROL STUDY - GOTNET. A STUDY COMPARING "CARE AS USUAL" WITH NURSE LED CLINIC, TIGHT CONTROL AND PERSON CENTRED CARE IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) AND WITH MODERATE/HIGH DISEASE ACTIVITY.
----------	-----------------------------	-------------	---

 **Poster Tour: A walk through PsA progress**

Chair	McInnes Iain (United Kingdom)
-------	----------------------------------

Chair	Fragoulis George E. (United Kingdom)
-------	---

Abstract	Ruwaard Jill (Netherlands)	SAT0433	ANTI-TNF TREATMENT IN RHEUMATOID ARTHRITIS AND ANKYLOSING SPONDYLITIS PATIENTS IS ASSOCIATED WITH A STRONG INCREASE OF PALMOPLANTAR PUSTULOSIS BUT NOT OF PSORIASIS VULGARIS.
----------	-------------------------------	---------	---

Abstract	Tsoi Man Fung (Hong Kong)	SAT0434	NETWORK META-ANALYSIS ON THE EFFICACY OF NOVEL THERAPEUTIC AGENTS IN PATIENTS WITH PSORIATIC ARTHRITIS
----------	------------------------------	---------	--

Abstract	Pinto-Tasende Jose (Spain)	SAT0435	IL17 CORRELATES POSITIVELY WITH TGF-BETA 1 AND DKK1 AND INVERSELY WITH BMP2 AND 4 IN SYNOVIAL MEMBRANE OF PATIENTS WITH PSORIATIC ARTHRITIS.
----------	-------------------------------	---------	--

Abstract	Kavanaugh Arthur (United States)	SAT0436	DURABILITY OF APREMILAST RESPONSE IN PATIENTS WITH
----------	-------------------------------------	---------	--

PSORIATIC ARTHRITIS: LONG-TERM (208-WEEK) RESULTS FROM THE PALACE 1 TRIAL

Abstract	Kristensen L (Denmark)	SAT0437	IXEKIZUMAB IMPROVES NAIL AND SKIN LESIONS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND PRIOR TNF INADEQUATE RESPONSE
Abstract	Bahadur Sardar (United Kingdom)	SAT0438	PSORIATIC ARTHRITIS AND NODAL OSTEOARTHRITIS CAN BE DIFFERENTIATED USING HAND RADIOGRAPHS: A NOVEL METHOD
Abstract	Burmester Gerd (Germany)	SAT0439	INTEGRATED SAFETY SUMMARY OF TOFACITINIB IN PSORIATIC ARTHRITIS CLINICAL STUDIES
Abstract	Michelsen Brigitte (Norway)	SAT0440	DO DEPRESSION AND ANXIETY INFLUENCE THE CHANCE OF REMISSION IN PATIENTS WITH PSORIATIC ARTHRITIS? REAL LIFE DATA FROM THE NOR-DMARD STUDY
Abstract	Coates Laura (United Kingdom)	SAT0441	COMPARISON OF DIFFERENT REMISSION TARGETS IN PATIENTS WITH PSORIATIC ARTHRITIS AND EVALUATION OF THEIR PROGNOSTIC VALUE

 **Poster Tour: Comorbidities and outcomes in RMDs**

Chair	Finckh Axel (Switzerland)		
Chair	Hetland Merete (Denmark)		
Abstract	Chatzidionysiou Katerina (Sweden)	SAT0669	HOW DO WE USE BIOLOGICS IN PATIENTS WITH A HISTORY OF MALIGNANCY? AN ASSESSMENT OF TREATMENT PATTERNS USING SCANDINAVIAN REGISTERS
Abstract	Fernandes Gwen (United Kingdom)	SAT0670	THE PREVALENCE OF NEUROPATHIC PAIN-LIKE SYMPTOMS AND ASSOCIATED RISK FACTORS IN THE NOTTINGHAM COMMUNITY: A CROSS-SECTIONAL STUDY
Abstract	Nikiphorou Elena (United Kingdom)	SAT0671	THE IMPACT OF OBESITY ON TREAT TO TARGET GOALS AND FUNCTIONAL ABILITY IN THE ERAS/ERAN UK PROSPECTIVE COHORTS
Abstract	Whittle Rebecca	SAT0672	RISK OF FRAGILITY FRACTURE

(United Kingdom)

AMONG PATIENTS WITH
PSORIASIS: A POPULATION BASED
MATCHED COHORT STUDY FROM
THE UNITED KINGDOM

Abstract Wibetoe Grunde SAT0673
(Norway)

RISK AGE AND RELATIVE RISK OF
CVD IN INFLAMMATORY JOINT
DISEASES

Abstract Strangfeld Anja SAT0674
(Germany)

EARLY TREATMENT RESPONSE TO
CONVENTIONAL DMARD THERAPY
IN RHEUMATOID ARTHRITIS IS A
BETTER PREDICTOR OF LOW
DISEASE ACTIVITY OR TREATMENT
ESCALATION AT 12 AND 24
MONTHS THAN AUTOANTIBODIES
OR EROSIONS

Abstract Brinkmann Gina SAT0675
(Norway)

THE ROLE OF EROSIONS TYPICAL
OF RHEUMATOID ARTHRITIS IN
THE 2010 ACR/EULAR
RHEUMATOID CLASSIFICATION
CRITERIA: RESULTS FROM A VERY
EARLY ARTHRITIS COHORT

Abstract Yates Mark (United SAT0676
Kingdom)

(SERONEGATIVE) MALES SHOW
BETTER EULAR TREATMENT
RESPONSE THAN FEMALES IN
NEWLY DIAGNOSED RHEUMATOID
ARTHRITIS (RA)

Abstract Skorpen Anna SAT0677
Carina (Norway)

THE IMPACT OF DISEASE ACTIVITY
DURING PREGNANCY IN WOMEN
WITH SLE ON THE OCCURRENCE
OF PREECLAMPSIA AND
PREMATURE BIRTH

Abstract Murphy Dan (United SAT0678
Kingdom)

SIGNIFICANTLY INCREASED
SEROPOSITIVITY, RHEUMATOID
FACTOR TITRES AND RHEUMATOID
NODULES IN CORNISH KAOLIN
WORKERS.

Poster Tour: From the heart of rheumatology

Chair Szekanecz Zoltán
(Hungary)

Chair Madruga Dias Joao
(Portugal)

Abstract Tejera Segura SAT0088
Beatriz (Spain)

HDL CHOLESTEROL EFFLUX
CAPACITY IN RHEUMATOID
ARTHRITIS PATIENTS:
CONTRIBUTING FACTORS AND
RELATIONSHIP WITH SUBCLINICAL
ATHEROSCLEROSIS

Abstract Kang Eun Ha SAT0089
(Korea, Republic

COMPARATIVE CARDIOVASCULAR
SAFETY OF ABATACEPT AND

Of)

TUMOR NECROSIS FACTOR
INHIBITORS IN RHEUMATOID
ARTHRITIS PATIENTS WITH AND
WITHOUT TYPE 2 DIABETES: A
POPULATION-BASED COHORT
STUDY

Abstract	Rollefstad Silvia (Norway)	SAT0090	SUCCESS RATE OF BLOOD PRESSURE GOAL ACHIEVEMENT IN INFLAMMATORY JOINT DISEASES
Abstract	Ten Brinck Robin (Netherlands)	SAT0091	IS CLINICAL ARTHRITIS ALWAYS PRECEDED BY SUBCLINICAL INFLAMMATION? A LONGITUDINAL STUDY AT JOINT LEVEL IN PATIENTS WITH ARTHRALGIA THAT DEVELOPED ARTHRITIS
Abstract	Skeoch Sarah (United Kingdom)	SAT0092	PROGRESSION OF ATHEROSCLEROSIS OVER 5 YEARS IN A COHORT OF EARLY INFLAMMATORY ARTHRITIS PATIENTS: RESULTS FROM THE NORFOLK ARTHRITIS REGISTER
Abstract	Rodríguez-Carrio Javier (Spain)	SAT0093	HIGH TRIGLYCERIDES AND LOW HDL LIPID PROFILE AS A SURROGATE MARKER OF HDL DYSFUNCTION IN RA: POTENTIAL LINKS WITH INFLAMMATION AND OXIDATIVE STATUS
Abstract	Rempenault Claire (France)	SAT0094	METABOLIC AND CARDIO- VASCULAR BENEFITS OF HYDROXYCHLOROQUINE IN PATIENTS WITH RHEUMATOID ARTHRITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS.
Abstract	Segura Beatriz (Spain)	SAT0095	INCRETINS-INSULIN AXIS IN PATIENTS WITH RHEUMATOID ARTHRITIS
Abstract	Koivuniemi Riitta (Finland)	SAT0096	MYOCARDIAL FUNCTION IMPROVES IN RHEUMATOID ARTHRITIS PATIENTS TREATED ACTIVELY A MAGNETIC RESONANCE FOLLOW-UP STUDY
Abstract	Giollo Alessandro (Italy)	SAT0097	FACTORS ASSOCIATED WITH ATHEROSCLEROSIS PROGRESSION IN PATIENTS WITH LOW-ACTIVE RHEUMATOID ARTHRITIS.

Poster Tour: How B and T cells contribute to rheumatic disease

Chair
Taams Leonie
(United Kingdom)

Chair	Scherer Hans-Ulrich (Netherlands)		
Abstract	Chen Wei (United States)	SAT0027	IMMUNOMODULATORY EFFECTS OF MGD010, A DART® MOLECULE TARGETING HUMAN B-CELL CD32B AND CD79B
Abstract	Ringheim Garth (United States)	SAT0028	AIOLOS OVEREXPRESSION IN SYSTEMIC LUPUS ERYTHEMATOSUS B-CELL SUBTYPES AND BAFF INDUCED MEMORY B-CELL DIFFERENTIATION ARE REDUCED BY CC-220 MODULATION OF CEREBLON ACTIVITY
Abstract	Néel Antoine (France)	SAT0029	B CELL DEPLETION AFFECTS CD8 T CELLS IN ANCA-ASSOCIATED VASCULITIS
Abstract	Dekkers Jacqueline (Netherlands)	SAT0030	BREACH OF AUTOACTIVE B-CELL TOLERANCE BY POST-TRANSLATIONALLY MODIFIED FOREIGN PROTEINS
Abstract	Gjertsson Inger (Sweden)	SAT0031	DETECTION AND ISOLATION OF ANTIGEN SPECIFIC B CELLS IN PATIENTS WITH RHEUMATOID ARTHRITIS
Abstract	Gerstner Christina (Sweden)	SAT0033	EX VIVO ANALYSIS OF AUTOANTIGEN-SPECIFIC T CELL RESPONSES USING A MULTI HLA-CLASS II TETRAMER APPROACH
Abstract	Wasén Caroline (Sweden)	SAT0032	SMOKING CONTRIBUTES TO EXHAUSTED STATE OF CD4+ T CELLS IN RHEUMATOID ARTHRITIS
Abstract	Dulic Sonja (Hungary)	SAT0034	ANALYSIS OF THE T-CELL SUBSET COMPOSITION IN ANKYLOSING SPONDYLITIS PATIENTS WITH LONG-STANDING ANTI-TNF THERAPY
Abstract	Hur Eun Mi (United States)	SAT0035	INHIBITION OF PROTEIN KINASE C THETA BY THE SELECTIVE INHIBITOR CC-90005 INDUCES T CELL ANERGY
Abstract	Steel Kathryn (United Kingdom)	SAT0036	IL-17+CD8+ T CELLS ENRICHED IN THE SYNOVIAL FLUID OF PSA/SPA PATIENTS EXHIBIT A PRO-INFLAMMATORY CYTOKINE PHENOTYPE

Poster Tour: Imaging advances in vasculitis, crystal and connective tissue disease

Chair Terslev Lene

	(Denmark)		
Chair	Dalsgaard Nielsen Berit (Denmark)		
Abstract	De Miguel Eugenio (Spain)	SAT0609	GIANT CELL ARTERITIS: ATHEROSCLEROSIS AS PITFALL IN THE HALO SIGN
Abstract	Estrada Paula (Spain)	SAT0610	TEMPORAL ARTERY ULTRASOUND IN THE DIAGNOSIS OF GIANT CELL ARTERITIS IN A COHORT WITH ELEVATED CLINICAL IMPRESSION
Abstract	Milchert Marcin (Poland)	SAT0611	INTIMA-MEDIA THICKNESS REFERENCE RANGES DEPICTING HALO SIGN FOR THE DIAGNOSING OF LARGE VESSEL GIANT CELL ARTERITIS BY ULTRASOUND
Abstract	Blockmans Daniel (Belgium)	SAT0612	THE USE OF 18F-FDG-PET IN THE DIAGNOSIS OF POLYMYALGIA RHEUMATICA (PMR) – A PROSPECTIVE STUDY OF 99 PATIENTS SUSPECTED OF PMR
Abstract	Bertolazzi Chiara (Mexico)	SAT0613	HIGH PREVALENCE OF SUBCLINICAL ATHEROSCLEROSIS IN GOUT AND ASYMPTOMATIC HYPERURICEMIA: A STUDY BASED ON CAROTID ULTRASOUND.
Abstract	Bhadu Danveer (India)	SAT0614	ULTRASOUND AND URATE CRYSTAL DEPOSITION: HOW MANY JOINTS TO SCREEN?
Abstract	Perricone Carlo (Italy)	SAT0615	THE RS11803505 IL-23R POLYMORPHISM IS A RISK FACTOR FOR THE DEVELOPMENT OF MSUS-DETECTED EROSIONS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
Abstract	Budde Petra (Germany)	SAT0616	DIAGNOSTIC MODELING OF SYSTEMIC LUPUS ERYTHEMATOSUS BASED ON NEW AND TRADITIONAL AUTOANTIBODIES- DEMONSTRATION OF FEASIBILITY
Abstract	Delli Konstantina (Netherlands)	SAT0617	SALIVARY GLAND ULTRASOUND CAN DIFFERENTIATE PRIMARY SJÖGREN'S SYNDROME FROM SYSTEMIC DISEASES WITH SALIVARY GLAND INVOLVEMENT
Abstract	Lüders Susanne (Germany)	SAT0618	DISTURBANCES OF THE ACRAL PERFUSION DETECTED BY FLUORESCENCE OPTICAL IMAGING ARE ASSOCIATED WITH

THE DEVELOPMENT OF ISCHEMIC
COMPLICATIONS IN PATIENTS WITH
SYSTEMIC SCLEROSIS

Poster Tour: Infection Related Rheumatic Disease: clinical and epidemiologic aspects

Chair	Calabrese Leonard (United States)		
Chair	Thomas Konstantinos (Greece)		
Abstract	Md Yusof Md Yuzaiful (United Kingdom)	SAT0556	RISK FACTORS FOR SEVERE INFECTION AND RATIONALE FOR IMMUNOGLOBULIN MONITORING DURING RITUXIMAB TREATMENT IN AUTOIMMUNE RHEUMATIC DISEASES
Abstract	Marques Claudia (Brazil)	SAT0557	CHIKUNGUNYA OUTBREAK IN BRAZIL: DEMOGRAPHIC AND CLINICAL CHARACTERIZATION OF 732 PATIENTS – CHIKBRASIL COHORT
Abstract	Marques Claudia (Brazil)	SAT0558	CONCORDANCE BETWEEN CLINICAL-EPIDEMIOLOGICAL CRITERIA AND CHIKUNGUNYA FEVER SEROLOGY
Abstract	Vivekanantham Arani (United Kingdom)	SAT0559	SEPTIC ARTHRITIS IN COVENTRY IN THE UK: 5 YEAR DATA
Abstract	Garcia-Mira Yaiza (Spain)	SAT0560	COEXISTENCE OF SEPTIC AND CRYSTAL-INDUCED ARTHRITIS: A DIAGNOSTIC CHALLENGE.
Abstract	Saroux Alain (France)	SAT0561	USEFULNESS OF POLYMERASE CHAIN REACTION FOR DIAGNOSING WHIPPLE'S DISEASE IN RHEUMATOLOGY
Abstract	Dantas Andrea (Brazil)	SAT0562	CHIKUNGUNYA FEVER IN PATIENTS WITH PRIOR RHEUMATIC DISEASES: IS IT MORE SEVERE?
Abstract	Bhama Manoj (India)	SAT0563	EVALUATION OF ROLE OF SLEEP DISTURBANCE, DEPRESSION, OBESITY, AND PHYSICAL INACTIVITY IN FATIGUE IN CHIKUNGUNYA ARTHRITIS
Abstract	LLANO HERNÁNDEZ KEILA (Spain)	SAT0564	SUBLINGUAL VACCINE: NEW CHALLENGE IN THE PREVENTION OF RECURRENT INFECTIONS IN AUTOIMMUNE DISEASES
Abstract	Petersen Soeren Kjaer (Denmark)	SAT0565	THE FREQUENCY OF SEPTIC ARTHRITIS AFTER ARTHROCENTESIS AND INTRA

ARTICULAR GLUCOCORTICOID
INJECTION IS LOW**Poster Tour: Innate mediators and autoantibodies in Rheumatic disease**

Chair	Herrmann Martin (Germany)		
Chair	Canavan Mary (Ireland)		
Abstract	Kusche Yvonne (Germany)	SAT0010	THE DAMP PROTEIN S100A8/A9 IS CRUCIALLY INVOLVED IN MYELOID-DERIVED SUPPRESSOR CELL (MDSC) DIFFERENTIATION AND FUNCTION IN COLLAGEN-INDUCED ARTHRITIS
Abstract	Sommerlatte Sabine (Germany)	SAT0011	THE ACTIVATION OF MUSCARINIC ACETYLCHOLINE RECEPTORS INFLUENCES THE ONTOGENY OF NEUTROPHILS
Abstract	Cremers Niels (Netherlands)	SAT0012	S100A8/A9 INCREASES THE MOBILIZATION OF LY6C HIGH MONOCYTES TO THE SYNOVIUM DURING EXPERIMENTAL OSTEOARTHRITIS
Abstract	Canavan Mary (Ireland)	SAT0013	THE PATHOGENIC ROLE OF MYELOID CD141+ DENDRITIC CELLS IN INFLAMMATORY ARTHRITIS
Abstract	Skriner Karl (Germany)	SAT0014	THE MUTATED RNA SPLICING PROTEIN HNRNP-A3 IS A NOVEL AUTOANTIGEN IN SYSTEMIC RHEUMATIC DISEASES A LINK TO WARBURG EFFECT IN RA
Abstract	Van Dam L. (Netherlands)	SAT0015	ANCA-ASSOCIATED VASCULITIS- AND SYSTEMIC LUPUS ERYTHEMATOSUS-INDUCED NEUTROPHIL EXTRACELLULAR TRAPS HAVE INTRINSICALLY DIFFERENT FEATURES
Abstract	Cruz González Daniela (Mexico)	SAT0016	A NEW SUBSET OF NK CELLS, WITH ENHANCED CYTOTOXIC FUNCTION, IS INCREASED IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS.
Abstract	Baker Matthew (United States)	SAT0017	INVESTIGATING NOVEL AUTOANTIBODIES IN PATIENTS WITH GRANULOMATOSIS WITH POLYANGIITIS
Abstract	Pala Ozlem (United States)	SAT0018	EFFECTS OF ANTI-TNF ALPHA THERAPY ON B CELLS IN RHEUMATOID ARTHRITIS (RA)

PATIENTS

Abstract	Engdahl Cecilia (Sweden)	SAT0019	ESTROGEN INFLUENCES THE SIALYLATION PROFILE AND INFLAMMATORY PROPERTIES OF ANTIBODIES- A POTENTIAL EXPLANATION FOR THE SEX DIFFERENCES AND INCREASED RISK FOR RA IN POSTMENOPAUSAL WOMEN
----------	-----------------------------	---------	--

 **Poster Tour: Last news on systemic sclerosis and myositis**

Chair	Cutolo Maurizio (Italy)		
Chair	Sulli Alberto (Italy)		
Abstract	Milo Jay (United States)	SAT0372	CLINICAL AND SEROLOGICAL ASSOCIATIONS OF AUTOANTIBODIES TO BICD2 AS A NOVEL MARKER FOR SYSTEMIC SCLEROSIS
Abstract	Khanna Dinesh (United States)	SAT0373	EVALUATION OF AMERICAN COLLEGE OF RHEUMATOLOGY PROVISIONAL COMPOSITE RESPONSE (CRISS) INDEX IN THE FASCINATE TRIAL
Abstract	Cooper Robert G. (United Kingdom)	SAT0374	THE EUROMYOSITIS REGISTRY: AN INTERNATIONAL DESCRIPTION OF MYOSITIS
Abstract	Ahmed Sakir (India)	SAT0375	METABOLOMICS OF SERA REVEALS POTENTIAL BIOMARKERS OF SKIN FIBROSIS IN SYSTEMIC SCLEROSIS THAT CORRELATE WITH PRO-FIBROTIC GENE EXPRESSION IN SKIN BIOPSIES.
Abstract	Yeker Richard (United States)	SAT0376	ANTI-NT5C1A AUTOANTIBODIES ARE FREQUENT IN JUVENILE MYOSITIS AND ASSOCIATED WITH INCREASED ILLNESS SEVERITY
Abstract	Trombetta Amela Chiara (Italy)	SAT0377	RELIABILITY OF A NEW AUTOMATED SYSTEM FOR ABSOLUTE CAPILLARY NUMBER COUNTING (AUTOCAPI) ON SYSTEMIC SCLEROSIS NAILFOLD VIDEOCAPILLAROSCOPIC IMAGES
Abstract	Stamenkovic Bojana (Serbia)	SAT0378	BONE MARROW OEDEMA AND SYNOVITIS ON MRI OF THE HAND ARE ASSOCIATE WITH DIGITAL ULCERS, ACTIVE DISEASE AND IMPAIRED FUNCTIONAL CAPACITY IN SYSTEMIC SCLEROSIS

Abstract	Millan Arciniegas Ana (Spain)	SAT0379	NAILFOLD CAPILLAROSCOPY FINDINGS IN PATIENTS WITH INFLAMMATORY MYOPATHY AND/OR SPECIFIC OR ASSOCIATED ANTIBODIES.
Abstract	Blagojevic Jelena (Italy)	SAT0380	CLASSIFICATION, CATEGORISATION AND ESSENTIAL ITEMS FOR DIGITAL ULCER (DU) EVALUATION IN SYSTEMIC SCLEROSIS (SSC): A DESSCIPHER/EUSTAR SURVEY
Abstract	Ruaro Barbara (Italy)	SAT0381	CORRELATION BETWEEN THREE DIFFERENT METHODS TO ASSESS DERMAL THICKNESS IN SYSTEMIC SCLEROSIS PATIENTS WITH DIFFERENT PATTERNS OF NAILFOLD MICROANGIOPATHY
📍 Poster Tour: New treatment options in SLE, Sjögren's and APS			
Chair	Aringer Martin (Germany)		
Chair	Bootsma Hendrika (Netherlands)		
Abstract	Merrill Joan (United States)	SAT0219	EFFICACY AND SAFETY OF ATACICEPT IN PATIENTS WITH HIGH DISEASE ACTIVITY IN A 24-WEEK, RANDOMIZED, PLACEBO-CONTROLLED, PHASE IIB STUDY (ADDRESS II)
Abstract	White Wendy (United States)	SAT0220	EFFECTS OF TYPE I INTERFERON INHIBITION ON BLOOD LEUKOCYTE SUBSETS IN PATIENTS TREATED IN A PHASE IIB CLINICAL STUDY OF ANIFROLUMAB IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Abstract	Cascino Matthew (United States)	SAT0221	SIX-MONTH PROTEINURIA MEASUREMENT PREDICTS RENAL RESPONSE AT 18 MONTHS IN LUPUS NEPHRITIS: ANALYSIS OF TWO PHASE III RANDOMIZED CLINICAL TRIALS
Abstract	Furie Richard (United States)	SAT0222	BIIB059, A MONOCLONAL ANTIBODY TARGETING BDCA2, SHOWS EVIDENCE OF BIOLOGICAL ACTIVITY AND EARLY CLINICAL PROOF OF CONCEPT IN SUBJECTS WITH ACTIVE CUTANEOUS LE
Abstract	Ramachandran Sulabha (United States)	SAT0223	INDIRECT COMPARATIVE CLINICAL EFFECTIVENESS OF INTRAVENOUS AND SUBCUTANEOUS

FORMULATIONS OF BELIMUMAB FOR THE TREATMENT OF ADULT PATIENTS WITH ACTIVE, AUTOANTIBODY-POSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS WITH HIGH DISEASE ACTIVITY

Abstract Wang Qian (China) SAT0224

THE ROLE OF INTENSIVE IMMUNOSUPPRESSIVE THERAPY IN THE MANAGEMENT OF SLE-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION: A SINGLE-CENTER COHORT STUDY

Abstract Gaudy Allison (United States) SAT0225

CEREBLON MODULATOR CC-220 DECREASES NAÏVE AND MEMORY B CELLS AND PLASMACYTOID DENDRITIC CELLS IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) PATIENTS: EXPOSURE-RESPONSE RESULTS FROM A PHASE 2A PROOF OF CONCEPT STUDY

Abstract Catlett Ian (United States) SAT0226

A FIRST-IN-HUMAN, STUDY OF BMS-986165, A SELECTIVE, POTENT, ALLOSTERIC SMALL MOLECULE INHIBITOR OF TYROSINE KINASE 2

Abstract Hammond Edward (United States) SAT0227

HEALTH CARE UTILIZATION AND COSTS OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) IN THE UNITED STATES: SYSTEMATIC REVIEW

Abstract Spinelli Francesca Romana (Italy) SAT0228

APOPTOTIC EFFECT OF BLYS ON ENDOTHELIAL CELLS AND ENDOTHELIAL PROGENITOR CELLS IS MEDIATED BY BLYS RECEPTORS AND IS REVERTED BY BELIMUMAB

Abstract Saavedra Miguel (Mexico) SAT0229

THE USE OF ANTIMALARIAL DRUGS DURING PREGNANCY CAN PREVENT THE DEVELOPMENT OF PREECLAMPSIA IN WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS

Abstract Satybaldyeva Maria (Russian Federation) SAT0230

NEW ORAL ANICOAGULANTS IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME

Poster Tour: RA - risk factors and consequences

Chair Petersson Ingemar (Sweden)

Chair	Verstappen Suzanne (United Kingdom)		
Abstract	Gerlag Daniëlle (United Kingdom)	SAT0037	THE EFFECTS OF B CELL DIRECTED THERAPY ON DISEASE RELEVANT BIOMARKERS IN SUBJECTS AT RISK OF RHEUMATOID ARTHRITIS
Abstract	Baraka Eman (Egypt)	SAT0038	SERUM B LYMPHOCYTE CHEMOATTRACTANT PROTEIN 13 (CXCL 13) AND MUSCULOSKELETAL ULTRASONOGRAPHIC FINDINGS IN EARLY RHEUMATOID ARTHRITIS
Abstract	Lim Siok Hoon Lily (Canada)	SAT0039	LARGE TENDER JOINTS HAVE THE GREATEST IMPACT ON LONGITUDINAL TRAJECTORIES OF FUNCTION IN EARLY RHEUMATOID ARTHRITIS
Abstract	Carpenter Lewis (United Kingdom)	SAT0040	ASSESSING 5-YEAR RADIOGRAPHIC PROGRESSION IN RHEUMATOID ARTHRITIS PATIENTS WITH MODERATE DISEASE: FINDINGS FROM A UK MULTI-CENTRE PROSPECTIVE OBSERVATIONAL STUDY
Abstract	Fleischmann R (United States)	SAT0041	EFFICACY OF ABATACEPT VERSUS ADALIMUMAB IN PATIENTS WITH SEROPOSITIVE, EROSION EARLY RA: ANALYSIS OF A RANDOMIZED CONTROLLED CLINICAL TRIAL (AMPLE)
Abstract	Eun Jung Su (Korea, Republic Of)	SAT0042	SEVERITY OF RADIOGRAPHIC DESTRUCTION ON PERIPHERAL JOINTS IS A STRONG INDEPENDENT RISK FACTOR FOR CAROTID ATHEROSCLEROSIS
Abstract	Fevang Bjorg-Tilde (Norway)	SAT0043	FACTORS AFFECTING THE NEED FOR ORTHOPAEDIC SURGERY IN PATIENTS WITH RHEUMATOID ARTHRITIS. RESULTS FROM 1010 PATIENTS DIAGNOSED WITH RA FROM 1972-2009.
Abstract	Paalanen Kirsi (Finland)	SAT0044	A 10-YEAR FOLLOW UP STUDY OF EARLY SERONEGATIVE ARTHRITIS DIAGNOSED AT AN ADULT AGE
Abstract	Hetland Merete Lund (Denmark)	SAT0045	11 YEARS' FOLLOW-UP OF A DANISH 2-YEAR TREAT-TO-TARGET RANDOMIZED CONTROLLED TRIAL IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS:

BASELINE PREDICTORS OF
FUNCTIONAL AND RADIOGRAPHIC
OUTCOMES

Abstract	Cavaco Marco (Portugal)	SAT0046	TNF ANTAGONIST DRUG SAFETY ASSESSMENT BY PHARMACOVIGILANCE SIGNALING AND POST-MARKETING ADVERSE EVENT REPORTS
----------	----------------------------	---------	---

Poster Tour: SSc, myositis and rare diseases: etiology

Chair	Riemekasten Gabriela (Germany)		
Chair	Humrich Jens (Germany)		
Abstract	Kozlova Anastasiia (Switzerland)	SAT0312	MICRORNA-125B AS A POTENTIAL FIBROTIC AND APOPTOTIC REGULATOR IN SYSTEMIC SCLEROSIS
Abstract	Di Benedetto Paola (Italy)	SAT0313	ROLE OF CD248 MOLECULE AS POTENTIAL REGULATOR OF TRANS-DIFFERENTIATION TOWARD MYOFIBROBLASTS OF PERIVASCULAR STROMAL CELLS IN SYSTEMIC SCLEROSIS PATIENTS.
Abstract	Ekström Gunilla (Sweden)	SAT0314	A NOVEL HIGHLY SELECTIVE 5- HYDROXYTRYPTAMINE 2B (5-HT2B) RECEPTOR ANTAGONIST AMELIORATING FIBROSIS IN PRECLINICAL MODELS OF SYSTEMIC SCLEROSIS
Abstract	Codullo Veronica (Italy)	SAT0315	IMATINIB-LOADED TARGETED GOLD NANOPARTICLES AMELIORATE EXPERIMENTAL LUNG FIBROSIS INDUCED BY BLEOMYCIN
Abstract	González-Tajuelo Rafael (Spain)	SAT0316	ANGII INVOLVEMENT IN LUNG ENDOTHELIAL DYSFUNCTION AND PAH DEVELOPMENT IN PSGL-1 DEFICIENT FEMALE MICE
Abstract	Juhl Pernille (Denmark)	SAT0317	TYPE VI COLLAGEN FORMATION: A NEW OBJECTIVE BLOOD-BASED MARKER REFLECTING FIBROSIS OF THE SKIN IN SYSTEMIC SCLEROSIS
Abstract	Bergmann Christina (Germany)	SAT0318	EPIGENETIC REGULATION OF FRA2 BY JMJD3 REGULATES FIBROBLAST ACTIVATION IN SYSTEMIC SCLEROSIS
Abstract	Budde Petra (Germany)	SAT0319	MULTIPARAMETRIC DETECTION OF AUTOANTIBODIES TO INVESTIGATE

RELATIONSHIPS BETWEEN
SEROLOGICAL AND CLINICAL
SUBSETS OF SYSTEMIC
SCLEROSIS PATIENTS

Abstract Riemekasten SAT0320
Gabriela (Germany) SSC- IGG EFFECTS ARE MEDIATED
THROUGH DISTINCT PATHWAYS IN
THP-1 CELLS

Abstract Scotece Morena SAT0321
(Finland) MKP-1 AS A PROTECTIVE FACTOR
AND NOVEL DRUG TARGET IN
SCLERODERMA: MKP-1 DEFICIENT
MICE DEVELOP MORE SEVERE
DERMAL FIBROSIS IN A WIDELY
USED EXPERIMENTAL MODEL OF
SCLERODERMA.

 **Poster Tour: Steps forward in osteoarthritis research**

Chair Kloppenburg
Margreet
(Netherlands)

Chair Sellam Jeremie
(France)

Abstract Hayward Richard SAT0483
(United Kingdom) OSTEOARTHRITIS(OA) AND SOCIO-
ECONOMIC STATUS(SES)
PREDICTS THE ONSET OF
COMORBIDITIES LINKED TO
FREQUENT HEALTHCARE
CONSULTATION

Abstract Shmagel Anna SAT0484
(United States) LOW MAGNESIUM INTAKE IS
ASSOCIATED WITH INCREASED
PAIN IN SUBJECTS WITH
RADIOGRAPHIC KNEE
OSTEOARTHRITIS: DATA FROM THE
OSTEOARTHRITIS INITIATIVE.

Abstract Ilias Dragos (United SAT0485
Kingdom) INCREASED EXPRESSION OF
OSTEOPROTEGERIN IN CD271+
MULTIPOTENTIAL STROMAL CELLS
FROM FEMORAL HEADS OF
PATIENTS WITH HIP
OSTEOARTHRITIS

Abstract Verhoeven Frank SAT0486
(France) CATASTROPHIZING IN
OSTEOARTHRITIS OF THE KNEE:
DOES THE LEQUESNE SCORE
TAKE IT IN COUNT? A
PROSPECTIVE STUDY

Abstract Wright Anthony SAT0487
(Australia) A RANDOMIZED, BLINDED,
COMPARATOR-CONTROLLED TRIAL
INVESTIGATING A 4-WEEK COURSE
OF LYRICA IN SUBJECTS WITH
KNEE OSTEOARTHRITIS WHO
EXHIBIT NEUROPATHIC PAIN,

			COMPARED WITH A 4-WEEK COURSE OF PARACETAMOL
Abstract	Kessler Christian (Germany)	SAT0488	COMPARATIVE EFFECTIVENESS OF AYURVEDA AND CONVENTIONAL CARE IN KNEE OSTEOARTHRITIS - A RANDOMIZED CONTROLLED TRIAL
Abstract	Meng Tao (Australia)	SAT0489	ASSOCIATION OF CHILDHOOD OVERWEIGHT MEASURES WITH ADULTHOOD KNEE CARTILAGE DEFECTS AND BONE MARROW LESIONS: A 25-YEAR COHORT STUDY
Abstract	Jeffries Matlock (United States)	SAT0490	GENOME-WIDE DNA METHYLATION PROFILING OF OSTEOARTHRITIS PERIPHERAL BLOOD MONONUCLEAR CELLS REVEALS SLOWED EPIGENETIC AGING AMONG RAPID RADIOGRAPHIC PROGRESSORS: DATA FROM THE OSTEOARTHRITIS INITIATIVE (OAI)
Abstract	Shirinsky Ivan (Russian Federation)	SAT0491	USE OF HISTAMINE H1-RECEPTOR ANTAGONISTS IS ASSOCIATED WITH DECREASED PREVALENCE OF RADIOGRAPHIC KNEE OSTEOARTHRITIS: A CROSS-SECTIONAL ANALYSIS OF OSTEOARTHRITIS INITIATIVE DATA
Abstract	Bierma-Zeinstra Sita (Netherlands)	SAT0492	INTRAMUSCULAR CORTICOSTEROID INJECTION VERSUS PLACEBO INJECTION IN HIP OSTEOARTHRITIS: A 12- WEEK BLINDED RANDOMIZED CONTROLLED TRIAL
Abstract	Zheng Shuang (Australia)	SAT0493	MAINTAINING SUFFICIENT SERUM VITAMIN D LEVELS OVER TWO YEARS IS ASSOCIATED WITH IMPROVED KNEE STRUCTURAL AND SYMPTOMATIC OUTCOMES IN PEOPLE WITH KNEE OSTEOARTHRITIS: A POST HOC ANALYSIS OF THE VIDEO TRIAL
Abstract	Goicoechea Carlos (Spain)	SAT0494	EARLY TOLL-LIKE RECEPTOR 4 BLOCKADE IMPEDES THE BEHAVIOURAL AND HISTOLOGICAL CHARACTERISTICS OBSERVED IN A MIA-INDUCED ANIMAL MODEL OF OSTEOARTHRITIC PAIN.

Poster Tour: Trends in non-TNF alpha biologicals for RA II

Chair Bijlsma Johannes

W.J. (Netherlands)

Chair	van Spil W. Erwin (Netherlands)		
Abstract	Thomas Konstantinos (Greece)	SAT0176	PATTERNS OF BIOLOGIC DMARD MONOTHERAPY IN A LARGE NATIONWIDE RHEUMATOID ARTHRITIS COHORT: DATA FROM 1036 PATIENTS
Abstract	Soule B (United States)	SAT0177	SAFETY EVENTS ARE SIMILAR WITH ABATACEPT VS PLACEBO TREATMENT IN RA: RESULTS FROM INTEGRATED DATA ANALYSIS FROM NINE CLINICAL TRIALS
Abstract	Guerrero Edurne (Spain)	SAT0178	PULMONARY INVOLVEMENT IN RHEUMATOID ARTHRITIS TREATED WITH BIOLOGIC
Abstract	Paulding Charles (United States)	SAT0179	THE ASP358ALA VARIANT IN THE IL6R GENE IS SIGNIFICANTLY ASSOCIATED WITH DIFFERENCES IN SOLUBLE IL-6R PROTEIN LEVELS BUT NOT WITH DIFFERENCES IN SARILUMAB RESPONSE IN RHEUMATOID ARTHRITIS (RA) PATIENTS
Abstract	Genovese Mark (United States)	SAT0180	EFFICACY AND SAFETY OF SARILUMAB 200 MG Q2W ADMINISTERED AS COMBINATION THERAPY OR MONOTHERAPY IN DIFFERENT PATIENT POPULATIONS WITH ACTIVE RA
Abstract	Sheng-Xiao Zhang (China)	SAT0181	LOW DOSE INTERLEUKIN-2 COMBINED WITH TOCILIZUMAB SELECTIVELY INCREASES REGULATORY T CELLS HELPING REFRACTORY RHEUMATOID ARTHRITIS PATIENTS ACHIEVE REMISSION MORE RAPIDLY
Abstract	McQuarrie Kelly (United States)	SAT0182	SIRUKUMAB LEADS TO SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENTS IN HEALTH-RELATED QUALITY OF LIFE THAT MEET OR EXCEED NORMATIVE VALUES IN PATIENTS WITH RHEUMATOID ARTHRITIS REFRACTORY TO TNF INHIBITORS IN POST HOC ANALYSES OF A PHASE 3 TRIAL
Abstract	Sanmarti Raimon (Spain)	SAT0183	CLINICAL REMISSION IN SUBJECTS WITH RHEUMATOID ARTHRITIS

TREATED WITH SUBCUTANEOUS TOCILIZUMAB AS MONOTHERAPY OR IN COMBINATION WITH METHOTREXATE OR OTHER SYNTHETIC DMARDS: A REAL-WORLD CLINICAL TRIAL (TOSPACE).

Abstract Ruiz-Esquide SAT0184
Virginia (Spain)

THERAPEUTIC DRUG MONITORING ON RHEUMATOID ARTHRITIS PATIENTS WITH REDUCED DOSES OF INTRAVENOUS TOCILIZUMAB.

Abstract Torikai Eiji (Japan) SAT0185

BIO-HOLIDAY THERAPY WITH A TIGHT CONTROL STRATEGY IN RHEUMATOID ARTHRITIS PATIENTS WITH CLINICAL DISEASE ACTIVITY INDEX REMISSION ENABLES MAINTENANCE OF BONE METABOLISM STATUS.

Abstract Takeuchi Tsutomu SAT0186
(Japan)

EFFECTS OF DENOSUMAB, A SUBCUTANEOUS RANKL INHIBITOR, ON THE PROGRESSION OF STRUCTURAL DAMAGE IN JAPANESE PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH CSDMARDS: RESULTS FROM THE 12-MONTH DOUBLE BLIND PHASE 3, DESIRABLE STUDY

Abstract Tanaka Yoshiya SAT0187
(Japan)

SAFETY, PHARMACOKINETICS AND EFFICACY OF E6011, AN ANTI-FRACTALKINE MONOCLONAL ANTIBODY, IN A FIRST-IN-PATIENT PHASE 1/2 STUDY IN RHEUMATOID ARTHRITIS; ADDITIONAL DATA OF 400 MG COHORT

 **Saturday 17.06.2017 12:00 - 13:30**

 **WIN & HOT Session - Hall 6**

 **WIN & HOT Session**

Chair Sanmarti Raimon
(Spain)

Chair Jani Meghna
(United Kingdom)

Speaker Smolen Josef S.
(Austria)

WIN Session: Rheumatoid arthritis treatment

Speaker Wulfraat Nico SP0175
(Netherlands)

WIN Session: Juvenile idiopathic arthritis

Clinical Science Session - Hall 8

Systemic sclerosis

Chair	Vonk Madelon (Netherlands)		
Chair	Siegert Elise (Germany)		
Speaker	Cutolo Maurizio (Italy)	SP0176	Targeting vasculopathy from the beginning
Speaker	Denton Christopher (United Kingdom)	SP0177	New approaches by targeting soluble mediators
Speaker	van Laar Jacob M. (Netherlands)		Advances in immunosuppressive therapeutical approaches
Speaker	Distler Oliver (Switzerland)		Addressing most promising antifibrotic and epigenetic targets
Abstract	Agueusop Inoncent (Germany)	OP0339	IDENTIFICATION OF A TRANSCRIPTOMIC SIGNATURE CORRELATED WITH MODIFIED RODNAN SKIN SCORE (MRSS) IN PATIENTS WITH DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS

Challenges in Clinical Practice Session - Hall 7A

The challenges of MRI in axSpA

Chair	Navarro-Compán Victoria (Spain)		
Chair	Pimentel dos Santos Fernando (Portugal)		
Presenter	Moltó Anna (France)		Case 1 presentation: A post-partum sacral fissure mimicking sacroiliitis
Discussant	Hermann Kay-Geert (Germany)		Case 1 discussion: A positive MRI is not always axSpA
Presenter	Baraliakos Xenophon (Germany)		Case 2 presentation: When MRI makes the difference
Discussant	Rudwaleit Martin (Germany)		Case 2 discussion: The value of a positive MRI in axSpA

From Bench to Bedside - Hall 7B

How diet influences musculoskeletal diseases

Chair	So Alexander (Switzerland)
Chair	Richette Pascal

(France)

Speaker	Choi Hyon (United States)		Fructose, obesity and health
Speaker	Choi Hyon (United States)		Dietary influences on hyperuricemia - what do we know
Speaker	Richette Pascal (France)		Drastic weight loss and its effects on health
Abstract	Nielsen Sabrina (Denmark)	OP0340	WEIGHT LOSS FOR OVERWEIGHT AND OBESE INDIVIDUALS WITH GOUT: A SYSTEMATIC REVIEW OF LONGITUDINAL OBSERVATIONAL STUDIES

Clinical Science Session - N103 / N104

Can targeting disease activity in hand osteoarthritis improve our treatment in the 21st century?

Chair	Bijlsma Johannes W.J. (Netherlands)		
Chair	van Spil W. Erwin (Netherlands)		
Speaker	Wittoek Ruth (Belgium)	SP0179	What is disease activity in finger OA?
Speaker	Chevalier Xavier (France)	SP0180	Biologics and other inflammatory therapies in finger OA. What have we learned?
Speaker	Kloppenburg Margreet (Netherlands)		Thumb base OA requires a different approach than finger OA, but why and how?
Abstract	Tan Ai Lyn (United Kingdom)	OP0341	CAN PAIN IN HAND OSTEOARTHRITIS BE ASSOCIATED WITH MRI COLLATERAL LIGAMENT ABNORMALITIES?
Abstract	van Beest Sjoerd (Netherlands)	OP0342	ASSESSMENT OF STRUCTURAL DAMAGE OF THE THUMB BASE IN PATIENTS WITH HAND OSTEOARTHRITIS: COMPARING THE NEWLY DEVELOPED OMERACT MAGNETIC RESONANCE IMAGING SCORING SYSTEM WITH STANDARD RADIOGRAPHY

Basic and Translational Science Session - South Auditorium

Why we do develop autoimmunity?

Chair	Huizinga Tom (Netherlands)		
Chair	Scherer Hans-Ulrich (Netherlands)		

Speaker	Riemekasten Gabriela (Germany)	SP0181	Failure of natural regulatory autoantibody network as cause of autoimmunity
Speaker	Scherer Hans-Ulrich (Netherlands)	SP0182	Alterations in the antibody repertoire and sugar modulation as cause for autoimmunity
Speaker	Humrich Jens (Germany)	SP0183	Failure of Treg control to understand autoimmunity
Speaker	Lamprecht Peter (Germany)	SP0184	Role of microenvironment and endogenous pathways to break tolerance
Abstract	Natalello Gerlando (Italy)	OP0343	THE INTESTINAL INVOLVEMENT IN SYSTEMIC SCLEROSIS IS CHARACTERIZED BY A PECULIAR GUT MICROBIOTA

Health Professionals Session - N101 / N102

Closing the gap between objective measures and self-report in Fibromyalgia

Chair	Geenen Rinie (Netherlands)		
Chair	Gobbo Montoya Milena (Spain)		
Speaker	Henriksen Marius (Denmark)	SP0185	Divergences between objective and self-reported physical function in fibromyalgia
Speaker	Walitt Brian (United States)	SP0186	Cognitive fog: subjective and objective understandings of the symptom of dyscognition
Speaker	Estévez-López Fernando (Spain)	SP0187	Pain catastrophizing and self-efficacy in women with fibromyalgia: the al-Ándalus project
Speaker	Piggott Louise (United Kingdom)	SP0188	Self management of fibromyalgia from a patient perspective
Abstract	Vervoort Vera (Netherlands)	OP0344-HPR	DEVELOPMENT OF RESPONDER CRITERIA FOR MULTICOMPONENT NON-PHARMACOLOGICAL TREATMENT IN FIBROMYALGIA.

The Young Rheumatologist - N111 / N112

Interactive cases from the HOT and WIN Sessions

Chair	Romao Vasco C (Portugal)		
Chair	Iagnocco Annamaria (Italy)		
Speaker	Kloppenburger		WIN Session: Interactive clinical

	Margreet (Netherlands)		aspects and cases on osteoarthritis
Speaker	Machado Pedro (United Kingdom)		WIN Session: Interactive clinical aspects and cases on axial and peripheral spondyloarthritis
Speaker	Luqmani Raashid (United Kingdom)	SP0189	HOT Session: Interactive clinical aspects and cases on vasculitis treatment
Speaker	McInnes Iain (United Kingdom)		WIN Session: Interactive clinical aspects and cases on : rheumatoid arthritis – what have therapeutics taught us

Joint Session PARE / HPR - N115 / N116

Suffering in silence. Optimizing the management of psychological well-being for people with RMDs

Chair	Makri Souzi (Belgium)		
Chair	Zangi Heidi A. (Norway)		
Speaker	Dures Emma (United Kingdom)	SP0190	Facts and figures: How mental health care addresses the psychological burden of RMD's in Europe
Speaker	Marchal Anja (Belgium)		A personal account of learning to disclose: How psychological support can help to break the vicious circle of hiding and ignoring
Speaker	Christodoulou Vasiliki (Cyprus)		Mindfulness and acceptance – How to use your body and mind to manage your life with a rheumatic disease
Abstract	Cattelaens Karl (Germany)	OP0345-PARE	GROWING UP WITH ARTHRITIS – YES WE CAN! A PROJECT OF DEUTSCHE RHEUMA-LIGA IN CO-OPERATION WITH THE GERMAN ARTHRITIS RESEARCH CENTER. WITH FINANCIAL SUPPORT BY THE GERMAN FEDERAL MINISTRY OF HEALTH.
Abstract	Mingolla Serena (Italy)	OP0346-PARE	“LISTENING TO PAIN - UN DOLORE DA ASCOLTARE” MULTIDISCIPLINARY SUPPORT FOR WOMEN WITH FIBROMYALGIA

EULAR Projects in Health Professionals - N117 / N118

Showcasing the EULAR Online Course for Health Professionals

Chair	van den Ende Els (Netherlands)		
-------	-----------------------------------	--	--

Chair	Niedermann Karin (Switzerland)		
Speaker	Oesch Peter (Switzerland)	SP0191	Principles of non-pharmacological management of regional musculoskeletal disorders
Speaker	Vliet Vlieland Thea (Netherlands)	SP0192	Principles of non-pharmacological management of rheumatic diseases
Speaker	Vriesevink Joke (Netherlands)	SP0193	Principles of non-pharmacological management of fibromyalgia
Speaker	Hilfiker Roger (Switzerland)	SP0194	Principles of assessment in clinical practice
Abstract	Nisar Muhammad (United Kingdom)	OP0347-HPR	TRAINING RHEUMATOLOGY NURSE SPECIALISTS: WHAT DOES THE FUTURE HOLD?

Practical Skills Session - N107 / N108

Ultrasound, Clinical, diagnostic and therapeutic skills II

Chair	Roccatello Dario (Italy)		
Chair	Damjanov Nemanja (Serbia)		
Speaker	Mandl Peter (Austria)	SP0101	Diagnostic and therapeutic ultrasound-guided procedures
Speaker	Doherty Michael (United Kingdom)	SP0102	How to perform a quick and efficient physical examination
Speaker	Caporali Roberto (Italy)		How to read and interpret imaging tools: X-Ray
Speaker	Hammer Hilde Berner (Norway)	SP0103	How to assess US competency skills
Speaker	not confirmed yet		Q&A

Practical Skills Session - N109 / N110

Laboratory course – from the clinic to the lab and back II

Chair	Dörner Thomas (Germany)		
Chair	Burmester Gerd Rüdiger (Germany)		
Speaker	Dörner Thomas (Germany)		ANA diagnostic and antiphospholipid syndrome (APS) as inherited coagulation disorder
Speaker	Miossec Pierre (France)		Vasculitis, systemic autoimmunity
Speaker	Feist Eugen (Germany)	SP0149	New trends in biomarkers in inflammatory joint diseases

🕒 Saturday 17.06.2017 13:45 - 14:45

🏠 Highlight Session - Hall 8

🏠 Clinical Basic Translational Highlight Session

Chair	Fonseca Joao Eurico (Portugal)		
Chair	Landewé Robert B.M. (Netherlands)		
Speaker	Dörner Thomas (Germany)		Basic and Translational Highlights
Speaker	Carmona Loreto (Spain)		Clinical Highlights

🏠 Highlight Session - N101 / N102

🏠 HPR Highlight Session

Chair	Barbosa Lurdes (Portugal)		
Chair	Prior Yeliz (United Kingdom)		
Speaker	Ferreira Ricardo (Portugal)	SP0195	Highlights from the Health Professional sessions
Speaker	Samaranayaka Muditha (United Kingdom)		Highlights from the Scientific programme
Speaker	Rhodes Carol (United Kingdom)		Highlights from the PARE programme

🏠 Highlight Session - N115 / N116

🏠 PARE Highlight Session

Chair	Caeyers Nele (Belgium)		
Chair	Kouloumas Marios (Cyprus)		
Speaker	Primdahl Jette (Denmark)		Highlights from the Health Professionals programme
Speaker	Aletaha Daniel (Austria)		Highlights from the Scientific Programme